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INTRODUCTION 
                        Siddha Medicine is not purely a medical system for curing the physical body, 
its a way of life formulated by Siddhars through their vision and realisation for getting peace 
for the mind, health, for the physical body and purity for the Soul. 
                         Contemporary Tamil literature mentions the origin of the medical system 
from south India in the state tamilnadu as a part of trio Indian medicine ayurveda, siddha and 
unani. Reported to have surfaced more than 2500 years ago, the Siddha system of medicine is 
considered one of the most antiquated traditional medical systems. The siddha is floruished in 
the period of Indus valley civilization. 
                       Siddha focussed to `Ashtamahasidddhi‟that is the eight supernatural power, 
those who attained  or achieved the above said power are known as siddhars.sage Agathiyar 
is considered as the guru of all siddhars. 
                           Siddhars were of the concept that a healthy soul can only be developed 
through a healthy body, they wrote scripture on all aspects of life from arts of science and 
truth of life to miracle cure of diseases. 
                         Siddha medicine is claimed to revitalize and rejuvenate dysfunctional organs 
that cause the disease and to maintaine the ratio of vatha, pitha and kabha. 
                         It is assumed that when the normal equilibrium of the three humors is 
disturbed disease is caused.The factors that affect their equilibrium are environmental,                                                                      
climatic conditions,diet, physical activities and stress. Under normal conditions the ratio 
between the three humors are 4:2:1(Vatha, pitha and kabha respectively). 
                        According to the Siddha medicine, various psychological and physiological 
functions of the body are attributed to the combination of seven elements: first is saram 
(plasma) responsible for growth, development and nourishment; second is cheneer (blood) 
responsible for nourishing muscles, imparting colour and improving intellect; the third is 
ooun (muscle) responsible for shape of the body; fourth is kollzuppu (fatty tissue) responsible 
for oil balance and lubricating joints; fifth is elumbu (bone) responsible for body structure 
and posture and movement; sixth is moolai (brain) responsible for strength; and the last is 
sukila (semen) responsible for reproduction.  The physiological components of the human 
beings are classified as vata (air), pitta (fire) and kapha (earth and water). 
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                          Traumatological aspects have also been dealt in siddha system of medicine in 
the name of varmam. 
                       The yogic techniques are very closely interwoven with the siddha system in all 
its manifestations 
                          Thokkanam is a special kind of treatment in siddha system.It is of nine types. 
Solid research has proven that massage therapy can Sooth chronic joint and muscle pain. 
 In Siddha System, there are 80 types of vatha diseases, pitha is 40 types and kabha is 
20types. 
 According to yougi vaithiya sinthamani                                                                                                   
                              vd;dNt thjk; jhd; ±ñ ;gjhFõ 
 
                 CEGANAVATHAM is one among the 80 types of vatha disease.    The 
symptomological description of the disease CEGANAVATHAM may be correlate to the 
symptoms of CERVICAL SPONDYLOSIS  
                           
       Cervical spondylosis is defined as arthrosis of the posterior intervertebral joints in the 
cervical vertebrae. It is common in the middle aged and in the elderly particularly in those 
whose occupation involves a posture of prolonged neck flexion.  The prevalence of the 
disease in 2011 is about 20- 25% of Population by the age of 50 Years & increases to 70 -
85% by the age of 65 Years.  
                 
     The disease is more prevalent nowadays due to life style modifications . Pain in neck and 
other symptoms of the disease has impaired normal activity in our day today life. Cervical 
spondylosis is more common in the elderly where advanced changes leads to disabling pain 
and paresis.The etiology is thought to be related to ageing process and (or) mechanical 
overload applied to the spine. 
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The author‟s choices of medicines for clinical study are: 
 i.kariuppu chenduram-Internal medicine. 
  Ref:Anuboga Vaithiya Navaneetham part-3 by Hakeem B.M.Abdula     
                   Saib.(Thamarai Noolagam- Publications)         
                Dose – 260 mg twice daily with honey after food. 
ii. kunthirika thylam – 50 ml (External medicine). 
Ref:  Pharmacopoeia of hospital of Indian medicine. 
The medicines were prepared by the author in PG Gunapadam Laboratory, at National 
Institute Of Siddha under  the guidance of the concerned Lecturers, and were tried in 10 
selected IP cases and 30 selected OP cases of “Ceganavatham” of varied etiology and the 
clinical study was undertaken in the Maruthuvam dept.                              
A comprehensive knowledge of siddha and modern concept about etiology, signs and 
symptoms, pathology, and bio-chemical,toxicological and pharmacological analysis also 
discussed in this study. 
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AIM AND OBJECTIVES 
AIM: 
     To document the siddha drug Kariuppu Chenduram (internal) and kunthirika 
thylam(external) in the treatment of  ceganavatham(cervical spondylosis) by the standard 
process of evaluation of safety and efficacy of the drug. 
 
OBJECTIVES 
PRIMARY OBJECTIVE:    
       To evaluate the therapeutic efficacy of siddha drug Kariuppu Chenduram (internal) 
and kunthirika thylam (external) in the treatment of  ceganavatham(cervical spondylosis) 
SECONDARY OBJECTIVE: 
 
1. To evaluate the safety profile (acute, long term toxicity studies) of this drug. 
2. To study the effect of other co-factors such as age, sex and siddha parameters. 
 
 
 
 
 
 
 
 
9 
 
LITERATURE REVIEW 
SIDDHA ASPECTS 
 
                In siddha literatures diseases are classified as 4448 types. Among 4448 types the vatha 
constitutes 84 types. 
This mentioned as 
  ehslh ehw;gj;J ehY E}W 
  eaKlNd ehw;gj;J vl;L Nuhfk; 
  ghug;gh thjkJ 84. 
- ,uj;jpd RUf;f ehb E}y;. 
According to Yugi Vaidhiya Chinthamani, Vadha is of 80 types. 
                              vd;dNt thjk; jhd; ±ñ ;gjhFõ 
 
THE UYIR THATHUKKAL -THE THREE VITAL HUMORS:                  
                      Vatha,pitha and kabha are the three vital humors.The action of the three humors 
which is found essential for the chemical changes of blood and other thathus  .Moreover the 
action of these three humors correspond to the Ahayam,vayu,fire,water,earth 
respectively. when the normal equilibrium of the three humors is disturbed disease is caused 
              The relation between panchabootham and Uyir thathukkal 
Uyir Thathukkal    Panchabootham 
Vatham   _                 Aahaayam (Space) 
                     Vayu (Air) 
Pitham   _                 Theyu (fire) 
Kabam   _                 Appu (Water) 
      Prithivi (Earth)  
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The formation of Uyir Thathukkal, 
ãÅ¨¸ Å¡Ô×õ ¯Â¢÷ ¾¡Ð×õ 
 "¯½÷ó¾ «À¡Éý ¯Úõ «ó¾ Å¡¾ò¾¢ø 
    Ò½÷ó¾ À¢Ã¡½ý ÒÌõ «ó¾ô À¢ò¾ò¾¢ø 
    «¨½ó¾ ºÁ¡Éý «¼íÌõ ¸Àò§¾¡Î 
    þ¨½ó¾¢¨Å ãýÚìÌ ±Îò¾ ÌÈ¢ ´ý§È" 
- À¾¢¦½ý º¢ò¾÷ ¿¡Ê º¡Š¾¢Ãõ 
The Vali naadi is formed by the combination of Abanan and Idagalai. 
The Azhal nadi is formed by combination of Piranan and Pinkalai.  
The Iyya naadi is formed by combination of Samanan and Suzhumunai. 
 VATHA DISEASES 
            Geneis of Vadha 
 Vatha - LOCATIONS: 
             Below the navel. 
  ‘ehnkd;w thjj;Jf; fpUg;gplNk Nfsha; 
    ehgpf;Ff; fPnod;W etpy yhFk;.‛ -A+fpKdp  
         When vali bootham and Aakaya bootham are combined vadha is formed. Generally “Vatham” 
lives in, 
1. Abaanan 
2. Edakalai 
3. Kamakodi 
4. Undhiyin Keezh moolam 
5. Hip region 
6. Bones 
7. Muscles 
8. Nerves 
9. Joints 
10.  Skin 
11.  Hair follicles and 
12.  Stools. 
11 
 
Physiologically “Vatham”, which has no alterations, lives in Gastro Intestinal Tract, Bones, 
Ear, Thigh, Hip and Skin. 
According to vaidya chatakam, vatham dwells in the following places  
               Umbilicus,rectum,faecalmatters,abdomen,anus,bones,hib-joints,skin,navel plexus,joints,hair 
follicles and muscles. 
                                      «È¢ó¾¢Îõ Å¡¾ Á¼íÌ ÁÄò¾¢É¢ø 
                                       - ¾¢ÕãÄ÷ 
               According to saint Thirumoolar the place of vatham is anus. 
FUNCTIONS OF VATHAM: 
1. Body ache 
2. Pricking pain 
3. Tearing pain 
4. Nerve weakness 
5. Mental distress 
6. Movements 
7. Joints pain 
8.  Traumatic pain 
9.  Dislocation of joints 
10.  Weakness of organs 
11. Paralysis of limbs 
12.  Polydypsia 
13.  Severe pain in calf and thigh muscles 
14.  Bony pricking pain 
15.  Anuria and constipation 
16.  Unable to do flexion and extension of the limbs 
17.  All tastes to be like astringent 
18.  Excess salivation. 
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Properties of vatham: 
           1.Helps in respiration                                                 
           2.To activate the body,mind and the intellect. 
           3.To activate the fourteen natural reflexes. 
           4. To activate the seven physical constituents in junctional co-ordination. 
           5.To strengthen  the five sense organs. 
  Qualities of vatham: 
         1.spreading 
         2.dryness 
         3.changing its place quickly 
         4.subtle 
RELATION WITH TASTE 
 The tastes, which increase „Vatham‟ are sour and astringent. 
 ‘GspJtH tpQ;Rq;fwp ahw;G+hpf; Fk;thjk; 
   xspAtH ifg;Ngwpy; gpj;JrPWk; - fpspnkhopNa 
   fhHg;gpdpg;G tpQ;rpw;fgk; tpQ;RQ; rl;bujr; 
   Nrug; GzH NehaZfhNj‛    -§¿¡ö ¿¡¼ø 
 
 The tastes, which neutralizes Vatham, are Sweet, Sour and Salt. 
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RELATION WITH FIVE ELEMENTS: 
Vatham       - Air + Sky. 
 The six tastes and their constituent elements are as follows. 
 1. Sweet   =  Earth + Water   
 2. Sour              =         Earth + Fire 
 3. Salt   =        Water + Fire 
 4. Bitter =        Air + Sky 
 5. Pungent =        Air + Fire 
 6. Astringent    =        Earth + Air 
DESCRIPTION OF VATHAM: 
The siddha classical texts divide the general principles of Vatham into ten subsidiary forms 
that differ from one another by their localizion in the body (Anatomical) and by their particular 
functions (Physioloical). They are 
1. PRAANAN : (Heart Centre) 
  It maintains the action of the heart, the functioning of the mental faculties of perception and 
concentrations and also cares for the arteries, veins and nerves. It regulates the respiration and 
digestion. It is otherwise called as “Uyirkkaal”. 
2. ABAANAN (Moolaadharam Centre) 
 It controls the excretion. It is focussed in the lower part of the gut and also occupies the sites 
in the bladder and genitals. It has a tendency to travel downwards. It moves in the whole Genito 
Urinary Tract and regulates the defaecation, micturition, menstruation, parturition and ejaculation. It 
is otherwise termed as “Kezhnokkumkaal”. 
3. VIYAANAN: (Fore head Centre) 
  It helps in the circulation of energy throughout the entire nervous system and the movements 
of various parts of the body. It also transports nutrients and blood throughout the entire body. It is also 
known as “Paravukaal.” 
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4. UDHAANAN: (Throat Centre) 
 It controls speech and breathing. It is also responsible for the physiological reflex actions like 
vomiting, hiccup, cough, etc., It has the tendency to travel upwards. It is otherwise named as 
“Melnokkukaal.” 
5. SAMAANAN: (Navel Centre) 
 It corresponds to the solar plexus in the navel region and controls digestion. It selects the 
useful substances from the swallowed food and supplies them to the whole body. It balances the other 
„Vayus” it is also called “Nadukkaal.” 
 
6. NAAGAN: 
 It is responsible for the intelligence of an individual, winking, singing and pilo erection. 
 
7. KOORMAN: 
 It is responsible for yawning, closing of mouth (immovable of lower jaw) winking, shedding 
of tears, vision and opening of the eyes. 
8. KIRUGARAN: 
 It is responsible for salivation and nasal secretion. It helps in digestion and meditation. It 
produces cough and sneeze. 
 
9. DHEVATHATHAN: 
 It is responsible for laziness, lassitude, to quarreling arguing, begging and also for much 
anger. It helps movements of the eyeball in various directions and is present in genital and anal 
region. 
 
10. THANANJEYAN: 
 It is present in nose and responsible for swelling of the body and tinnitus. It leaves from the 
body by blowing up the cranium only on the third day after death. 
10 
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FEATURES OF INCREASED OF VATHAM: 
                  1.person is physically weak emaciated,dark in complextion.                  
                  2.Desired towards hot food stuffs 
                  3Presence of tremors 
                  4.Distended abdomen 
                 5.Constipation 
                6.Reduction in strength 
                7.Insomnia  
                8Diminished activities of five sense organs 
                9.Blabbering speech 
                10. Vertigo 
                11.Loss of perseverance. 
FEATURES OF DECREASED VATHAM 
            1.Body pain 
            2.feeble voice 
            3.decreased activities 
            4.dull mental power 
            5.Episodes of syncope 
         
¯½×Å¨¸¸û (Diet which induce vatham) 
A. Quotes under Sababathi Kaiyedu : 
                "ÅÇ¢ ¾Õ ¸¡ö¸¢ÆíÌ Å¨ÃÅ¢Ä¡ ¾Â¢Äø §¸¡¨Æ 
                 ÒÇ¢ ¾Â¢÷ §À¡ýÁ¢ÌìÌ Ó¨ÈÂ¢Ä¡ ×ñÊ §¸¡¼ø 
                 ÌÇ¢÷¾Õ ÅÇ¢Â¢ü §È¸í ÌÉ¢ôÒÈ ×ÄÅø ¦ÀñÊ÷ 
                 ÌÇ¢¾Õ ÁÂì¸õ ¦Àü§È¡÷ ¸Ê¦ºÂø ¸ÕÅ¢Â¡Áø." 
-ºÀ¡À¾¢ ¨¸§ÂÎ 
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According to Sababathi Kaiyedu, increased intake of tubers, increased exposure to 
wind, living in higher altitudes, increased sexual desire, increased exposure to chill weather 
will aggravate Vali diseases. 
. Quotes under Pararasa sekaram, 
              "¦¾¡Æ¢ø ¦ÀÚ ¨¸ôÒì¸¡÷ò¾ø ÐÅ÷ò¾ø Å¢ïÍ¸¢Ûï§º¡Úõ 
                À¨ÆÂ¾¡õ ÅÃÌ Áü¨Èô ¨Àó¾¢¨ÉÂÕó¾¢É¡Öõ 
                ±Æ¢ø ¦ÀÈô À¸ÖÈí¸¢ þÃÅ¢É¢ÖÈí¸¡¾¡Öõ 
                Á¨Æ ¿¢¸¡ ÌÆÄ¢É¡§Ä Å¡¾í§¸¡ À¢ìÌí¸¡§½. 
- ÀÃÃ¡º §º¸Ãõ  
According to Pararasa Sekeram, increased intake of bitter taste, astringents, sour 
tastes, increased intake of old cooked rice, intake of grains, day slumber and staying back at 
night will increase Vali. 
  SEASONAL VARIATIONS OF VATHAM: 
                                    Vatham aggravates in its own place in summer,influences other humors in 
monsoon season and is normal in spring. 
                                 In summer due to seasonal variations all the useful plants and human body gets 
dry.the vatham as such though it should have a different state of growth due to its own heat.  Vatha 
kuttram attains thannilai valarchi (mild derangement) during mudhuvenil kaalam and vetrunilai 
valarchi (much derangement) during  Kaar kaalam 
THINAIGAL: 
 Nilam is classified into five types. They are, 
1. Kurinji   :             Mountain and its surroundings. Kabanoigal  
and liver diseases are common 
2. Mullai   :            Forest and its surroundings, pitha noigal, vatha   
                                            noigal, liver diseases are common 
3. Marutham       :           Field and its surroundings safest place to    
                                          maintain good health. 
4. Neidhal   :          Sea and its surrounding, Vatha diseases and  
                                                       liver enlargements are common. 
5. Paalai   :         Desert and its surroundings, Vatha, Pitha and    
                                           kaba noigal are common. 
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CLASSIFICATION OF VATHA DISEASES: 
 Various siddha texts gives different classifications of Vatha diseases as follows: 
SI.No.                 Name of the siddha Test                                                              Types 
1.                    Agasthiyar -2000                                                                                               80 
vz;gJ thjkhF kpUtifg;gLj;jpf; fhzpd; 
ez;GW miuf;FNkNy ehw;gJ thjkhFk; 
gz;Nruiuf;Ff; fPNo gj;J ehd;fhFnkd;W 
tz;LNrH FoypdhNs thjj;jpd; $WjhNd 
2.                   Agasthiyar Gurunaadi – 235                                                                          84 
3.                    Agasthiyar Rathina Surukkam – 500                                                            84 
                      ‘kw;wNk thjNuhfk; tif vz;gj;J ehNy‛ 
4.                    Ashtaanga Sangiragam                                                                                  85 
5. Bohar Vaidhiyam – 700                                                                                                   80 
‘thr;nrd;w thjk; vz;gJTk; NghFk;’ 
6.  Jeeva Rakshaamirdham                                                                                         80 
7. Noi Naadal and Noi Mudhal Naadal – part II                                                        85 
8. Thanvandhiri Vaidhiyam                                                                                       80 
9. Theraiyar Vaagadam                                                                                              81 
10. Yogi Vaidhya Sindhaamani Perunool – 800                                                             80 
‘vd;dNt thjkJ vz;gjhFk;‛ 
11. Yogai Vaidhya Sindhaamani Perunool -800                                                           84 
‘Mkg;gh thjk; nkz;gj;J ehY 
mjDila Fzh Fzq;f ylq;fyhf’ 
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CLINICAL FEATURES: 
 The signs and symptoms of Vatha diseases have been Mentioned  in various  siddha classical 
text books they are as follows Agasthiyar Naadi: 
 ‘nrhy;yNt thj kJ kPwpw;why; 
  NrhHtile;j thA tpdhy; Njfnkq;Fk; 
  Nky;y iffhy; mrjp Az;lhFk; 
  Nka;Klq;Fk; epkpunthz;zhj; jpkpH cz;lhFk;‛ 
        - mfj;jpaH ehb 
1. Weakness of the limbs 
2. Sluggishness, 
3. Stiffness   
In Agasthiyar - 2000 
 ‘thjj;jpd; FzNknjd;dpy; kaf;Fe;jpnaq;Fk; kyHrptf;Fk; 
  ghjq;FspHe;J rUthq;fk;gw;wp elf;FKfq; fLf;FQ; 
  rPjj;JlNd tapWGz;zhQ; rphpg;gpj; jJe;njwp %r;rhk; 
  Nghjj; jz;zPHjhd; thq;Fk; GfOk; gQ;r FzkhNk‛ 
1. Giddiness 
2. Stabbing pain in the face 
3. Redness of eyes 
4. Peptic Ulcer 
5. Abdominal distension 
6. Joint pain in upper and lower limbs 
7. Numbness in the limbs 
8. Oliguria, 
9. Drowsiness and 
10.  Chillness of body 
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Naadi: 
                         The naadi can be felt one inch below the wrist on the radial side by means of palpation 
and percussion with the tip of the index, middle and ring finger corresponding of Vatham, Pitham and 
Kabam respectively. The three humours exist in the ratio of 1:1/2:1/4 normally. Derangement of this 
ratio leads to various diseases. 
 In cases of vatha diseases the following stages of Naadi are seen 
1. ‘thjnkDk; ehbaJ Njhd;wpy; 
  rPje;jnkhL tapW nghUky; jpul;rpthA 
 rPjKWq; fpuhzp kNfhjuk; ePuhik 
  jpus;thA #iytyp fLg;Gj; jpiu‛ 
- rjfehb 
  2.  ‘nrhy;yNt thjkJ kPwpw;whdhy; 
Nrhh;tile;j thAtpdhy; Njfnkq;Fk; 
 nky;y iffhy; fsrjpAz;lhFk; 
 nka;Klq;f epkpunthz;zhj; jpkpUz;lhFk;‛ 
- mfj;jpah; ehb 
‘fhzg;gh thjkPwpy; fhy;iffs; nghUe;jp NehFk;‛ 
- fhtpa ehb. 
Vatha Pitha Naadi 
 ‚nghUshd thjj;jpy; gpj;jQ; Nrh;e;J 
 fUthd NjfkjpYisr;ry; Nrhk;gy; 
 iffhy; jwpg;…‛ 
 ……………Cd; Fiwjy; 
- rjfehb 
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‘jpUj;jkhk; thjj;NjhNl jPq;nfhL gpj;jQ; Nrhpw; 
 nghUe;Jfs; NjhWk; nehe;J NghjNt gpbf;Fk;‛ 
           - Nehapd; rhuk; 
Vatha Kaba Naadi 
 ‘ghq;fhd thjj;jpy; Nrj;Jk ehb 
  ghprpj;jhy; jpkph;NkT Kisr;ryhFk;‛ 
                                               - rjfehb 
 ‘thjj;jpy; Nrj;Jkkhfpy; typNahL tPf;fKz;lhk;‛ 
        - mfj;jpah; ehb 
Pitha Vatha Naadi 
 ‚gpj;jj;jpy; thjkhfpy; gplhpAq; fhYq; ifAq; 
 Fj;jJ NghNyahFq; FWfp nka;gjWk; gpd;Nd‛ 
        - mfj;jpah; ehb 
Pitha kaba Naadi 
 ‚gpj;jj;jpy; Nrj;Jkkhfpy; tha;FsWkpff 
  gpj;jKnkLj;Jf; nfhl;bg; gplhpapy; NehtjhNk‛ 
- mfj;jpah; ehb 
Kaba Vatha Naadi 
 ‘fz¼¡§Â¡ º¢§Äügdj;jpy; thjehb 
  fye;jpLfpy; tapWnghUky; fdj;jtPffk; 
 cz;lhNyh Xq;fhuQ; rj;jp tpf;fy; 
  cWj;jpul;ir tha;Ttyp rd;dpNjhlk;‛- rjfehb 
  
In all Cegana vatham patients Vatha, Pitha, Thondha naadi was noted.                            
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CEGANA VATHAM 
DEFINITION: 
 Ceganavatham is one of the vatha disease described in „Yugi Vaidhya Sindhamani -
800‟. It is a condition dealing with the involvement of the neck which is identical to the 
cervical spine, comprising the symptoms of pain in the nape of the neck, radiating pain in the 
upper limbs, feeling of heaviness in the body, mental depression, giddiness, burning sensation 
of the eyes and constipation. 
Aetiology: 
 The common aetiological factors for all types of Vatha diseases including 
“Ceganavatham” have been described generally in Yoogi Vaidhya Sindhamani -800, 
Agasthiyar kanma kaandam – 300 and Agastthiyar Gunavagadam 
1. In Agasthiyar Gunavagadam, 
 ‘njhy;iy nra;a ,d;Dk;ntF thjNeha;fs; 
  njhy;Yyfpy; khe;jUf;Ff; fhz;gJz;L 
  vy;iyapy;iy thjNeha; NeHikjd;id 
  ,ay;ghf mwpe;jplNt tpguq; NfNs‛ 
 
‘tptuklh mrjprd;dp %is NehT 
  tphpthd %isaJ kpUJthfp 
  ,tdpjdpy; jplkhfg; NghtjhYk; 
  mg;gNd %j;jpuf; Fz;bf;fha; tpahjpahYk; 
  jtKdptH jPHfhf;if NkfNuhfk; 
  jd;ikAs;s Kj;jz;Lf; nfhb tpahjp 
  mtkpyhg; ghpr euk;gOj;jq;fz;lha; 
  mZFklh thjNeha; MFk;ghNu‛. 
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‘mZFklh khkprj;jpd; tpahjpahYk; 
   mg;gNd #jfj;jpd; ngUf;fhYk; 
   Fzkpy;yh ,urk; tq;fk; jpd;dyhYk; 
        FbnfLj;j thjkJ cz;lhkg;gh‛ 
       -mf];jpah; Fzthflk; 
            1. Diseases of brain 
2. Renal disorders 
3. Sexually transmitted disease 
4. Disease of the vertebral column and spinal cord 
5. Menorrhogia 
6. Taking improperly prepared medicines of mercury and lead will  cause Vatha 
disease. 
In Agasthiyar Kanma kaandam -300, 
 ‘E}nyd;w thjk; te;jtif jhNdJ 
   Jz;ikaha;f; fd;kj;jpd; tifiaf; NfS 
  fhypNy Njhd;wpaJ fLg;g NjJ 
   iffhypy; Klf;fpaJ tPf;fNkJ 
  NfhypNy gLfpd;w tpUl;r khd 
   Foe;ij kue;jd;id ntl;ly;Nky; Njhy;rPty; 
  ehypNy rPtnre;J fhy; Kwpj;jhy; 
   ey;y nfhz;G jio Kwpj;jy; eypj;jy; jhNd‛ 
       -ghly;  56 
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 1. Cutting the trees 
  2.  Breaking the legs of living animals 
  3.  Cutting the branches and leaves of living trees 
In Yoogi Vaidhya Sindhaamani, the following causes are given as follows: 
 ‘jhndd;w frg;NghL Jth;g; Giwg;G 
   rhjfkha; kpQ;RfpYk; rikj;j tz;zk; 
 Mndd;w thwpdJ Grpj;j yhYk; 
  Mfhaj; NjwyJ Fbj;jhyhYk; 
 ghndd;w gfYwf;f kpuhtpopg;G 
  gl;bdpNa kpfTWjy; ghu nka;jy; 
 Njndd;w nkhopahh; Nkw;rpe;ij ahjy; 
  rPf;fpukha; thjkJ nrdpf;Fe; jhNd‛ 
       -ghly; 244 
 ‘gfuNt thjkJ Nfhgpj; jg;Ngh 
  gz;ghf ngz;Nghf kJjhd; nra;apy; 
 efuNt ntFJ}u top elf;fpy; 
  espuhd fhw;WNk gdpNkw; gl;lhy; 
 kpfuNt fha;fs; fdpfpoq;F jd;id 
  kpftUe;jp kPwpNa japh;jhd; nfhz;lhy; 
 KfuNt KJnfYk;ig KWf;fp nehe;J 
  Koq;fhYk; fizf;fhYk; fLg;G cz;lhNk‛ 
                                      - ghly; 285 
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1. Consumption of bitter, astringents and pungent taste foods excessively. 
2. Eating previously cooked food 
3. Drinking polluted water 
4. Changing sleep rhythm 
5. Excessive starvation 
6. Lifting heavy objects 
7. Excessive lust 
8. Walking long distance 
9. Living in chill environment 
10. Excessive consumption of tubers, fruits, curd etc. 
Kanma Vinai is also implicated in the aetiology of Vatham. 
The aetiological factors are as follows, 
 ‘E}nyd;w thjk; te;jtif jhNdJ 
   Jd;ikaha;f; fý ;kj;jpd; tifiaf; Nf§Ç 
 
      fhypNy Njhd;wpaJ fLg;g NjJ 
  iffhypy; Klf;fpaJ tPf;fNkJ 
 NfhypNy gLfpd;w tpUl;r khd 
  Foe;ij kue;jd;id ntl;ly;Nky; Njhy;rPty; 
 ehypNy rPtnre;J fhy; Kwpj;jy; 
  ey;y nfhz;G jio Kwpj;jy; eypj;jy; jhNd‛ 
      -mfj;jpah; fd;k fhñlk; 
  
‘vd;dNt thje;jh ndz;gjhFk; 
  ,fj;jpNy kdpjh;fSf; nfa;AkhW 
 gpd;dNt nghd;djidNa NrhuQ;nra;J 
  nghpNahh;fs; gpuhkziuj; J}ldpj;Jk; 
 td;d Njtr; nrhj;jpy; NrhuQ;nra;J 
25 
 
  khjhgpjh FUit kwe;j Ngh;f;Fk; 
 fd;dNt epe;ij nra;jhy; 
  fhaj;jpw; fye;jpLNk thje;jhNd‛ 
      -A+fp itj;jpa rpe;jhkzp 800 
 ‘Mdhd tud;widNa kjpahkhe;jh; 
  mfjp guNjrpah;fl; fd;d kPahh; 
 Nfhdhd FUnkhopia kwe;j Ngh;fs; 
  nfhiy fsT ngha;fhkq; Fwpj;j Ngh;f;F 
 Cdhd rle;jd;dpy; thjk; te;J 
  cw;gtpf;Fk; Ntjj;jpd; cz;ikjhNd‛ 
      -A+fp itj;jpa rpe;jhkzp 800 
1. Cutting trees, tree bark, tender leaves 
2. Breach of trust 
3. Abusing elderly and priest 
4. Exploitation of charitable properties 
5. Ingratitude with mother, father and guru 
6. Irrespectful attitude with god 
7. Refusing food for destitutes and hermits 
8. Involvement in murder theft, lustfull activities 
In Agasthiyar Gunavagadam the following causes are given, 
          ‘jd;ikas;s Kj;jz;Lf; nfhb tpahjp 
   mtkpyhg; ghpR euk;gOj;jq; fz;lha; 
  mZFklh thjNeha; MFk;ghNu 
   mZFklh khkprj;jpd; tpahjpahYk; 
  mg;gNd #jfj;jpd; ngUf;fhYk; 
   Fzkpy;yh ,urk; tq;fk; jpd;dyhYk; 
  FbnfLj;j thjkJ cz;lhkg;gh‛ 
                                             - mfj;jpah; fd;k fhñ ;lk; 
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1. Diseases of the vertebral column and spinal cord 
2. Diseases of muscles 
3. Menorrhogia 
4. Mercury poisoning 
5. Lead poisoning 
6. Taking im-properly prepared medicines of mercury and lead will  cause Vatha disease. 
CLINICAL FEATURES: 
 The signs and symptoms of Cegana vatham described in Yoogi Vaithya Sinthamani 
and Pararasasekaram by the following verses. 
 ‘NfSNk fOj;jpd; fPoiuf;F NkYk; 
  nfbahd fukpuz;L kpfNt nehe;J 
 thSNk rhPunky;yhq; fdj;jpUf;Fk; 
  thypgh;f;F kdq;fz;Z kaf;fkhFk; 
 VSNk ,uz;L fz;Zk; vhpr;rYz;lhk; 
  Vw;wkha; kye; ¾¡Dk; ,Wfpf; fhZk; 
 NjSNk nfhl;bdJ Nghw; fLf;Fk; 
  Nrfdtsp NehapD}l jPh;ìfe;jhNd‛ 
-A+fp itj;jpa rpe;jhkzp 
 ‘fz;lNjhh; rpfd;d thjq; fOj;jpd; fPoiuf;F NkYk; 
 kpz;lyq; fukpuz;L kpf nehe;J fdj;jpUf;Fk; 
 kz;bNa jpkph;j;Jf; Fj;Jk; typ kpFj;JisTz;lhFk; 
 tz;lkh; FoypdhNs kjpapdhYd;DthNa‛ 
       -guuhrNrfuk; 
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1. Pain in the neck 
2. Radiating pain to the shoulders and upper limb 
3. Heaviness of the body 
4. Mental depression 
5. Giddiness 
6. Burning sensation of the eyes 
7. Constipation 
8. Pain like scorpion sting 
9. Tingling sensation and numbness of the upper limbs. 
En vagai thervu 
‘ ehbg; ghprk; eh epwk; nkhop tpop  
   kyk; %j;jpukpit kUj;JtuhAjk;‛ 
- Njiuah; 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram 
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Naadi: 
Naadi means a vital force responsible for birth (- Agathiyar) 
This vital force is divided into three humours, vatham, pitham and kabam. It can be assessed 
in 10 sites. The commonest site is wrist (over radial artery). 
In ceganavatham, 
Vathapitham 
“¦À¡ÕÇ¡É Å¡¾ò¾¢ø À¢ò¾ï§º÷óÐ 
¨¸¸¡ø ¾È¢ôÒ ¿¡¸ºìÌÁýÉõ”           
                                                      - º¾¸ ¿¡Ê 
                         
Pithavatham 
“À¢ò¾ò¾¢ø Å¡¾Á¡¸¢ø À¢¼¡¢Ôõ ¸¡Öõ ¨¸Ôõ Ìò¾Ð §À¡§Ä Â¡Ìí ÌÚ¸¢ ¦ÁöÀÐÚõ 
À¢ý§É” 
                               
Sparism: 
 By sparisam the temperature of the skin, smoothness of roughness, sweat, dryness, 
hard patches, swelling, abnormal growth, tenderness and nourishment can be felt. 
 In Ceganavatham there was tenderness in the cervical region for all the patients. 
Naa:  
                  Examination of the tongue for its colour, coating dryness, deviation, sensory 
changes, ulcer, conditions of the tooth and gums are noted for all the ceganavatham patients. 
Niram: 
 Colour indicating vatha, pitha, kaba and thridhosas. Yellow or pallor or redness of the 
skin, bluish discolouration of the face, conjunctiva can be noted. There was no specific 
abnormality in niram of ceganavatham cases. 
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Mozhi: 
 Clarity of speech, or any disturbance, loud voice, slurring, crying, talks induced by 
hallucination, undue argument can be made out. 
 Mozhi was normal in all Cegana vatham cases. 
 
Vizhi 
              Testing for acuity of vision, colour, redness, pallor, whiteness, burning sensation, 
excessive lacrimation. 
         Burning sensation of the eyes is present. In aged patients acuity of vision is diminished  
in ceganavatham. 
 
Malam  
             The faeces should be semi- solid without hardness and looseness. 
                  Nature, quantity, colour, odour, froth, presence of blood and mucous are 
noted.Some Patients have constipation. 
 
Moothiram 
            The urine is examined by neerkuri and neikuri.   
              Some patients have oliguria.                                              
In Siddha system of medicine, besides Ennvagai thervugal, a disease can be diagnosed 
by means of Kanmendhiriyam, Gnannendhiriyam Uyir thaathukkal, Udal thaathukkal, 
Thinaigal and Paruva kalangal. 
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1. Gnaanendhiriyam: 
 The five Gnaanendhiriyam are 
1. Mei   - Feels all types of sensations 
2. Vaai  - For taste 
3. Kan   - For vision 
4. Mookku   - For smell 
5. Sevi   - For hearing 
 In ceganavatham patients mei is affected in all cases.In some persons kan is affected 
due to age condition. 
 
Kanmendhiriyam: 
1. Kai    - Works done by the hands 
2. Kaal  - For walking 
3. Vaai  - For speaking 
4. Eruvai  - For defaecation 
5. Karuvai  - For reproduction 
In ceganavatham  kai is affected i.e., pain and numbness along both upper limbs 
presents. 
 
3. Uyir Thaathukkal: 
1. Vatham: 
 In Ceganavatham the following Vayus are affected. 
a) Viyanan: 
     Neck pain, restricted movement of neck, radiating pain in the shoulders, and upper 
limbs, tingling sensation, numbness and giddiness. 
b) Abanan: 
Constipation 
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c) Samanan: 
Indigestion, imbalance in the functions of other vayu. 
d) Udhanan: 
cough 
e) Naagan: 
Sluggishness, mental depression 
f) Devathathan: 
Sleeplessness 
PITHAM: 
 Pitham is located in Urinary bladder, Heart, Head, Umbilicus, pinkalai, Piraana, 
Abdomen, Stomach, Sweat, Blood, Eye and skin. It is classified into five types they are 
1. Anar pitham     :  It digests all the ingested food particles 
2. Ranjaga pitham    :  It gives colour to the blood 
3. Saadhaga pitham     :  It is used to complete the work properly   
                                              what we think in our mind. 
4. Alosaga pitham          :          It gives vision to the eye 
5. Piraasaga pitham       :          It gives colour to the skin. 
Saadhaga pitham is commonly affected in Cegana vatham. 
KABHAM: 
 Kabham is located in Samaanan, Semen, Fat, Bone marrow, Nose, Chest, Nerves, 
Bones, Brain, Large intestine, Stomach and pancreas. It is divided into five types. They are 
1. Avalambagam             :  It controls the other four types of kabham 
2. Kiledhagam                      :      It moistens the food 
3. Podhagam             :  It helps to know the taste 
4. Tharpagam              :  It gives cooling effect to the eyes. 
5. Sandhigam            :  It gives lubrication effect to the joints 
In Cegana Vatham Tharpagam and Sandhigam are affected. 
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Noi Kanippu Vivaadham (Differential Diagnosis) 
 Some other types of Vatha diseases resembling the symptoms of Cegana vatham are 
mentioned. Careful and clear history taking and examination will reveal the diagnosis. They 
are, 
1. Kanda Kiraga Vatham 
2. Kumba Vatham 
3. Paanikamba Vatham 
4. Pei Vatham 
5. Sirakamba Vatham 
 
1. Kanda Kiraga Vatham: 
‘tifahd Fuyjidg; gw;wp nehe;J 
  khh;NghL gplhpjdpy; typAz;lhfp 
Efuhd rhPunky;yhk; nehe;j ohw;wp 
 Ezf;fkha; RthrkJ Gwg;g lhky; 
Kifahd ehthNy %r;R khwp 
 Kfj;jpNy tpah;thfp tpyhNeh Tz;lhk; 
Gifahd td;dj;ijg; gUnfhl;lhJ 
 Ghpa fz;l fpuhfj;jpd; gz;G jhNd‛. 
     -A+fp itj;jpa rpe;jhkzp - 800 
The Clinical features are, 
1. Pain in the throat, chest and occipital region 
2. Anorexia 
3. Breathing through mouth 
4. Backache 
5. Sweating on face  
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2.Kumba Vatham: 
‘eypyNt Njhs;kPJk; fuj;jpd; kPJ 
 eype;J nkj;j thfpNa erTz;lhFk; 
ftpyNt fd;dnkhL eade;jhDkq; 
 fLj;JNk tpWtpWg;G nkhpTk; fhZk; 
JtpyNt Jbg;ghFk; rpuR jd;dpw; 
 Row;wpNa ehgpf;fPo; typA Kz;lhFk; 
mtpyNt mbehf;fp yod;W fhZ 
 kyUNk tUFk;g thje;jhNd‛ 
-A+fp itj;jpa rpe;jhkzp -800. 
The clinical features are, 
             1.Burning pain in shoulder and upper limbs 
            2.Burning sensation in the cheek and eyes 
3.Twitching over the scalp 
4.Pain in the lower abdomen 
5.Glossitis. 
2. Paanikamba Vatham: 
‘khHf;fkha; tha;T kha; nka;ep iwe;J 
 tapWjdpw; grpapyh J}Z kw;W 
ehh;f;fkha; Qhyj;J elf;if aw;W 
 eLf;fkh; ifapuz;Le; jpkpU Kz;lhk; 
Ch;f;fkh Awf;fkpy;yh Jzh;r;rp aw;W 
 cjwpNa rhPuk; vq;F Kyh;e;J fhZk; 
ghh;f;fkha; tha;tpl;L myj;j yhFk; 
 ghzpf; fk;gthj;jpd; ghq;FjhNd‛-A+fp itj;jpa rpe;jhkzp -800 
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The clinical features are, 
1. Anorexia 
2. Tingling sensation and numbness of upperlimbs 
3. Tremor of upper limbs 
4. Sleeplessness and 
5. Dryness all over the body 
3. Peivatham: 
 ‚ngw;wpahk ngUikahq; fhYk; ifAk; 
  ngUtapW neQ;NrhL tpuY %f;Fk; 
 Vw;wpah nkwpfGj;J nkq;Fk; gw;wp 
  Vf;fkha; nehe;; ÐÎõ ngq;Fk; tPq;fp 
 Cw;wpah KzNt jpkph;j; njLj;J 
  cWjpaha;g gpbf;fT nkhzhk yhFe; 
 rj;jpaha; tha;fre;J kaf;f khFe; 
  jhpj;jpl nthz;zhJ Nga; thje; jhNd‛. 
      -A+fp itj;jpa rpe;jhkzp - 800. 
The clinical features are, 
1. pain and swelling in neck, upper and lower limb 
2. Weakness of hand muscles, difficulty in holding things in the hand 
3. Vomiting 
4. Giddiness and 
5. Swelling all over the body. 
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5. Sirakamba Vatham: 
‘jk;gkha; cjpufz;l euk;gpw; Gf;fpj; 
 jiyNahL rhPunkyhe; jhf;fpg; Gf;Fk; 
fk;gkhq; fhjpuz;L kpFTq; Nfsh 
 ifNahL fhypuz;Lk; trf; NflhFk; 
epk;gkha; epidT jhd; fyq;fpf; fhZk; 
 neL %r;Rq; nfhl;lhtp epj;jpiu ahFk; 
rpk;gkha; jiyeLq;fpf; fdg;G Kz;lhQ; 
 rpuf;fk;g thj nkd;Nw nrg;gyhNk‛. 
      -A+fp itj;jpa rpe;jhkzp -800. 
 
The main clinical features are, 
1. Stiffness of neck 
2. Deafness 
3. Yawning 
4. Over sleeping 
5. Tremor in the head and neck 
6. Difficulty in using lower and upper limbs 
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 LINE OF TREATMENT: 
In Siddha system the treatment is mainly based upon the Mukkuttram principle. 
Treatment is not only for perfect cure but also for the prevention of diseases and rejuvenation 
of udal kattukkal. The physician‟s duty is to diagnose the disease, trace the etiology and 
choose proper line of treatment.  
The management of the disease in Siddha is as follows, 
1. Neekkam(treatment) 
2. Niraivu(restoration) 
3. Kaappu(prevention) 
After occurrence of the disease, first it should be treated, restoration should be done 
and recurrence or further complications should be prevented.  
1. NEEKKAM: 
Nekkam is based on,  
 Balancing deranged thodams  to normal equilibrium state. 
 Treating with internal medicine and external medicine. 
 Deranged vatham has to be brought to its normal state by giving purgation. It is 
mentioned in the following verses, 
“Å¢§ÃºÉò¾¡ø Å¡¾õ ¾¡Øõ” 
       -º¢ò¾ ÁÕòÐÅ¡í¸ ÍÕì¸õ 
Purgative: 
Agasthiyar kuzhambu – 130mg given with ginger juice in early morning (for the first 
day only) 
Internal medicine: 
Kariuppu chenduram-260mg bd with honey , for 48 days(.Anuboga vaithiya 
navaneeetham part-3) Pg.no 36,37,2
nd
Edition:2001 
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External medicine: 
             Kunthirika thailam (Pharmacopoeia of hospital of indian medicine  
Pg.no:133,2
nd
edition 1995) 
 
Diet Restrictions: 
 Mustard, sesame oil, pumpkin, garlic, asafoetida, bengal gram, horse gram, sesbania, 
bitter guard, coconut, mango and jack fruit should be avoided by patients with vatha 
diseases.Sour and astringent diet should be avoided as it will increase vatham. 
 
 
“¸ÎÌ ¿üÈ¢Äò ¦¾ñ¦½ö ÜúÀ¡ñ¼í¸û ¸¼¨Ä 
ÅÎÅ¾¡¸¢Â ¦¾íÌÁ¡ ÅÕì¨¸ ¿ü¸¡Âõ 
ÁÊÅ¢Ä¡¾ ¦ÅûÙûÇ¢ ¦¸¡û Ò¨¸Â¢¨Ä ÁÐ¦Àñ 
                            Á¢¼Ú À¡¸§Ä¡ ¼¸ò¾¢ ¿£ì¸¢¼Ä¢îº¡ Àò¾¢Âõ” 
                                                                                     
     - º¢ò¾ ÁÕòÐÅ¡í¸ ÍÕì¸õ 
                 “ÒÇ¢ÐÅ÷ Å¢ïÍ ¸È¢Â¡ø â¡¢ìÌõ Å¡¾õ” 
    - §¿¡ö¿¡¼ø §¿¡öÓ¾ø ¿¡¼ø ¾¢ÃðÎ 
 
2. NIRAIVU: 
The patient is convinced to accept the eventuality of the disease and modification of 
life style. 
                  “´ýÈ¢Â Å¡¾À¢ò¾ ¸ÀÁ¢¨Å ÔÂÃ¡ Åñ½õ 
¿ýÚÚ ¸È¢¸¦ÇøÄ¡õ ¿¡Ù§Á º¨ÁôÀ¡Ã¡öó§¾¡÷ 
¾¢ýÈ¢Î Á¢ÇÌ Áïºû º£Ã¸ ÓÂ÷ó¾ ¸¡Âõ 
¦ÅýÈ¢ ¦¸¡û Íì§¸¡§¼Äõ ¦Åó¾Âõ ¯ûÇ¢ §º÷ò§¾” 
- §¿¡Â¢øÄ¡ ¦¿È¢ 
  To maintain normal level of three humours, pepper, turmeric, cumin seeds, asafoetida, 
dry ginger, cardamom, fenugreek and garlic should be added generously in diet. 
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3. KAAPPU: 
Siddha system prominently projects prevention of diseases. This is attained by the 
following methods, 
1. Maintaining equilibrium of three humors by adopting vaanthi, kazhichal, nasiyam, 
nei muzhukku techniques. 
2. Avoiding stress and strain. 
3. Maintaining good mental health by doing meditation. 
          In Ceganavatham, pain in neck, radiating pain in shoulder, upper limbs, and numbness 
can be reduced by manipulating the following varmam points, 
 Muduchi  
 Kakkattai kaalam 
 Manibanthagam  
 Savvu 
 Kavuli 
Referance: Shanmugam Asan Methodology. 
 
    
Exercises /asanas advised for Cegana vatham : 
1). Neck Bending 
a).Starting Position 
 Sit with both legs straight. 
 Place the palms on the floor by the side of the buttocks 
 Keep the back, neck and head straight 
 Close the eyes 
 This is Dandasana 
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b) Practice 
Stage - I (Forward – Backward movement). 
 Slowly move the head forward and try to touch the chin to chest. 
 Then move the head as far back as comfortable. 
 Try to feel the stretch of the muscles in front and back of the neck and the loosening 
of the spine in the neck. 
 Practice 10 times. 
 Inhale on the backward movement and exhale on the forward movement. 
Stage –II (Bending to Right and Left) 
 Close the eyes and face directly forward. 
 Slowly bend the head to the right and ear coming to the shoulder turning the head or 
lifting the shoulder. 
 Bring the head back to the normal position 
 Then bend in to the left side and try to touch the left ear to the left shoulder in the 
same fashion. Lift the head to the centre 
 This is one round. Practice 10 rounds 
 Inhale on the upward movement and exhale on the downward movement. 
Stage –III (Turing the head to Right and Left) 
 Keep the head upright and eyes closed. 
 Gently turn the head to the right so that the chin is in line with the  
shoulder. 
 Slowly turn the head to the left through the centre till the chin is in  
line with the shoulder. Bring the head to centre. 
 This is one round. Practice 10 rounds. 
 Inhale while turning to the front. Exhale while turning to sides. 
c) Note : (For all the three stages) 
 Move the head as far as comfortable. Do not strain 
 Keep the shoulders relaxed and unmoved 
 Feel the release of tension in the neck muscles and the shoulder muscles. 
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Contra - Indications 
 Should not be performed extreme positions by elderly people 
 Cervical spondylosis cases to avoid during acute pain 
Benefits 
 Theses asanas release tension (accumulated especially after prolonged work at a 
desk), and also heaviness and stiffness in the head, neck and shoulder region. 
Additional points to Note 
 Make the movements cautiously and slowly when there is Neck pain. 
 Practice them with normal breathing 
 Hold the neck in the final positions for a few moments 
 If you have pain at any stage, stop in that position for a while. As you bring your 
complete awareness to the area of pain, start breathing consciously and deeply, then 
continue the movement. 
 It can be practiced even while standing in Tadasana or sitting on a  
chair, or in Vajrasana. 
2.Neck Rotation 
a) Starting Position 
 Sit in Dandasana 
b) Practice 
Stage –I (Half Rotation) 
 Relax the head bending forward 
 Bring the right ear to the right shoulder in a circular way. 
 Bring the left ear to the left shoulder in a circular bending the head  
 forward. 
 Now relax the head forward again in a circular way and finally lift the head to normal 
position. This is one round. 
 Repeat 10 rounds clockwise and 10 rounds anti – clockwise with breathing. 
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Stage -11 (Full Rotation) 
 Relax the head forward trying to touch the chin to the chest. 
 Slowly rotate the head in as large a circle as possible, keeping the chin tucked in. 
 Practice 10 rounds clockwise and 10 rounds anti- clockwise while breathing normally. 
 
 
1. Note 
 In both cases (Half and full Rotations) you may take about one minute or even longer 
for one cycle. Allow normal breathing without trying to synchronise the breath & 
neck movements. 
 In full rotation, try to make the circle bigger and bigger. 
 Keep the eyes closed throughout the practice 
 Feel the shifting stretch around the neck and loosening up of the  
 joints and muscles of the neck. 
 Practice full rotation very carefully. Start with half rotation and  
then go for full rotation. 
 If there is pain in any position, hold the head in that position.  
Become aware of the point or area of pain and start breathing consciously and deeply. 
This will relieve you of pain and then you can continue. 
 Can be practiced in cross – legged sitting position, or sitting on a  
 chair. 
Contra - indications 
 Should be performed carefully by elderly people 
 Cervical spondylosis cases to avoid during acute pain 
Benefits 
 Theses practices release tension (accumulated especially after  
prolonged work at a desk), and also heaviness and stiffness in the head, neck and 
shoulder region. 
 
42 
 
IV) Thokkanam (Massage Theraphy) 
 Thokkanam is systemic manupulation of the body parts by the physician. 
 ‘njhf;fzj;jpdhypuj;jk; Njhy; Cdpit fl;F 
  kpf;f rTf;fpak; rkPuDk; Nghk; - nka;f;fjpf 
  Gl;bAwf;fk; Gzh;r;rp apit fjpf;Fk; 
  gl;l miyr;ryWk; ghh;‛ 
  -gjhh;j;j Fzrpe;jhkzp 
Thokkanam acts directly on vascular system, nervous sytem, lymphatic system and 
musculo – skeletal system and brings the affected body to normal condition physically and 
mentally. It also gives a sense of well being, gives a good sleep and increases vital power and 
also provides relaxation. 
 Vatha diseases are relieved specially by thokkanam. The following verse reveals that, 
 ‘kj;jdkhfpa njhf;fzj;jpd; nray; tFg;ghNd - rjh 
  epj;jKk; thjk; gpzpj;j gpzpg;ig nrFg;NgNd‛.  
       - Njiuah; kfh fhpry; 
 Among the nine types of Thokkanam, only two must be done in the case of Sagana vatham. 
 1. Pidiththal (Effleurage and petriassage) 
 2. Izhuththal (Traction) 
 In pidiththal, Strokes are slided smoothly and by kneeing and in Izhuththal, traction like 
method is performed. 
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MODERN ASPECT 
 
THE ANATOMY 
The Vertebral column: 
The Vertebral column which lodges and protects the spinal cord, its meninges and the 
continuation of the central nervous system lies in the dorsum of the body. It forms a pillar which 
contains 33 segments and lengths about 70 cm in an average male and 60 cm in a female. It supports 
the body weight and transmits it to the ground through the lower limbs. 
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THE CERVICAL VERTEBRAE  
The cervical vertebrae are the smallest of the movable vertebrae. The cervical 
segment of vertebral column contains 7 vertebrae which include 3 atypical and 4 typical 
vertebrae.  
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TYPICAL CERVICAL VERTEBRA 
Parts of the typical Cervical Vertebra: 
1. Body 
2. Vertebral Foramen      
3. Vertebral Arch 
 i. Pedicles     
ii. Laminae  
iii. Articular facets  
iv. Transverse processes  
v.  Spinous process 
vi. Foramen Transversarium  
 
 
 
 
THE ATYPICAL CERVICAL VERTEBRAE:  
 The following three are the atypical cervical vertebrae: 
1. Atlas (first cervical vertebra) 
2. The Axis (second) 
3. The seventh cervical vertebrae 
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JOINTS OF THE VERTEBRAL COLUMN   
                 The vertebrae from the 2
nd
 cervical to 1
st
  sacral are articulated to  one 
another by a  series  of  cartilaginous  joints  between vertebral bodies and a series of  
synovial  joints between the vertebral arches. The vertebral bodies are united by 
anterior posterior longitudinal ligaments and by intervertebral disc of fibrocartilage.  
        
JOINTS OF THE CERVICAL SPINE  
1. Atlanto-occipital Joint:  
Flexion, extension and slight lateral flexion are possible movements of this joint.  
2. Atlanto-axial Joints:  
Consists of a pair of lateral atlanto-axial joints and median atlanto-axial joint.    
Movement - Rotatory movements around a vertical axis  
 
3. The Uncovertebral (Luschka‟s) joints: 
Luschka‟s joints are not true synovial joints.  
Luschka‟s joints are important, because  
 They are the commonest sites of osteophyte formation. The osteophytes may 
compress the cervical nerves.  
 Vertebral artery lies lateral to the joints intruding on the canal and can cause 
distortion of the artery and leads to Vertebro basilar insufficiency in atherosclerotic 
vessels.  
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 Typical Cervical Vertebrae: 
1.  Body: 
 It is small and oval.  It‟s superior surface is concave transversely with upward 
projecting lips on each side and its inferior surface is saddle shaped, convex from side to 
side and concave from before backwards. 
2.  Vertebral Foramen: 
 It is larger than the body and triangular in shape. 
3.  Vertebral Arch: 
i)  Pedicles: 
 These are short and directed outwards and backwards from the middle of postero 
lateral parts of the body and they form the postero medial wall of the foramen 
transversarium. 
ii)  Laminae: 
 These are long and narrow, being thinner above than below. 
iii)  Articular Facets: 
 The superior and inferior articular processes form the articular pillars which project 
laterally at the junction of the pedicle and the lamina.  The superior articular facets are flat 
and directed backwards and upwards.  The inferior articular facets are also flat but 
directed forwards and downwards. 
iv)  The Spine: 
 It is short and bifid. 
Foramen Transversarium: 
 It transmits the vertebral artery, vertebral veins and sympathetic plexus. 
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The Atypical Cervical Vertebrae: 
1.  Atlas: 
 It is the first cervical vertebrae which lodges the skull.  It has no body and spine.  It 
has anterior and posterior arch, right and left lateral masses and transverse processes. 
 The anterior arch bears an anterior tubercle in the anterior aspect.  Its posterior aspect 
bears an oval facet which articulates with dens.  The posterior surface of the posterior 
arch has a median posterior tubercle.  The two lateral masses bear an elongated superior 
articular facet for atlanto-occipital joint and an inferior articular facet for atlanto axial 
joint. 
2.  The Axis: 
 The Axis has a peg like projection in its upper part of the body known as the dens (or) 
odontoid process.  It has circular facet anteriorly articulating with atlas.  There are two 
articular facets on either side of the dens on the upper surface of the body.  The laminae 
are thick.  The spine is large and bifid.  The transverse process is small and possesses a 
tubercle in its tip. 
 3.  The Seventh Cervical Vertebrae: 
 It is also known as the “Vertebral Prominent”.  The transverse process does not 
posses anterior tubercle.  The foramen transversarium is small (or) absent.  It transmits 
accessory vertebral vein only.  The spine is long. 
Movements of the Vertebral Column: 
The greater thickness of the discs in the cervical and lumbar regions as compared with the 
thoracic region is associated with the greater individual range of movements occurring in 
those regions. 
Flexion (or) forward bending, extension (or) backward bending, lateral flexion and 
rotation are possible in vertebral column. 
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NORMAL X-RAY 
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MOVEMENTS: 
MOVEMENTS MUSCLES NERVE SUPPLY 
Flexion  Sternocleidomastoid   Accessory ventral rami of  cervical spinal 
nerves C2, C3, C4  
Longus Coli  Cervical Ventral rami C2 – C6  
Longus Capitis Cervical  Ventral rami C1 – C3  
Rectus Capitis Anterior   C1 Ventral ramus  
Splenius Cervicis  and Capitis,   
Erector Spinae  
Dorsal cervical nerve  
Extension  
 
Rectus capitis posterior major 
and minor  
Dorsal rami C1 
 Obliques capitis superior  C1 – Dorsal ramus 
 Trapezius Accessory 
 Sternocleido mastoid Accessory, Ventral rami  of Cervical 
spinal nerves  C2 , C3, C4  
Lateral flexion and 
rotation 
Scalene Cervical Ventral rami C3 – C8 
 Longus Coli  Cervical Ventral rami C3 – C8 
 Levator Scapulae Cervical Ventral rami C3 C4, C5 
 Rectus Capitis  C1 – Ventral ramus 
 Splenius  Cervical dorsal ramus  
 Longismus obliques capitis 
superior and inferior 
C1 Dorsal ramus  
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NERVE AND ROOT SUPPLY OF MUSCLES 
UPPER LIMB         SPINAL ROOT 
SPINAL ACCESSORY NERVE 
Trapezius        C3C4 
BRACHIAL PLEXUS 
Rhomboides                  C4C5 
Serratus anterior      C5C6C7 
Pectoralis Major 
 Clavicular                 C5C6 
Sternal                 C6C7C8 
Supra Spinatus                 C5C6 
Infra Spinatus                 C5C6 
Latissimus Dorsi                C6C7C8 
Teres Major                 C5C6C7 
Axillary Nerve 
Deltoid                  C5C6 
Musculo Cutaneous Nerves 
 Biceps                   C5C6 
Brachialis                 C5C6 
Radial Nerve 
 Triceps 
 Lateral Head                         C6C7C8 
 
Medial Head 
 Brachio radialis                     C5C6 
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 Extensor Carpi radialis longus                 C5C6 
Posterior Interosseous Nerve 
 Supinator       C6C7 
 Extensor Carpi Ulnaris                 C7C8 
 Externsor digitorum                C7C8 
 Abductor pollicis Longus                  C7C8 
Extensor pollicis Longus              C7C8 
Extensor pollicis brevis                C7C8 
Extensor indicis                C7C8 
Median Nerve 
 Pronator teres                 C6C7 
 Flexor Carpi radialis                C6C7 
 Flexor digitorum superficialis               C7C8T1 
 Abductor pollicis brevis                C8T1 
 Flexor pollicis brevis                C8T1 
 Opponens pollicis               C8T1 
 Lumbricals I & II               C8T1 
Anterior Interosseous Nerve 
 Flexor digitorum profundus I & II              C7C8 
 Flexor pollicis longus                C7C8 
Ulnar Nerve 
 Flexor carpi ulnaris               C7C8T1 
 Flexor digitorum profounds III & IV             C7C8 
 Hypothenar muscle                  C8T1 
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 Abductor pollicis                 C8T1 
 Flexor pollicis brevis                 C8T1 
 Palmar interossei                 C8T1 
 Dorsal interossei                 C8T1 
 Lumbricals III &IV                 C8T1 
 
 
 
CERVICAL SPONDYLOSIS 
 Nomenclature 
 Cervic(o)  - Latin Word, Means neck. 
 Spondylo  - Greek Word, Means Vertebra 
 Osi     -  Condition 
  Is a type of pathological condition in cervical vertebra. 
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DEFINITION:  
 Cervical spondylosis is defined as arthrosis of posterior intervertebral joints in the 
cervical vertebrae , caused by degeneration of intervertebral discs which fragment 
and collapse with normal ageing
 
with subsequent changes in the bones and soft 
tissues. 
 Location: 
o Generally the C5 & C6 roots are most commonly affected by cervical 
Spondylosis as a result of the increased mobility at the C5-C6 & C6-C7 levels.  
o Acute disc lesions are seen most often at the C7 level followed by C6 
o High level cervical disc involvement are very uncommon 
o T1 Radiculopathy is caused by the result of involvement by Pancoast tumor in the 
apical pleura. 
 
 
 
 
 
 
55 
 
AETIOLOGY  
I. Degenerative Causes  
They are primary and secondary  
 Primary - Senility, genetic factors, metabolic factors and manual labour   
 Secondary- Osteoarthritis, rheumatoid arthritis, metastatic carcinoma or 
lymphomas of the spine and TB spine.  
II. Injury  
 Automobile accidents with “Whiplash” injury, athletic injury  
 Sudden jerks on the arms during fall down  
 Previous injury with fracture or disc prolapse  
 
III. Occupational causes  
The physical discomfort, which arises through an occupation is occupational stress. 
The physical strain, intensity of work and duration of working hours all constitutes the 
occupational strain.   
IV. Hereditary factors  
Congenital narrowing of the cervical spinal canal (myelopathy is often seen when 
canal‟s sagital diameter is 12mm or less). Segmental defects – Hemi vertebra, fused vertebra.  
V. Acquired narrowing of cervical spinal canal due to Osteophytes  
This occurs due to the following reasons like, 
Ossified Posterior Longitudinal Ligament (OPLL).  
Facet joint hypertrophy (results in foraminal stenosis and compression of root of 
radicular artery). 
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Hypertrophied Ligamentum Flavum (Compress the cord during extension). 
Outgrowths of bone sometimes occur with aging. Intervertebral disc  protrusions  are  
commonest  in  the  Cervical  region  which  is  due  to degeneration of the  inter vertebral 
disc. If this involves several discs with osteoarthrosis , this is liable to interfere with blood 
supply of the cord  leading  to further damage.   
 
PATHOLOGY: 
  Cervical spondylosis is very common and histological evidence of 
degenerative changes is present in virtually even present over the age of 70. 
Osteophytes may form posteriorly with osteoarthritis of the apophyseal joints and 
also anteriorly in relation to degenerative changes  and narrowing of the 
intervertebral disc with sclerosis of the bony end plates. The osteophytes may 
cause symptoms by encroaching on the spinal nerve foramina or in the cervical 
region on the vertebral artery foramen. In the cervical region intermittent pain and 
discomfort may be followed eventually by stiffness and limitation of movements. 
  At first injury to chondrocytes occur and therefore, the maintenance of 
articular cartilage imparirs and if this continues loss or decreased synthesis of 
proteoglycans occurs. Another theory is with decades of weight bearing,there is 
remodeling of the articular cartilage with redistribution of load stress chondrocyte 
intergrity mainly depends on normal level of loads. Chondrocyte degeneration or 
injury occurs as a result of overloading or under loading and loss of proteoglycans 
has been contributed by alteration of subsynovial weave of collagen fibres. 
 Chondrocyte injury causes release of degradative enzymes particularly proteoglycanase 
and cathepsins. At the same time the capacity of synthesis of proteoglycans diminished due to 
age and chondrocyte injury. Injury causes alteration in collagens and there occurs change 
from type II to type I. The Type I collagen withstands minimally to stress. All this causes 
cartilage injury. 
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Morphology: 
 The early changes appear to be erosion and flaking of cartilaginous surface with 
advance of the disease clefts appear within the cartilage at right angles to the surface. The 
clefts may penetrate to sub chondral bone producing cartilage fibrillation. Sometimes 
fragments of cartilage break off to create joint mice. This cartilage injury results in growth of 
blood vessels from the subchondral bone into articular cartilage. These occur focal cystic 
areas within the subchondral bone and they contain fibrous tissues. The further progression of 
the disease, leads to deep or complete erosion of cartilage layer. 
 The disappeared and leaves denuded subchondral bone which is dense smooth, 
glistening to ivory. This is known as Eburnation. The loss of cartilage accounts for the so 
called thinning of joint space, which is seen radiographically. 
 Osteophytes developing from margins of articular cartilage may sometime extend to 
the ligamentous and capsular attachment and is called “bone spurs” of osteoarthritis. When 
large spurs project from opposing bones come into contact causing pain and limitations to 
movements. These bony spurs accounts for nodules known as “Heberden‟s nodes.” 
Intervertebral disc prolapse 
 This is common cause of compression of the nerve roots and more rarely causes 
compression of the cord. The inter vertebral disc consists of a central module semifluid 
matrix, the nucleus pulposus, surrounded by a ring of fibrous tissue and fibrocartilage, the 
annulus fibrosus. The posterior segment of the annulus is thinner and less firmly attatched to 
bone and following unusual stress part of the martix of the nucleus pulposus may hereniate 
through it. The lesion often termed “Slipped disc” may occur after injury and symptoms 
depend on the direction taken by the extruded matrix. It usually tracks posterior laterally 
around the expansion of the posterior longitudinal ligament, appearing at one side and 
compressing the spinal nerve in the intervertebral foramen. Disc protrusion occurs, 
principally in C5 –C6 and C6 – C7 discs. 
 A single mid line posterior disc protrusion may compress the spinal cord, obstructing 
the anterior spinal artery, and is a rare but important cause of permanent damage to the spinal 
cord if surgical treatment is delayed. 
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 When there are several protrusions, the resulting compression may impair the 
circulation and variable effects of ischaemia of the spinal cord may result. There may be 
cavitation of the cord and loss of nerve cells in the severely affected areas, the condition 
being known as “Spondylotic myelopathy”. Nerve root compression is common than 
myelopathy. 
Common signs and symptoms: 
1.Pain in the neck, radiating to the shoulder blades, top of the shoulders, upper arms and 
hands or back of the head. 
2. Crunching sounds with movement of the neck or shoulder muscles. 
3.Numbness and tingling sensation in the arms, hands and fingers, some loss of feeling in     
the hands and impairment of reflexes, 
4.Muscle weakness and deterioration. 
5.Neck stiffness. 
6.Head ache. 
7.Dizziness and unsteady gait. 
8.With advanced stages, loss of bladder control and leg weakness. 
 
Neural compression syndrome: 
Most of the patients suffer from either radiculopathy (or) myelopathy.  They may be 
acute, sub acute or chronic. 
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SUMMARY OF THE SITE OF LESION  
Cervical spondylosis can produce cord compression (upper motor neuron signs) or 
root compressions (lower motor neuron signs) 
C5 
 
Motor Raised elbows (axillary n.)  
Reflex   Biceps  (musculocutaneous n.)  
Sensory Upper, Lateral arm, near/over deltoid (axillary  n. )  
Pain Upper, Lateral arm, never below elbow  
C6 Motor Elbow supination (radial  n.)  / pronation  (median n.) 
Reflex   Brachioradialis (radial n.) 
Sensory Lateral forearm (musculocutaneous  n.)  
Pain Lateral forearm, possibly  to  thumb 
C7 Motor Elbow extension (radial n.) 
Reflex   Triceps (radial n.)  
Sensory Over triceps, mid -forearm and middle finger  
Pain Deep pain in triceps, front and back  of  forearm  and to  
middle finger  
C8 
 
Motor Thumb  index pinch (ant interosseus n. off median n. at the elbow) 
Sensory Medial forearm (antebrachial cutaneous n.)  
Pain Medial forearm, into the 2 medial fingers 
T1 Motor Finger abduction  (ulnar n) 
Sensory Medial arm (brachial cutaneous n)  
Pain Deep pain in axilla and shoulder / pain radiating to arm. 
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Investigation: 
1. Plain X- ray of cervical spine, including A.P.. Lateral and oblique views 
show 
 - Disc space narrowing 
 - Osteophyte formation 
 - Degeneration in facet and uncovertebral joints 
 - Foraminal stenosis (Seen on oblique films) 
 - Central stenosis 
2. Mylogram – May show compression of the spinal cord 
3. C.T Scan (computerized Tomography) 
 - Confirms degenerative changes 
 - May demonstrate posterior osteophytes and disc herniation 
4. MRI (Magnetic Resonance Imaging) 
 - Neural compression 
 - Intrinsic cord changes 
 - Disc degeneration 
5. Examination of CSF: 
 very high protein 
6. Other tests: 
 Nerve conduction studies. 
DIFFERENTIAL DIAGNOSIS  
1. Cervical rib  
2.  Periarthritis shoulder 
3. Syringomyelia  
4. Spinal cord tumors  
5. Carcinomatous infiltration or radiotheraphy 
6. Peripheral nerve lesions (distal ulnar or median nerve)    
7. Motor neuron disease  
61 
 
COMPLICATIONS  
1. Cord compression-Quadriplegia, spastic gait, affecting the bladder.   
2. Nerve root compression – Neurological injury, Brachialgia  
3. VBI (Vertebro basilar insufficiency)  
.Management: 
1. Non – Operative: 
1. Analgesics 
2. Local modalities 
3. Exercise programme and cervical traction. 
2. Operative: 
 Operative treatment should be considered. 
1. In the presence of intractable pain. 
2. where there is evidence of radiculopathy or myelopathy. 
3. Where osteophytes are producing vertebro basilar insufficiency. 
Physiotheraphy: 
 In acute exacerbation of disease affecting the cervical spine, rest may be the initial 
treatment. 
Cervical Collar: 
 Cervical collar is advised to wear as temporary collar (Which is often made from 
Plastazote) for day time to restrict movement, and a soft collar for support at night.  A patient 
who is given a collar should be advised that the restriction in neck movement will alter other 
proprioception, for example he will need to take care in the dark or on entering darkened 
rooms when he may lose his balance.  A patient wearing a collar should not drive because 
judgement of relative distances will be impaired.  In the cases of vertebro basilar 
insufficiency (VBI) cervical collar may be advised to the sufferers according to the severity. 
Cervical Traction: 
 Vertebral traction should be the first choice of pain relief for patients suffering nerve 
root pain.  Intermittent sustained traction is carried out after careful positioning of the 
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involved segmenthas been localized. In such cases the treatment atleast once a day is 
essential, prolonged pain relief will take several days to obtain. 
 Cervical traction provides positive patient response and can relieve the pain 
associated with certain neck disorders.  It applies a stretch to muscles, ligaments and tissue 
components of the cervical spine.  It provides relief by promoting separation of the 
intervertebral joint space, which contains the disc and may reduce a “bulge” or impingement 
of structures within the foramen.  It is no indicated for use in condition of instability such as 
with “whiplash” injury.  It is most commonly used when the patient is in the supine position 
(lying on the back with knees bent at a 45  angle) with the neck placed at 20  - 30  of flexion 
(forward tilt).  Using traction in this position helps stretch the posterior neck muscles and 
facilitate intervertebral separation, which relieves pressure that may be pinching nerves, 
therefore, promoting muscle relaxation and intervertebral separation. 
Exercise for Cervical Spondylosis: 
 To start with, exercises should be done sitting and the feet must rest on the floor or 
stool.  Exercises should be done in front of a mirror, in order to get correct movements. 
1. Static Head & Neck Exercise:  (no movement take place, muscles are strengthened) 
 Place your hand on your forehead, with the hand stop forehead from bending forwards – 3 
times increase to 5. 
 Place the hand behind the head, with yours hand stop the head from bending backwards -
3 times increases to 5. 
 Place right hand on right cheek and ear, stop the head from bending on right side – 3 
times increases to 5. 
 Place the left hand on left cheek and left ear, stop the head from bending on left side – 3 
times increase to 5. 
 Place right hand on right lower jaw stop the head from turning to right side -3 times 
increase 5. 
 Place left hand on left lower jaw, stop the head from turning to the left side 3 times 
increase to 5. 
 In order words give resistance with your hands to work the muscles as much as 
possible.  Continue the above static exercises.  If these suit, otherwise discontinue the static 
exercises. 
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2. Excercise for Shoulder: 
 Arms lift forwards, up and down – 5 times increase to 7-10 times 
 Arms lift sideways, up and down – 5 times, increase to 7 -10 times 
 Arms lift forwards, part and together – 5 times increase to 7 -10 times  
 Fingers on the shoulder with elbows bent: 
 Elbows circling forwards, upwards, backwards & downwards – 5 times increased 
to 7 – 10 times 
 Elbows circling backwards, upwards, forwards & downwards – 5 times increase 7 
-10 times 
 Right hand meeting left hand at the back (Right hand to be carried above the right 
shoulder, left hand carried from left side at the back and try to touch the right hand) 
Repeat the left hand carried above the left shoulder and the right hand turned in, carried 
from the side of trunk -3 times each side, increase to 5 -7 times. 
 
PATIENT EDUCATION: 
1. Do not getting look down to read (or do any other work). Bring the reading materials 
to the eye level. 
2. All neck movements can be performed with practice, by using trunk movements. 
3. Use a low level pillow supporting the head and neck; pillow line upto the shoulders 
level. Otherwise not to be encouraged. 
Prevention: 
1. Avoid sitting in cramped position. 
2. Sleep without pillows 
3. Use a soft fabric collar or towel to support the neck. 
4. Wear protective headgear for contact sports 
5. Use seat belts in vehicles . 
Prognosis: 
 The assessment of prognosis is attained by studying the pathological condition of the 
spinal cord and nerve roots. Improvement can be felt with some of the reversible changes 
with drug treatment. In complicated cases improvement is not possible. The signs and 
symptoms due to myelopathy are unmanageable. Long history of suffering multiple disc 
lesions and in severe compression of spinal cord may adversely affect the prognosis. 
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PROPERTIES OF TRIAL DRUG 
 
±ÕìÌ 
:  
§ÅÚ ¦ÀÂ÷:«Õì¸ý 
Botanical name: Calotrophis gigantean.Linn 
Family:asclepediaceae 
Eng.name:madar 
Action:   
             Anthelmentic 
             Alternative 
             Laxative 
             Stimulant 
Organoleptic characters: 
  Taste   : Bitter, pungent 
Potency  : Hot 
Pirivu   : pungent 
Ì½õ 
       ±Ä¢Å¢¼õ Ìð¼¨ÁÂ §ÁÚ ¸¢ÕÁ¢ 
       ÅÄ¢Ý¨Ä Å¡ÔÅ¢¼ Áó¾õ-ÁÄÀó¾õ 
       ±øÄ¡ Á¸Ö ¦ÁÕì¸¢¨Ä¨Âì¸ñ¼¡ø 
       Å¢øÄ¡÷ Ñ¾§Ä Å¢ÇõÒ.-    
                                                    Ì½À¡¼õ ãÄ¢¨¸ 
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    Phytochemicals: 
Calotropin,leucocyanidin,calophyllolide posses anti -inflammatory action.The ethanolic 
extract of  calotropis gigantea(leaf) possess anti-inflammatory activity against carragenan 
induced paw oedoma.  
In ayurveda  the leaves of C. gigantea are used in the treatment of paralysis, swellings and 
intermittent fevers. Leaves of  C. gigantea  were reported to carry antioxidant activity.  
 
¸È¢ÔôÒ 
English name:sodium chloride 
 
Ì½õ 
               «Çò¾¢Ö¨È ¿øÖô ÀÉø Å¡¾õ Á¡üÚí 
        ¸ÇòÐ§¿¡ö ¾ý¨Éì ¸¨ÇÔõ-¸¢¨Çò¾¸À 
        ¬¸¨¼Â Åø¨Ä§¿¡ö «‰¼ÌýÁÓõ §À¡ìÌí 
        ¸¡º¢É¢Ôû Á¡§¾ ¸ÆÚ 
                               Ì½À¡¼õ ¾¡Ð º£Å ÅÌôÒ 
Action: 
           Laxative 
           Emetic  
           Anodyne  
Organoleptic characters: 
  Taste   : Salt 
             Pirivu   : Salt 
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CHEMICAL PROPERTIES 
Characters 
White, crystalline powder or colorless crystals. 
Freely soluble in water, cally insoluble in 
ethanol. 
Acidity or Alkalinity Comply with the standard 
Appearance of solution Clear and colorless 
Iodides No blue color is abserved 
Bromides Comply with the standard 
Ferro cyanides Comply with the standard 
Nitrites ≤0.01 
Phosphates ≤0.0025% 
Sulfates ≤0.02% 
Aluminum ≤0.00002% 
Barium Comply with the standard 
Potassium ≤0.05% 
Iron ≤0.0002% 
Magnesiumandalkaline-earth metals 
Calculated as Ca 
≤0.01% 
Arsenic ≤0.0001% 
Heavy metals(pb) ≤ 5ppm 
Loss on drying ≤0.5% 
Bacterial end toxins ≤ 5 I.U. 
Assay 99.0~100.5% 
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¿ø¦Äñ¦½ö: 
 Botanical Name  : Sesamum indicum,Linn. 
Family   : Pedaliaceae 
 English name:Sesame,Gingeli oil plant,Gingelly 
 Sans name:Tilam 
 Hindi name:Thil 
Parts used   : Leaf, flower, unripe fruit, seed 
Organoleptic characters: 
  Taste   : Sweet. 
Potency  : Hot 
Pirivu   : Sweet 
Activities: 
Oil : 
 Demulcent 
 Laxative 
 Nutritive 
 Emollient   
Phytochemicals: 
 Sesamin  
 Sesemol  
General characters: 
“Òò¾¢¿ÂÉìÌÇ¢÷îº¢ âÃ¢ôÒ ¦ÁöôÒÇ¸ï 
ºòÐÅí ¸ó¾¢ ¾É¢Â¢Ç¨Á - ¦Áò¾×ñ¼¡í 
¸ñ§½¡ö ¦ºÅ¢§¿¡ö ¸À¡ÄÅÆø ¸¡º§¿¡ö 
           Òñ§½¡ö§À¡ ¦Áñ¦½öÂ¡ü §À¡Üú.”- Ì½À¡¼õ ãÄ¢¨¸ 
Uses: 
 Gingelly or sesame oil: oil extracted from seed of Sesamum indicum: It has actions. On 
external application it heals burns and ulcers. Recently, sesame oil and its lignan sesamol 
have been proved to be potent anti-inflammatory agents. They have an excellent protective 
effect against endotoxin-associated inflammatory damage because they inhibit the release of 
inflammatory mediators. Sesamol also inhibits endotoxins from binding to its receptor; this 
reduces inflammatory transcription factor NF-κB activation. In summary, sesame oil or 
sesamol may be beneficial for reducing the inflammatory response in inflammation-
associated diseases.  
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â¨Éì ¸ñ Ìí¸¢Ä¢Âõ 
 
BOTANICAL NAME:Pistacia lentiscus 
FAMILY: Anacardiaceae 
ACTION:Stimulant diuretic 
COMPONENT: the major component of the drug are α-Pinene, β-myrcene, β-pinene, 
limonene, and β-caryophyllene . The topical anti-inflammatory activity of essential oil of 
Pistacia lentiscus L. was studied using carrageenan induced rat paw edema and cotton pellet 
induced granuloma. It can be concluded that the essential oil of Pistacia lentiscus reduces 
leukocyte migration to the damaged tissue and exhibits anti-inflammatory activity.  
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PREPARATION OF THE TRIAL DRUGS 
INTERNAL DRUG: KAIUPPU CHENDURAM 
Ref:Anuboga Vaithiya Navaneetham part-3 
KARIUPPU CHENDURAM 
        «Çò¾¢Ö¨È ¿øÖô ÀÉø Å¡¾õ Á¡üÚí 
        ¸ÇòÐ§¿¡ö ¾ý¨Éì ¸¨ÇÔõ-¸¢¨Çò¾¸À 
        ¬¸¨¼Â Åø¨Ä§¿¡ö «‰¼ÌýÁÓõ §À¡ìÌí 
        ¸¡º¢É¢Ôû Á¡§¾ ¸ÆÚ  
                            -  Ì½À¡¼õ ¾¡Ð º£Å ÅÌôÒ 
 
INGREDIENTS: 
 Eruku leaf  ( Calotropis gigantea .linn 
 Kariuppu ( Sodium Chloride )        
PURIFICATION OF DRUGS: 
Calotropis gigantea    -  wipe the leaf with a clean cloth. 
Sodium Chloride      -   first dissolve with butter milk and then dry it in sunlight.  
 
METHOD   OF  PREPARATION: 
          Kariuppu (sodium chloride) is kept in a mortar . The paste of tender leaf of Calotropis 
gigantea is placed in a fine cloth and the juice is squeezed out, the juice is added to kariuppu 
kept in mortar and grounded for 3 hours . Then  the contents are made into cakes and dried. 
The dried cakes are placed in a mud pot and covered by another mud pot of same  size. It is 
sealed by using 3 layers of mud pasted cotton cloth and dried. The dried mud pot is subjected 
to pudam by  using  cowdung cakes weighing 20 times of dried drug containing mud pot. The 
same process is repeated for 4 more time . 
                         Dose     : 2 kundri alavu (260mg)Twice daily   
Adjuvant     : Honey. 
Route of drug administration :oral route 
Duration       : 48 days  
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PROTOCOL 
TITLE: 
THE CLINICAL AND  PRE CLINICAL STUDY  TO EVALUATE THE 
THERAPEUTIC EFFICACY OF KARIUPPU CHENDURAM  (INTERNAL ) AND 
KUNTHIRIKA THAILAM (EXTERNAL) IN THE TREATMENT OF “CEGANA 
VATHAM” (CERVICAL SPONDYLOSIS). 
 
OBJECTIVE: 
Primary objective: 
To evaluate the therapeutic efficacy of KARIUPPU CHENDURAM  (INTERNAL ) 
AND KUNTHIRIKA THAILAM (EXTERNAL) in      
Cegana Vatham. 
Secondary objectives: 
To evaluate the safety profile (acute, long term toxicity studies) of the trail drug. 
To study the other co factors such as age, sex and siddha parameters. 
STUDY DESIGN & CONDUCT OF STUDY: 
STUDY TYPE : An open clinical trial 
STUDY PLACE : OPD. & IPD. Of Ayothidoss Pandithar Hospital, National Institute of 
Siddha, Tambaram sanatorium, Chennai-47. 
STUDY PERIOD : 12 months 
SAMPLE SIZE : 40 patients  
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TREATMENT: 
NAME OF THE MEDICINE: 
KARIUPPU CHENDURAM  (Internal) 
Reference  :Anupoga vaithya navaneetham part-3 
                                   Author hacki pa.mu.Abdullah saayabu                                           
                                   Pg.no 36,37,2
nd
Edition:2001 
  Dose   : 2 kundri alavu (260mg)Twice daily  
                                      after food   
Adjuvant   : Honey. 
Route of drug administration:oral route 
Duration     : 48 days  
Diet restriction   : To avoid root tubers, tamarind, tea , coffee,             
smoking and alcohol.   
                                                         
KUNTHIRIKA THAILAM (External). 
Reference     : (Pharmacopoeia of hospital of indian     
                                        medicine  Pg.no:133,2
nd
edition 1995) 
  Dosage                          : Sufficient quantity (50ml) 
  SOURCE OF RAW DRUGS: 
                            The required raw drugs are purchased from  a well reputed country 
shop.The  raw drugs are athendicated by the head of the department of gunapadam,NIS .The 
raw drugs are purified and the medicine is prepared in Gunapadam lab of National Institute of 
Siddha.  
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STANDARD OPERATING PROCEDURE 
KARIUPPU CHENDURAM: 
INGREDIENTS: 
 Eruku leaf  ( Calotropis gigantea .linn 
 Kariuppu ( Sodium Chloride )        
PURIFICATION OF DRUGS: 
 Calotropis gigantea    -  wipe the leaf with a clean cloth. 
 Sodium Chloride      -   first dissolve with butter milk and then dry it in sunlight. 
  METHOD   OF  PREPARATION: 
          Kariuppu (sodium chloride) is kept in a mortar . The paste of tender leaf of Calotropis 
gigantea is placed in a fine cloth and the juice is squeezed out, the juice is added to kariuppu 
kept in mortar and grounded for 3 hours . Then  the contents are made into cakes and dried. 
The dried cakes are placed in a mud pot and covered by another mud pot of same  size. It is 
sealed by using 3 layers of mud pasted cotton cloth and dried. The dried mud pot is subjected 
to pudam by  using  cowdung cakes weighing 20 times of dried drug containing mud pot. The 
same process is repeated for 4 more time . 
 
KUNTHIRIKA  THAILAM: 
INGREDIENTS: 
                     1)  Poonaikan kungiliyam(Pistacia lentiscus)  -4 palams.(140 gram) 
                      2)  Gingelly oil                  -40 palams(1400 ml) 
PURIFICATION OF DRUGS:  
                        Poonaikan kungiliyam    –  boil in tender coconut water7. 
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METHOD   OF  PREPARATION: 
Mix the  ingredients 1 & 2 and boil till kungiliyam dissolves. 
INCLUSION CRITERIA: 
 Age: 20-50 years. 
 Sex:  Both sex.                                                                                        
  Neck pain radiating to upper limbs with or without numbness, giddiness and 
neck stiffness. 
 Patient who are willing to withdrawl NSAID. 
 Radiological diagnosis of cervical spondylosis. 
 Willing to be attented in the hospital or attend the opd once in 12 days for 48 
days. 
EXCLUSION CRITERIA: 
 Cervical rib 
 Traumatic conditions 
 Rheumatoid arthrities 
 Ankylosing spondylosis 
 Tuberculosis in spine 
 Diabetes mellitus 
 Hypertension and cardiac diseases 
 Renal disease 
 Narcotic addicts 
 Pregnancy and lactations 
 
WITHDRAWAL CRITERIA 
 Intolerance to the drug and development of serious adverse reactions during 
drug trial. 
 Poor patient compliance and defaulters. 
 Patient turned unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness 
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TESTS AND ASSESMENTS 
Clinical assessment 
Routine investigations 
Specific investigations 
CLINICAL ASSESSMENT:                                                             
  Pain below the neck, above the hip and in both upper limbs. 
 Scorpion sting like pain in  the above regions. 
 Heaviness of the body, 
 Burning sensation of the eyes and constipation. 
PAIN ASSESMENT: 
UNIVERSAL PAIN ASSESMENT SCALE
 
                                                                                                                                 
A.   0    : No Pain 
B. 1 -2 :  Mild pain 
C. 3-4 : Moderate pain(interferes with task) 
D. 5-6 :  Moderate pain(interfere with concentration) 
E.7-8   : severe pain 
F.9-10 :Worst pain  
77 
 
SIDDHA ASSESSMENT 
1.Thinai : 
 Kurinchi (hill areas) 
 Mullai ( forest ) 
 Marutham ( fertile land ) 
 Neidhal ( coastal area ) 
 Palai ( desert ) 
2. Paruva Kalam ( season )  
 Karkaalam 
 Koothir kaalm 
 Munpanikaalm 
 Pinpani kaalam 
 Ilavenil kaalam 
 Muthuvenil kaalam 
    3. Poripulankal: 
 Mei (Skin etc) 
 Vaai (Tongue etc) 
 Kan (Eye etc) 
 Mooku (Nose etc) 
 Sevi (Ear etc) 
4.Kanmedriyamand Gnanenthiriyam: 
 Vaai (Buccal cavity) 
 Kaal (Lower limbs) 
 Kai (Upper limbs) 
 Eruvaai (Anorectal region) 
 Karuvaai (Uro-genital region) 
                5. Ezhuudalkattugal: 
 Saram 
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 Senneer 
 Uoon 
 Kozhuppu 
 Enbu 
 Moolai 
 Sukkilam /suronitham 
6.Ennvagaithervu ( Eight types of Examination): 
 Naadi 
 Sparisam 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Malam 
 Moothiram 
-Neerkuri 
 -Neikuri 
 
SIDDHA PARAMETERS 
         Malam 
         Moothiram 
B .  ROUTINE INVESTIGATION 
 HB(gm/dl) 
 Total WBC Count(cells/cumm) 
 DC-  Polymorphs(%) 
 Lymphocytes(%)  
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 Eosinophils (%) 
 Monocytes (%) 
 Basophils(%)  
 Total RBC count million cells/cumm) 
 ESR(Men 6-12mm/hr  Women 7-18 mm/hr) 
  B.glucose (mg/dl)  
LIPID PROFILE 
 Serum cholesterol(mg/dl)- 
  HDL cholesterol(mg/dl)- 
  LDL cholesterol(mg/dl)- 
 VLDL cholesterol(mg/dl)- 
 Serum triglycerides  (mg/dl)-    
 KIDNEY FUNCTION TEST 
  B.urea(mg/dl)  
 S. total creatinine (mg/dl) 
LIVER FUNCTION TEST 
 S.total bilirubin(mg/dl)  
 S.direct bilirubin (mg/dl) 
 S. indirect bilirubin (mg/dl) 
 SGOT(u/l) 
 SGPT (u/l) 
 S.alkaline phosphataseu/l)  
 S.total protein(g/dl)  
 S. albumin (g/dl) 
 S.globulin (g/dl) 
 S. calcium (mg/dl) 
 S. phosphorous (mg/dl) 
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URINE EXAMINATION  
  Albumin 
 Sugar (Fasting & post prandial) 
 Deposits  
 Bile salts  
 Bile pigments 
 Urobilinogen  
MOTION -  Ova  
Cyst 
SPUTUM  - AFB 
 
SPECIFIC INVESTIGATIONS: 
X- ray   :  Cervical spine AP, lateral view. 
3. OTHER INVESTGATIONS: 
           CRP  , RA factor.      
STUDY ENROLLMENT: 
 In this study patients reporting at nis OPD with clinical features of pain in 
nape radiating to upper limbs, stiffness are chosen for enrollment based on the 
inclusion criteria. 
 The patients who are to be enrolled will be informed (Form IV A) about the 
study, trial drug, possible outcomes and objectives of the study in the language 
and terms understandable to them. 
 After ascertaining patient‟s willingness, informed consent will be obtained in 
written form from them in the consent form (Form IV A). 
 All these patients will be given unique registration card  with details like 
Patient‟s Registration number of study, Address, Phone number and Doctor‟s 
Phone number, etc, so as to report easily when any complication arise. 
 Complete clinical history, compliance and duration, examination findings will 
be recorded in the prescribed proforma in the history and clinical forms 
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separately. Screening Form I will be filled up: Form I-A, Form II and Form III 
will be used for recording the patient‟s history, clinical examination and 
laboratory investigations respectively. 
 Patients will be advised to take the trial drug and appropriate dietary advice 
will be given (Form IV D) 
 
CONDUCT OF THE STUDY: 
 Purgation with Agasthiyar kuzhambu – 130 mg early morning with ginger juice 
will be given for balancing the deranged mukkutram a day before treatment. 
 The trial drug KARIUPPU CHENDURAM  (internal) and KUNTHIRIKA 
THAILAM (external) are given continuously  for 48 days. 
  For In-patients, the trial drugs will be given daily. The clinical assessment will be 
made daily and recorded in the appropriate forms.  
 For out-patients, the trial drugs will be given in the Out-patient Department (Room 
No: 1) of our Hospital. The out-patients will be asked to follow regular check up in 
the OP Department once in 12 days for 48 days. In each visit, the clinical assessment 
will be recorded.  
 The laboratory and radiological investigations will be done before and after treatment 
and recorded in the prescribed format. 
  At the end of the treatment the patients are advised to have follow up visits in the 
OPD for 2 more months. 
  If any trial patient fails to collect the trial drug on prescribed day, but wants to 
continue in the trial from next day or two he/she will be allowed. 
  Defaulters for one week will not be allowed to continue and will be withdrawn from 
the study with fresh case being included. 
DATA MANAGEMENT: 
 After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Study No. and Patient No. will be 
entered on the top of file for easy identification. Whenever study patient visits 
OPD during the study period, the respective patient file will be taken and 
necessary recordings will be made at the assessment form or other suitable form. 
 The screening forms will be filed separately. 
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 The Data recordings will be monitored for completion and adverse event by HOD 
and Sr. Research Officer (Statistics) and adverse event by pharmacovigilance dept 
of NIS.All collected data will be entered into computer using ms access software 
.Data entry will be 100% cross checked manually. All forms will be further 
scrutinized in presence of Investigators by Sr. Research Officer (Statistics) for 
logical errors and incompleteness of data to avoid any bias. No modification in the 
results is permitted for unbiased reports. 
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STATISTICAL ANALYSIS: 
                            All collected data will be entered into the computer and manually cross-
checked the correctness of the data entry. The clinical symptoms and size of the stone will be 
analysed by comparing the two point of data(before and after treatment) paired test and chi-
square test will be employed to study the efficacy of treatment. Futher, the effect of age and 
sex will also be analysed. 
OUTCOME 
PRIMARY OUTCOME 
                          Reduction of neck pain and radiating to the upper limbs is assessed by  
pain assessment scale. 
SECONDARY OUTCOME 
                    1.Reduction in other clinical  symptoms. 
                    2.Siddha co-factors 
ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT: 
               If the trial patient develops any adverse reaction, he/she would be immediately  
withdrawn from the trial and reffered to the pharmacovigilance dept of NIS. 
ETHICAL ISSUES: 
1. Informed consent will be obtained from the patient explaining in the understandable 
language to the patient. 
2. After the consent of the patient (through consent form) they will be enrolled in the study.  
3. The data collected from the patient will be kept confidentially. The patient will be 
Informed   about    the diagnosis, treatment and follow-up.  
4. No other external or internal medicines will be used. There will be no infringement on the 
rights of patient. 
 5. To prevent any infection, while collecting blood sample from the patient, only   
disposable syringes, disposable gloves, with proper sterilization of lab equipments will   be 
used.                         
 6. Treatment would be provided free of cost.  
 7.The patient who are excluded (as per excluded criteria)are given proper treatment with full 
care at NIS. 
 8.In conditions of treatment failure , adverse reactions, patients will be given   
       alternative treatment at the National Institute of Siddha with full care throughout  the       
end.                                                     
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OBSERVATIONS AND RESULTS 
Results of the study were observed with respect to the following criteria; 
1. Age distribution 
2. Gender distribution 
3. Diet 
4. Religion 
5. Gunam  
6. Body constituent 
7. Seasonal variation 
8. Socioeconomic status 
9. Occupation 
10. Derangement of Vaatham 
11. Derangement of Pitham 
12. Kanmendrium 
13. Gnanenthiriam 
14. Derangement of Udal thathukkal  
15. Derangement of Envagai thervu  
17. Naadi 
                    18. Neikkuri 
                    19.Duration of illness 
                    20.Clinical features 
                    2 .Progress 
                    22.Nature of pain 
                   23.Aggrevating factor on movement 
                   24.Relieving factor  on rest 
                   25.Restriction of movement 
                   26.Result 
                   27.Statistical analysis 
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RESULTS AND OBSERVATION 
AGE DISTRIBUTION 
TABLE :1 
S.No Age distribution No. of Cases Percentage 
1                21-30 7 17.5% 
2                31-40 20 50% 
3                41-50 13 32.5% 
                         Total                     40           100% 
 
 
17.50%
50%
32.50%
Age distribution
21-30
31-40
41-50
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INFERENCE: 
                Out of the 40 cases taken for clinical trial, 7 (17.5%) cases were in the 21-30 years 
age group, 20(50%) cases were in the 31-40 years  age group and 13 cases (32.5%) were in 
the 41-50 years age group. 
 
 
GENDER DISTRIBUTION: 
TABLE :2 
S.No Sex No. of Cases Percentage 
1 Male 8 20% 
2 Female 32 80% 
 Total 40 100% 
 
 
 
INFERENCE: 
                 In the 40 cases treated, 8 (20%) were male and 32 (80%) were female. 
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DIETARY PATTERN: 
TABLE:3 
S.No Diet Habits No. of Cases Percentage 
1 Vegetarian 2 5% 
2 Non – Vegetarian 38 95% 
 Total 40 100% 
 
 
INFERENCE: 
             Out of the 40 cases, 2(5%) cases were vegetarians and the rest 38(95%) cases had 
both vegetarian and non-vegetarian foods for diet. 
 
5%
95%
Dietary Pattern
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DISTRIBUTION OF CASES BY RELIGION 
TABLE:4 
S.No Religion No. of Cases Percentage 
1 Christian 4 10% 
2 Muslim 3 7.5% 
3 Hindus 33 82.5% 
 
 
 
INFERENCE: 
                              Out of the 40 cases taken for clinical trial, 4 (10%) cases were christians, 
3(7.5%) cases were muslims and 33(82.5%) were hindus. 
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              DISTRIBUTION OF CASES BY GUNAM 
 
Table: 5 
GUNAM NUMBER OF CASES PERCENTAGE 
Sathuva gunam 0 0% 
Rasatha gunam 39 97.5% 
Thamo gunam 1 2.5% 
Total 40 100 
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INFERENCE:  Among the 40 patients selected, 39 (97.5%) cases were found to possess 
Rasatha gunam 
. 
 
BO
DY 
CO
NS
TI
TU
TION      :  Table 6 
 
 
 
 
 
 
 
 
 
 
S. No ConstitutionOf The Body No. Of Cases Percent 
1. 
2. 
3. 
4. 
Vadha Thegi 
Pitha Tegi 
Kabha Thegi 
Thontha Thegi 
0 
0 
0 
40 
0% 
0% 
0% 
100% 
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INFERENCE: All the 40 cases (100%) are found to be thontha thegi. 
 
 
 
 
 
SEASONAL REFERENCE : 
 
 
TABLE:7 
S.No Season No. of Cases Percentage 
1 Kaarkaalam 28 70% 
2 Koothirkaalam 12 30% 
3 Munpanikaalam - - 
4 Pinpanikalaam -  
5 Elavenil Kalaam - - 
6 Mudhuvenil Kaalam - - 
 Total 40 100% 
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INFERENCE :In the trial of 40 cases, majority of  28(70%) cases were registered in kaar 
kalam, 12(30%) during koothir kalam . 
 
 
SOCIO-ECONOMIC STATUS 
Table: 8 
SOCIO-ECONOMIC STATUS  
        (In terms of Income status) 
NUMBER OF 
CASES 
PERCENTAGE 
Poor 14 35% 
Upper Middle class 7 17.5% 
Lower Middle class 15 37.5 % 
Rich 4 10 % 
Total 40 100% 
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INFERENCE : The incidence of the disease was found to be higher in 15(37.5%) cases 
belonging to  lower middle class  and in 14(35%) cases belonging to poor class  
 
OCCUPATION: 
TABLE:9 
OCCUPATION 
PATIENTS 
NO. PERCENTAGE 
Clerical job 9 22.5% 
Driver 2 5% 
Teacher 2 5% 
Coolie 2 5% 
Software professional 7 17.5% 
Home maker 15 37.5% 
Tailor 3 7.5% 
Total 40 100% 
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Rich
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INFERENCE :Among 40 patients recruited for the clinical study 9 patients were from 
clerical job,each two cases were driver,  teacher and coolie.3 cases were tailor 7 cases were 
softwere proffesionels and 15 patients were home maker. 
DISTURBANCES IN VATHAM: 
TABLE:10 
VATHAM 
 PATIENTS 
AFFECTED 
 PATIENTS 
 RELIEVED FROM  
SYMPTOMS 
        BEFORE    
TREATMENT 
% AFTER 
TREATMENT 
% 
Pranan 0 - 0 - - 
Abanan 
(constipation) 
8 
20% 
2 
5% 
15% 
Uthanan 
(cough) 
4 
10% 
2 
5% 
5% 
Viyanan 40 100% 14 35% 65% 
Samanan 40 100% 14 35% 65% 
    Naagan  0 0% 0 0% - 
0.00%
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Koorman 0 0% 0 0% - 
Kirukaran 0 0% 0 0% - 
Devathathan 0 0% 0 0% - 
Dhananjayan 0 0% 0 0% - 
 
 
 
Inference:       
Among the 40 patients observed Viyanan (pain in neck) and Samanan (due to viyanan 
affected) were affected in almost all the cases, while Abanan (constipation) was affected in 8 
cases, Uthanan in 4 cases, before treatment. After treatment Viyanan and Samanan remained 
affected in 14 cases,abanan and uthanan in 2 cases. 
DISTURBANCES IN PITHAM: 
TABLE: 11 
PITHAM 
 PATIENTS AFFECTED  PATIENTS 
RELIEVED 
FROM 
SYMPTOMS 
BEFORE    
TREATMENT 
% 
AFTER 
TREATMENT 
% 
0%
20%
40%
60%
80%
100%
0%
20.00%
100.00%
10%
100%
0% 0% 0% 0% 0%
ca
se
%
vatham%
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Analpitham 8 20% 2 5% 15% 
Ranjagam 10 25% 8 20% 5% 
Sathagam 30 75% 4 10% 25% 
Prasagam 4 10% 0 0% 10% 
Alosagam 0 0% 0 0% 0% 
 
Inference:Among 40 patients sathagam (pain is present nape of the neck)  is affected in 
75%.ranjakam is affected in 25% of cases.prasagam is affected in 10%cases. 
DISTURBANCES IN KABAM: 
TABLE :12 
0%
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80%
Analpitham Ranjagam Sathagam Prasagam Alosagam
20%
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20%
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pitham%
KABAM 
 PATIENTS AFFECTED  PATIENTS 
RELIEVED 
FROM 
SYMPTOMS 
BEFORE    
TREATMENT 
% 
AFTER 
TREATMENT 
% 
Avalambagam 0       0% 0 0% 0% 
Klaethagam 5 12,5% 2 5% 7.5% 
Bothagam 5 12.5% 1 2.5% 10% 
Santhigam 40 100% 10 25% 75% 
Tharpagam 0 0% 0 0% 0% 
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Inference:    
Santhigam was affected in all the 40 patients. After treatment 30 got relieved. 
Bhothagam and klethagam is affected in 5 cases.klethagam is present in 2 cases and 
bhothagam is present in 1 case after treatment. 
KANMENTHIRIYAM: 
TABLE:13 
KANMENTHIRIYA
M 
PATIENTS AFFECTED  PATIENTS 
RELIEVED 
FROM 
SYMPTOMS 
BEFORE    
TREATMENT 
% AFTER 
TREATMENT 
% 
Kai 40 100% 4 10% 80% 
Kaal 0 0% 0 0% 0% 
Vai 0 0% 0 0% 0% 
Eruvai 8 20% 2 5% 15% 
Karuvai 0 0% 0 0% 0% 
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Inference:   
Kai was affected in all the 40 patients, 32 got relieved from symptoms after treatment. 
Eruvai was affected in 8 patients, 6 got relieved from symptoms after treatment . 
 
DISTURBANCES IN GNANENTHRIYAM: 
TABLE:14 
SL.NO GNANENTHRIYAM NO OF CASES PERCENTAGE 
1 Mei 40 100% 
2 Vai 0 0% 
3 Kan 12 30% 
4 Mooku 0 0% 
5 Sevi 0 0% 
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INFERENCE: 
Mei  (pain in neck and in upper limbs)is affected in all the 40 cases kan is affected 
in30% . 
       
DISTURBANCE IN UDAL THATHUKKAL 
TABLE:15 
UDAL THATHUKKAL NUMBER OF CASES PERCENTAGE 
Saaram 40 100% 
Senneer 40 100% 
Oon 40 100% 
Kozhuppu 40 100% 
Enbu 40 100% 
 Moolai 40 100% 
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Sukkilam/Suronitham Nil                   Nil 0 
 
 
INFERENCE:  
Saaram, Senneer, Oon, Kozhuppu, Enbu, Moolai were affected in all the 40 cases . 
ENVAGAI THERVUGAL: 
TABLE:16                                       
ENVAGAI THERVUGAL 
PATIENTS 
AFFECTED PERCENTAGE 
i. Niram 0 0% 
ii. Naa 8 20% 
iii. Mozhi 0 0% 
iv. Vizhi 10 25% 
v. Malam 8 20% 
vi. Neer 5 12.5% 
0%
50%
100%
100% 100% 100% 100% 100% 100%
AFFECTED UDAL THATHUKAL
PERCENTAGE
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vii. Sparisam 0 0% 
 
   
OBSERVATION: Among 40 patients 25% vizhi is affected and 20% of naa and malam is affected. 
There was no change in Niram, Mozhi and Sparisam 
 
 
a. NAADI 
TABLE:17 
NAADI NUMBER OF CASES PERCENTAGE 
Vathapitham 35 87.5% 
Pithavatham 5 12.5% 
Total 40 100% 
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Inferance: Majority of the cases 35 (87.5%) revealed Vatha Pitha naadi.    
 
 
 
 
 
NEIKKURI (Oil on urine sign) 
TABLE:18 
SPREADING PATTERN NUMBER OF 
CASES 
PERCENTAGE 
Aravenaneendathu  
Vathaneer (Spreading  like a snake) 
31 77.5% 
Aazhipolparaviathu  
Pitha neer (Spreading like a ring) 
2 5% 
87.5%
12.5%
NAADI
Vathapitham
Pithavatham
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Muththothu Ninrathu  
Kabaneer (Stands  like a  pearl) 
7               17.5%   
Total 40 100 
 
 
 
Observation:  Among the 40 cases 31 (77.5%) cases had Vatha neer in majority  
 
 
 
DURATION OF ILLNESS: 
TABLE:19 
DURATION OF ILLNESS 
PATIENTS 
NO. PERCENTAGE 
Up to 6 months 8 20% 
7 – 12  months 10 25% 
13 –18 months 18 45% 
77.5%
5%
17.5%
NEIKURI
VATHA NEER
PITHA NEER
KABA NEER
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19 – 24 months 4 10% 
25 – 30 months - 0 
Total 40 100% 
 
 
Inference:   
In about 18 cases( 45%)  duration of illness was 13-18 months,10 cases(25% )had 
illness for about 7-12 months,8 cases 20% patients had  illness for less than 6months,4 cases( 
10%) patients had illness for 19-24 months. 
CLINICAL FEATURES: 
TABLE:20 
Clinical Features 
PATIENTS 
No. Percentage 
Pain in neck 40 100% 
Radiating pain in  the upper limbs(UL) 36 90% 
Radiating pain to the shoulders 30 75% 
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Numbness in upper limbs(UL) 22 55% 
Giddiness 10 25% 
Burning sensation in upper limbs(UL) 4 10% 
Restriction of movements(ROM) 24 60% 
Swelling 10 25% 
 
 
 Inference:  All 40 patients neck pain is present.radiating pain is present in90%,shoulder pain 
in 75%numbness in 55% giddiness in 25%burning sensation in  10%,restriction of movement 
in 60%,swelling in 25%. 
PROGRESS: 
TABLE 21 
Clinical Features 
Patients 
Before Treatment Aftertreatment 
% Of  Patients 
Relieved From 
Symptoms 
 
 
Re Relieved From 
Pain in neck 40 3 92.5% 
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Inference:   
                Among 40 cases 92.5% are relieved from neck pain,84.2%relieved from 
radiating pain,93.3% relieved from shoulder pain, 90.9%relieved from 
numbness,70%relieved from giddiness,75% relieved from burning 
sensation,83.33%relieved from restrictations,60%relieved from swelling. 
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SYMPTOMS
IMPROVEMENT WITH TRIAL DRUGS
Radiating pain in  upper 
limbs 
36 6 84.2% 
Radiating pain to the 
shoulders 
30 2 93.3% 
Numbness in upper limbs 22 2 90.9% 
Giddiness 10 3 70% 
Burning sensation in upper 
limbs 
4 1 75% 
Restriction of movements 24 4 83.33% 
Swelling 10 4 60% 
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NATURE OF PAIN: 
NATURE OF PAIN 
  
No. of Patients 
 BEFORE 
TREATMENT 
%   AFTER 
TREATMENT 
% 
NO PAIN  0 -   26  
65 % 
MILD  0 -   8  
20 % 
MODERATE  32 80%   4  
10 % 
SEVERE  8 20%   2 
5 % 
TOTAL  40 100%   40 
100 % 
 
 
 
Inference: 
 Before treatment, 32 (80% ) patients were affected by moderate pain, 8 patients were 
affected by severe pain. After treatment, 26 (65%) patients were found to be with no pain, 
8(20%) patients with mild pain, 4(10%) patients with moderate pain and 2(5%) patients with 
no reduction in pain. 
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AGGRAVATING FACTOR ON MOVEMENT: 
 
Aggravating 
factor on 
Movement 
No. of Patients 
Percentage of 
Patients 
Relieved 
BEFORE 
TREATMENT 
% 
AFTER 
TREATMENT 
% 
Yes 40 100% 0 -        100% 
No 0 - 40 100% 0% 
Total 40 100% 40 100% 100% 
 
 
Inference: 
 Before treatment, all the 40 patients (100%) were affected by aggravating factor on 
movement. After treatment, all the 40 patients (100%) were relieved. 
 
RELIEVING FACTOR – REST: 
Relieving factor - Rest 
No. of Patients 
BEFORE 
TREATMENT 
% 
 
AFTER 
TREATMENT 
% 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
yes
no
100%
0%
0%
100%
Before
After
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Yes 18 45% 38 95% 
No 22 55% 2 5% 
Total 40 100% 40 100% 
 
  
 
 
Inference: 
 Before treatment, 45%(18) patients were relieved during rest. After treatment, 38 
patients (95%) were relieved during rest. 
 
 
 
 
 
 
 
RESTRICTION OF  MOVEMENTS: 
Restriction of movements 
No. of Patients 
BEFORE 
TREATMENT 
 
% 
AFTER 
TREATMENT 
 
% 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
yes no
45%
55%
95%
5%
before
after
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Partial 22 55% 4 10% 
Fully 2 5% 0 0% 
No 16 40% 36 90% 
Total 40 100% 40 100% 
 
 
 
Inference: 
 Before treatment 22(55%) patients had partial restriction  and 2(5%) patients were 
restricted fully. After treatment only 4(10%) has partial restriction and remaining 36(90%) 
patients were relieved from restriction  of movement. 
 
 
RESULT: 
Table22 
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90%
Partial Full No
55%
5%
16%
10%
0%
90%Restriction of Movements
Before
After
RESULT SUBJECTS 
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Inference:  Good improvement was seen in 65% of study subjects. 
       Moderate improvement was seen in 20% of study subjects. 
       Mild   improvement was seen in 10% of study subjects. 
       No improvement was seen in 5% of study subjects. 
 
 
STATISTICAL ANALYSIS 
                           Mean and Standard deviation was used to test the significance of treatment 
using  before and after treatment data on cervical spondylosis and Symptoms. 
NO. OF SUBJECTS PERCENTAGE 
Good 26 65% 
Moderate 8 20% 
Mild 4 10% 
Nil 2 5% 
Total 40 100% 
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       The level of significance probability 0.05 was used to test the treatment difference 
and the values are statistically significant. 
ESR (1/2 AN HOUR) 
 
ESR (1   HOUR) 
           ESR (1   
HOUR) 
Mean  Std.Deviation Std.Error 
Mean 
    t 
VALUE 
p VALUE 
Before 
treatment 
16.55 18.031 2.851 2.186 0.035 
After 
treatment 
11.75 6.690 1.058 
 
OBSERVATION: The statistical analysis reveals that there has been moderate significant 
reduction in ESR value after treatment. 
 
PAIN ASSESSMENT SCALE BEFORE AND AFTER TREATMENT 
Pain Scale    Mean  Std.Deviation Std.Error 
Mean 
    t 
VALUE 
p VALUE 
Before 
treatment 
5.65 1.424 0.225 24.085 P < 0.0001 
After 
treatment 
0.98 1.230 0.194 
                                The mean± standard deviation of pain scale  score at before and after 
treatment were 5.65 ± 1.424and 0.98 ±  1.230 respectively which is statistically highly 
significant (t= 24.0 p<0.0001) i.e. the symptoms have been reduced significantly after the 
treatment. 
                                    X-RAYS OF OPD AND IPD PATIENTS 
XRAY SHOWING LOSS OF CERVICAL LORDOSIS 
C099666  37/F 
           ESR 
(1/2 an hour) 
   Mean  Std.Deviation Std.Error 
Mean 
    t 
VALUE 
p VALUE 
Before 
treatment 
6.25 6.736 1.065 2.365 0.023 
After 
treatment 
4.60        3.177 
 
0.502 
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C96651 50/F 
 
 
 
 
B55586 26/M 
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X-RAY SHOWING OSTEOPHYTES AT C6-C7 
D004970 47/M 
 
 
 
X-RAY SHOWING DEGERATIVE CHANGES AT 
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C3-C5 &OSTEOPYHTES AT C4-C5 
IP4208 32/F 
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          URINE INVESTIGATIONS 
Sl.no Op/ip .no AGE SEX 
Albumin Sugar Deposits 
BT AT BT AT BT AT 
1 C94873 29 M Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
2 C96984 50 M Nil Nil Nil Nil 2-5 epi.cells 2-3epi.cells 
3 C93620 38 M Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
4 D004970 47 M Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells - 
5 B55586 26 M Nil Nil Nil Nil 
1-2 epi.cells, 
3 pus cells 
1-2 epi.cells, 
 
6 D000205 48 M Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
7 D000425 37 M Nil Nil Nil Nil 2-3 epi.cells 2-3 epi.cells - 
8 C099666 37 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
9 C96651 50 F Nil Nil Nil Nil 2-3 epi.cells 2 epi.cells 
10 D004308 45 F Nil Nil Nil Nil 1-2 epi.cells 2-3 epi.cells 
11 C098214 40 F Nil Nil Nil Nil 
1-2 epi.cells 
1-2 pus cells 
1-2 epi.cells 
12 C97940 48 F Nil Nil Nil Nil 2 epi.cells 2-4 epi.cells 
13 C97647 33 F Nil Nil Nil Nil 2 epi.cells - 2 epi.cells - 
14 C95513 40 F Nil Nil Nil Nil 3-6 epi.cells 2-4epi.cells 
15 C97598 48 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
16 C94733 32 F Nil Nil Nil Nil 
3-4 epi.cells, 
4-6pus cells. 
2-4 epi.cells 
 
17 C96802 24 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
18 C95436 38 F Nil Nil Nil Nil 
1-2 epi.cells, 
2-4 pus cells 
1-2 epi.cells, 
2 pus cells 
19 D000496 36 F Nil Nil Nil Nil 2 epi.cells 2-4 epi.cells 
20 D000006 32 F Nil Nil Nil Nil 1-2 epi.cells 2-4  epi.cells 
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                                              URINE INVESTIGATION 
Sl.no Op .no Age SEX 
Albumin Sugar Deposits 
BT AT BT AT BT AT 
1 C94833 26 F Nil Nil Nil Nil 2 epi.cells 3 epi.cells 
2 C098191 40 F Nil Nil Nil Nil 3  epi.cells 2  epi.cells 
3 D004664 42 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells - 
4 C95550 36 F Nil Nil Nil Nil 2-6 epi.cells 2 epi.cells 
5 C94392 31 F Nil Nil Nil Nil 3-6 epi.cells 4 epi.cells 
6 C098014 32 F Nil Nil Nil Nil 
1-2 epi.cells 
2-4 pus cells 
1-2 epi.cells 
7 C098239 38 F Nil Nil Nil Nil 2-4 epi.cells 1-2 epi.cells - 
8 D000836 25 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
9 C96489 31 F Nil Nil Nil Nil 2-5 epi.cells 2 epi.cells 
10 C09925 47 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
11 4185 48 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
12 4228 32 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
13 4258 37 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
14 4267 42 F Nil Nil Nil Nil 
3-5 epi.cells 
4-6 pus cells 
2-4 epi.cells 
 
15 4255 48 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells - 
16 4226 40 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells 
17 4208 42 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells - 
18 4251 34 F Nil Nil Nil Nil 2-5 epi.cells 2 epi.cells 
19 4175 42 F Nil Nil Nil Nil 4-6 pus cells 2 epi.cells - 
20 5217 26 M Nil Nil Nil Nil 2 epi.cells 2 epi.cells 
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                             PAIN SCALE RATING IN OPD AND IPD CASES 
 
 
S.No Op /Ip no AGE SEX 
Pain Scale Rating 
BT AT 
1. C94873 29 M 6 0 
2. C96984 50 M 6 2 
3. C93620 38 M 4 0 
4. D004970 47 M 4 0 
5. B55586 26 M 8 1 
6. D000205 48 M 6 0 
7. D000425 37 M 8 4 
8. C099666 37 M 6 0 
9. C96651 50 F 6 2 
10. D004308 45 F 6 0 
11. C098214 40 F 4 0 
12. C97940 48 F 4 0 
13. C97647 33 F 6 0 
14. C95513 40 F 4 0 
15. C97598 48 F 4 4 
16. C94733 32 F 6 0 
17. C96802 24 F 6 2 
18. C95436 38 F 4 0 
19. D000496 36 F 4 0 
20. D000006 32 F 6 2 
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PAIN SCALE RATING 
S.No 
NAME 
(Ip patients and op patients) 
AGE SEX 
Pain Scale Rating 
BT AT 
1. 
C94833 26 
F 6 0 
2. 
C098191 40 F 8 4 
3. 
D004664 42 
F 4 0 
4. 
C95550 36 
F 6 2 
5. 
C94392 31 
F 6 0 
6. 
C098014 32 
F 4 0 
7. 
C098239 38 
F 4 0 
8. 
D000836 25 
F 6 0 
9. 
C96489 31 
F 6 2 
10. 
C09925 47 
F 4 0 
11. 
4185 48 F 6 0 
12. 
4228 32 F 8 2 
13. 
4258 37 F 4 0 
14. 
4267 42 F 6 0 
15. 
4255 48 F 4 0 
16. 
4226 40 F 4 4 
17. 
4208 42 F 6 0 
18. 
4251 34 F 8 6 
19. 
4175 42 F 6 0 
20. 
5217 26 F 4 2 
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RADIOLOGICAL FINDINGS OF CERVICAL SPINE [AP & LATERAL VIEW] 
 
 
 
 
Sl. No OP/IP NO Age Sex 
Cervical 
Lordosis 
IVD space 
narrowing 
Degenerative 
changes 
Osteophytes 
BT AT BT AT BT AT BT AT 
1.  
C94873 29 M Lost Lost C4-6 C4-6 C4-6 C4-6 C4-6 C4-6 
2.  
C96984 50 M N N C4-5,C5-6 C4-5,C5-6 C4-7 C4-7 C4-7 C4-7 
3.  
C93620 38 M N N C3-4,C4-5 C3-4,C4-5 C4-6 C4-6 C4-6 C4-6 
4.  
D004970 47 M N N C2-3,C3-4 C2-3,C3-4 All All All All 
5.  
B55586 26 M Lost Lost C4-5,C5-6 C4-5,C5-6 C4-7 C4-7 C4-7 C4-7 
6.  
D000205 48 M N N C4-5,C5-6 C4-5,C5-6 C4-7 C4-7 C4-7 C4-7 
7.  
D000425 37 M N N C3-5,C5-6 C3-5,C5-6 C3-6 C3-6 C3-6 C3-6 
8.  
C099666 37 F N N C4-5,C5-6 C4-5,C5-6 C4-6 C4-6 C5-6 C5-6 
9.  
C96651 50 F N N C5-6,C6-7 C5-6,C6-7 C5-7 C5-7 C5-6 C5-6 
10.  
D004308 45 F N N C3-4,C4-5 C3-4,C4-5 C3-5 C3-5 C3-4 C3-4 
11.  
C098214 40 F N N C4-5 C4-5 C4-5 C4-5 C4-5 C4-5 
12.  
C97940 48 F N N C3-4,C4-5, C3-4,C4-5, C3-5 C3-5 C4-5 C4-5 
13.  
C97647 33 F N N C2-5 C2-5 C3-5 C3-5 C3-5 C3-5 
14.  
C95513 40 F N N C4-6 C4-6 C5-6 C5-6 C5-6 C5-6 
15.  
C97598 48 F N N C3-4,C4-5 C3-4,C4-5 C4-5 C4-5 C4-5 C4-5 
16.  
C94733 32 F N N C3-6 C3-6 C4-6 C4-6 C4-6 C4-6 
17.  
C96802 24 F N N N N C4-5 C4-5 C4-5 C4-5 
18.  
C95436 38 F N N C5-6,C6-7 C5-6,C6-7 C3-7 C3-7 C3-7 C3-7 
19.  
D000496 36 F N N C4-6 C4-6 C5-6 C5-6 C5-6 C5-6 
20.  
D000006 32 F N N C3-4,C4-5 C3-4,C4-5 C4-5 C4-5 C4-5 C4-5 
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RADIOLOGICAL FINDINGS OF CERVICAL SPINE [AP & LATERAL VIEW] 
Sl. 
No 
OP/IP 
No: 
Age Sex 
Cervical 
Lordosis 
IVD space narrowing 
Degenerative 
changes 
Osteophytes 
BT AT BT AT BT AT BT AT 
1.  
C94833 26 F Lost Lost C3-4,C4-5 C3-4,C4-5 C3-6 C3-6 C3-6 C3-6 
2.  
C098191 40 F N N C5-6 C5-6 C4-6 C4-6 C4-6 C4-6 
3.  
D004664 42 F Lost Lost C3-5 C3-5 C4-5 C4-5 C4-5 C4-5 
4.  
C95550 36 F Lost Lost N N C3-4 C3-4 C3-4 C3-4 
5.  
C94392 31 F N N C3-4 C3-4 C4-5 C4-5 C4-5 C4-5 
6.  
C098014 32 F N N N N C4-5 C4-5 C4-5 C4-5 
7.  
C098239 38 F N N C4-5,C5-6 C4-5,C5-6 C4-6 C4-6 C5-6 C5-6 
8.  
D000836 25 F N N N N C4-6 C4-6 N N 
9.  
C96489 31 F N N N N C3-5 C3-5 C3-5 C3-5 
10.  
C09925 47 F N N C3-7 C3-7 C4-6 C4-6 C4-6 C4-6 
11.  
4185 48 F N N N N C5-6 C5-6 N N 
12.  
4228 32 F N N C4-5, C5-6 C4-5, C5-6 C4-6 C4-6 C4-6 C4-6 
13.  
4258 37 F N N C3-4,C4-5 C3-4,C4-5 C3-5 C3-5 C3-5 C3-5 
14.  
4267 42 F N N N N C4-5 C4-5 C4-5 C4-5 
15.  
4255 48 F N N C5-6 C5-6 C4-6 C4-6 C4-6 C4-6 
16.  
4226 40 F N N C3-6 C3-6 C3-6 C3-6 C4-6 C4-6 
17.  
4208 42 F N N N N C3-4 C3-4 C3-4 C3-4 
18.  
4251 34 F N N C5-6 C5-6 C4-6 C4-6 C4-6 C4-6 
19.  
4175 42 F N N N N C4-6 C4-6 C4-6 C4-6 
20.  
5217 26 M N N N N C4-5 C4-5 C5-6 C5-6 
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DISCUSSION 
 The main aim of the treatment was to study the therapeutic effect of the drug 
kariuppu chenduram (int) and kunthirika thylam(ext). The clinical features of 
ceganavatham can be correlated to cervical spondylosis  in Modern science. As 
per yougi vaithiya chinthamani text, Pain below the neck, above the hip and in 
both upper limbs,Scorpion sting like pain in  the above regions,Heaviness of the 
body,Burning sensation of the eyes,Constipation is present. 
 
 The safety of the trial drug usage and standardization of the trial drug through 
biochemical analysis were also ensured during the study. 
                    
  The drug was prepared in the Gunapadam lab of National Institute of Siddha after 
the authentication of the raw drugs by the concerned department. The trial drug 
was prepared by the standard operating procedure as mentioned in the protocol. 
 The preclinical toxicity studies (Acute and sub acute toxicity) for the above said    
trial drug was conducted at National Institute of Siddha after getting the proper 
acceptance and permission from the Institutional Animal Ethical Committee 
(IAEC) (1248/ac/09/CPCSEA/december/ 2011) 
 
 The trial drug was proved to be safe for human beings from the observations     
made from the study                               .  
 The biochemical qualitative and quantitative analysis were done at the 
biochemistry lab of NIS and IIT Chennai respectively. It revealed the presence of 
effective minerals and the existence of the drug molecules at micro level. 
 The clinical study was conducted with a well defined protocol and a proper 
proforma after the approval of the Institutional Ethical Committee (IEC). After 
screening 60 cases reporting at the OPD of department of Maruthuvam , 40 cases 
were selected for induction to the trial. Before enrollment into the trial the 
informed consent was obtained from the patients. 
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 The patients were treated for a period of 48 days with kariuppu chenduram 
(int)260mg bd with honey and kunthirika thylam (ext).Clinical assessment was 
done during each visit in OPD patients (12days once) and daily for IPD patients 
and the data were noted in the prescribed proforma. 
 Laboratory investigations,x-ray and ecg were done on the 0day, & 48th day of the 
trial for both OP & IP patients. For IP patients, who was not in a situation to stay 
in the hospital for a long time was advised to attend the OPD for the continuation 
of the treatment.All the patients were put under observation for 2 months follow 
up period without the trial drug treatment. 
 
THE OBSERVATIONS DISCUSSED BELOW: 
GENDER DISTRIBUTION 
             The majority affected sex was male i.e, 8 cases (20%) and female was 32cases (80%)  
 
AGE DISTRIBUTION 
           This study showed that the highest incidence of ceganavatham was between   31 – 40 
years of age, i.e. 20 cases (50%). This may due to the work load. 
GUNAM DISTRIBUTION 
           All the 39 cases under this analysis were predominantly of Rasatha gunam and one 
case is of thamo   gunam assessed from interrogation and other observations. 
DIET 
            Among the 40 cases 38 cases (95%) were non-vegetarians.      
 
DISTRIBUTION OF CASES BY PARUVAKAALAM (SEASONS)  
              In this study, 28 cases (70%) were reported in kaar kaalam, 12cases (30%) in koothir 
kaalam .  
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OCCUPATIONAL REFERENCES 
               In this study 37.5% people are home maker,22.5% are clerical job,17.5% are 
software professionels,tailors are 7.5% and 5% is driver ,teacher and coolie. 
 
SOCIO-ECONOMIC STATUS: 
              In this study 35% of people is poor ,37.55% people is in lower middle class,17.5% 
of people is in lower middle class and rich peoples are 10%. 
DERANGEMENTS OF VATHAM 
Viyanan and samanan were affected in all the 40 cases (100%) .Uthanan is affected in 4 case 
and abanan is affected in 8 case.after treatmen 14 cases remain affected in viyanan and 
samanan.abanan and uthanan remain affected in 2 cases. 
DERANGEMENT OF PITHAM 
              Saathaga piththam was affected in 30 patients, analagam is affected in 8 
cases,ranjagam is affected in 10 cases, prasagam is affected in 4 cases.after treatment 2 cases 
2 cases remain affected renjagam is remain affected in 8 cases,sathagam is affected in 4 
cases. 
DERANGEMENT OF KABAM 
            Santhigam is affected in almost all the patients 100%.klethagam and pothagam is 
affected in 5 cases.after treatment klethaaagam  is affected in 2 cases pothagam is in 1 case 
and santigam remain affected in 10 cases. 
 DERANGEMENT OF GNANENTHIRIUM 
                 Mei is affected in all the 40 cases 100% kan is affected in 30% due to age factor. 
DISTRIBUTION OF UDAL THATHUS 
                              All the udal thathus are affected  except sukkilam and suronitham.  
DISTRIBUTION OF CASES BY EN VAGAI THERVU 
                           Naa is affected in 30%,vizhi is affected in 10 cases,malam is affected in 
20%,neer is affected in 12.5%. 
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DISTRIBUTION OF CASES BY NAADI 
87.5% of cases have vathapitham and 12.5% of cases have pithavatham. 
 
DISTRIBUTION OF CASES BY NEIKKURI 
                               Vathaneer is in 77.5% patients,17.5% have kabha neer and 5% have pitha 
neer. 
   
CLINICAL  FEATURES. 
      Among 40 subjects of the trial 100% subjects reported with pain in nape, 80% 
with radiating pain in upper limbs, 70% reported radiating pain in shoulders, 50% reported 
numbness in upper limbs, 17.5% with giddiness, 7.5% with burning sensation in upper limbs 
, 55% reported restriction of movements, 25% with swelling 
LABORATORY INVESTIGATION: 
Laboratory investigation of blood and urine were done for all 40 subjects prior to and 
after trial. There were no significant changes in the parameters. Pre-treatment and post-
treatment  results of Liver function tests and renal function tests were normal. 
X-RAY FINDINGS 
The radiographic studies of the subjects showed narrowed joint space and presence of 
osteophytes. The trial drug showed reduction in clinical signs and symptoms rather than any 
changes in radiographic studies. 
The treatment was aimed to normalize the deranged kuttram and to provide relief 
from symptoms. Before treatment the patients were advised to take Agasthiyar Kuzhambu-
130 mgs with palm jaggery, during early morning for purgation followed by rest on that day. 
The next day onwards treatment with the trial drugs kariuppu chenduram(internal) and 
kunthirika thailam (external) was started. During treatment, the subjects were advised to 
follow pathiyam (diet restrictions), to avoid lifting heavy weights and to avoid adopting 
postures involving prolonged neck flexion. 
After treatment, 92.5% subjects were relieved from pain in nape, 84.2% from 
radiating pain in upper limbs, 93.3% from radiating pain in shoulders, 90.9% from numbness 
126 
 
in upper limbs, 70% from giddiness, 75% from burning sensation in upper limbs, 83.33% 
from restriction of movements, 60% from swelling. 
 
 
Primary outcome: 
Effect of trial drugs in reducing pain in ceganavatham was statistically significant. 
92.5% subjects among 40 had reduction in neck pain, 84.2% among 38 had reduction 
in radiating pain in upper limbs and 93.3% among 30 had reduction in radiating pain in 
shoulders post-treatment. 
Secondary outcome: 
Effect of trial drugs in reducing restriction of movements in ceganavatham was good. 
83.33% among 24 had reduction in restriction of movements post-treatment. 
IMPROVEMENT: 
 Good improvement in 26 subjects,  
 Moderate improvement in 8 subjects, 
 Mild improvement in 4 subjects and 
 No improvement in 2 subjects. 
were reported in study subjects. 
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STATISTICAL ANALYSIS: 
I. PAIN ASSESSMENT SCALE BEFORE AND AFTER TREATMENT. 
BIO STATISTICAL ANALYSIS 
 The clinical trials of the drug KARIUPPU CHENDURAM(internal)and 
KUNTHIRIKA THYLAM(External) are differentiated in terms of percentages. The 
effectiveness of the drug is assessed by using paired comparison test (paired t test). The 
responses (intensity of pain) of the patients to the drug are analyzed.  
Assessment of the effectiveness of drug: 
 The effectiveness of the drug was assessed by the relief of the patients from pain, and 
which is measured using a standard pain scale. 
 INFERENCE: The test drug is is highly statistically significant (p<0.0001) and 
hence effective in reducing the pain 
 
ACUTE ORAL TOXICITY STUDY 
  Kariuppu chenduram at the dose of 9.36mg/kg/bw did not exhibit any 
mortality in mice. In Necropsy, the organs of the animal such as, Liver, Heart, Lungs, 
pancreas Spleen, Stomach, Intestine, Kidney, Urinary bladder, Uterus all appeared normal. 
LONG TERM TOXICITY STUDY 
  Kariuppu chenduram at the dose of 93.6mg/kg/bw (10x) did not exhibit any 
mortality in rats. Biochemical parameters and histopathology report were also normal. There 
were no signs of toxicity. 
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SUMMARY 
 The aim of the study was to evaluate the efficacy of the drug kariuppu chenduram 
(int) and kunthirika thylam(ext) Before initiating the clinical trial, approval was got 
from the Institutional Animal Ethical Committee and Institutional Ethical Committee 
for conducting the pre clinical studies and clinical studies respectively by submitting 
the well defined protocol and proforma. 
 The raw drugs were authenticated by the concerned department and the trial drug was 
prepared by the investigator in the Gunapadam lab of National Institute of Siddha as 
per the Standard Operating Procedure mentioned in the protocol. 
 The medicine was then subjected to pre clinical toxicity studies (Acute and long term 
toxicity studies) as per the protocol and the safety of the drug was ensured. 
 From the Acute oral toxicity study, the trial drug was found to be safe even at higher 
dose level of 9.36mg/kg/bw.  
 From the Long term toxicity study the trial drug at the dose of 93.6mg/kg/bw (10x) 
did not exhibit any mortality in rats. 
 The qualitative and quantitative bio chemical studies were done at the bio chemistry 
lab of National Institute of Siddha and IIT Chennai respectively. 
 The biochemical study of the trial drug reveals the presence of iron,calcium,sulphate 
and phosphate.,Among the 60 cases screened at the OPD of department of 
Maruthuvam NIS, 40 cases were recruited for the trial as per the inclusion and 
exclusion criteria. 
 Clinical diagnosis of ceganavatham was made by Siddha and Modern methodology. 
 Before inducement into the trial informed consent was obtained from the patients. Out 
of the 40 cases 30 cases were treated in OPD and 10 cases in IPD. 
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 The patients were treated for a period of 48 days The trial medicine selected for  
Internal  treatment were kariuppu chenduram 260mg bd with honey  referred under 
Siddha literature anuboga vaithhhya navaneetham part-3and kunthirika thylam 
external under siddha pharmacoepoeia..Required lab investigations were carried out 
before and after the treatment and the concerned data was recorded in the proforma.  
 Clinical assessment was done daily in all the IP patients and in OP patients it was 
assessed once in 12days. 
 During the study period, there was no event of any adverse reactions owing to the 
drug or disease. 
 Statistical analysis showed significant difference between before and after  treatment 
in  
 Good improvement was observed in 26 subjects, moderate improvement in 8 subjects, 
mild improvement in 4 subjects and no improvement was observed in 2 subjects . 
Effect of trial drugs in reducing restriction of movements in ceganavatham was good. 
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CONCLUSION 
 The safety studies (Acute toxicity and Long term toxicity) studies conducted revealed 
that the trial drug was safe even at higher dosage of 93.6mg/animal. There were no 
abnormalities found in blood investigation and histopathological examination .Hence 
it can be reasonably assumed that the drug is safe for human. 
 Clinical study revealed the therapeutic efficacy of the trial drug by showing,  
 65% of subjects had good improvement, 20% had moderate improvement, 10% had 
mild improvement and 5% had no improvement. 
 There were no adverse reactions complained during the trial. 
 Statistical analysis showed significant difference between before and after treatment 
in the pain scale reading  (p < 0.0001). 
 Pharmacological studies of the trial drug kariuppu chenduram(internal) and kunthirika 
thailam (external)  have shown significant anti- inflammatory and analgesic effects. 
The acute and chronic toxicity studies have shown no renal and hepato toxicity. 
Hence the trials drugs are very safe and effective. 
 Thus it is concluded that are effective in reducing pain, numbness, swelling and 
restriction of movements in ceganavatham.  
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ANNEXURE - I 
TOXICOLOGICAL EVALUVATION OF KARIUPPU CHENDURAM 
ACUTE TOXICITY STUDY OF KARIUPPU CHENDURAM 
[WHO guidelines, 1993] 
Principle: 
    Acute toxicity was carried out in Swiss albino mice with a single exposure of 
10 times of the recommended therapeutic dose of test compound the study duration will be 14 
days. 
Animal species  : Swiss albino mice 
Age / Weight / Size  :  6 weeks.  Mice-20-25gms. 
Gender   :   Both male and female 
Number of Animals   : Mice: 20 
Acclimatization Period : 7 Days 
Clinical dose   : 260 mg/day 
 
S.No Group No of mice 
1 Vehicle control  10  (5 male, 5 female) 
 
2 
Toxic dose 
10X therapeutic dose 
(9.36mg) 
10  (5 male, 5 female) 
 
Test Animals  
       Test animals were obtained from the animal laboratory of the King institute, 
Chennai and stocked at National institute of siddha, Chennai. All the animals were kept under 
standard environmental condition (27+ or – 2 degree c).The animals had free access to water 
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and standard pellet diet (Sai Durga foods pvt.ltd, Bangalore).The principles of laboratory 
animal care were followed and the  Institutional ethical committee approved the use of 
animals and the study design. (1248/ac/09/CPCSEA/december/ 2011) 
 Route of administration: 
  Oral route was selected, because it is the normal route of clinical 
administration. 
Test substance and vehicle 
        The kariuppu chenduram is LIGHT BROWN in colour with mild odour.  The 
test substance is insoluble in water, in order to obtain and ensure the uniformity in drug 
distribution the drug is dissolved by aqueous Tween 80 solution (10%).  
 
Administration of doses 
            kariuppu chenduram was suspended in aqueous Tween 80 solution (10%), 
with uniform mixing and it was administered to the groups in a single oral dose .The control 
groups were received equal volume of the vehicle. The animals were weighed before giving 
the drug. The dose level was calculated according to body weight, and surface area. Since the 
clinical dose was 260mg/day it was converted to animal dose (9.36mg) and then 
administered. The principle of laboratory animal care was followed. 
Observations 
  Observations were made and recorded systematically and continuously 
observed as per the guideline after substance administration. Animals were observed 
individually (visual observations included skin changes, alertness, grooming, aggressiveness, 
sensitivity to sound, touch and pain ,restlessness, tremors, convulsion, righting reflex, corneal 
reflex, gripping reflex, pinna reflex, writhing reflex, papillary reflex, urination, salivation, 
lacrimation for first 4 hrs, then periodically during the first 24 hrs. Animals were observed for 
body weight and mortality for 14 days. If animals dying during the period of study, the 
animals were sacrificed.  At the end of the 14
th
 day all animals were sacrificed and necropsy 
was done. 
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Body Weight 
  Individual weight of animals was determined before the test substance was 
administered and daily for 14 days. Weight changes were calculated and recorded. At the end 
of the test, surving animals were weighed and sacrificed. 
Results: kariuppu chenduram at the dose  9.36mg/animal did not exhibit any mortality in 
mice. 
  No behavior changes were noted for the first 4 hours and for the next 24 hours 
and throughout the study period of 14 days. No weight reduction was noted before and after 
the acute study duration. Reflexes were found to be normal before and after the study. All 
other observations were found to be normal before and after the study. In Necropsy, the 
organs of the animal such as, Liver, Heart, Lungs, Pancreas, Spleen, Stomach, Intestine, 
Kidney, Urinary bladder, Uterus all appeared normal. 
 
SUB ACUTE TOXICITY STUDY OF KARIUPPU CHENDURAM 
Animals             : Male and Female Wister albino rats 
Age                    : 6-8 weeks 
Weight   : 150-200 gms 
Gender   :  Both male and female 
Number of animals   : Rat: 40 
Acclimatization period : 7 Days 
Clinical dose   : 260mg/day 
Clinical duration  : 28 days 
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Animal source:      
   Test animals were obtained from the animal laboratory of the King 
institute, Chennai, and stocked at national institute of siddha, chennai. All the animals were 
kept under standard environmental condition (27+ or – 2 degree c) .The animals had free 
access to water and standard pellet diet (Sai durga foods pvt.ltd, Bangalore). The principles of 
laboratory animal care were followed and the Institutional ethical committee approved the 
use of animals and the study design. (1248/ac/09/CPCSEA/DECEMBER/IAEC 2011) 
Identification of animal:  
   By cage number, animal number and individual marking on fur. 
Housing and Environment: 
   The animals were housed in polypropylene cages provided with 
bedding of husk. Dark and light cycle each of 12 hours. 
Administration period: 
  The period of administration of the test substance to animals are depending on 
the expected period of clinical use. Since the clinical duration of the test drug is 28 days and 
as per WHO guidelines the administration period is reported to be 1 month. 
 
 
 
 
    S.No 
                 
             Group 
      
     No of Rats 
       1 Vehicle control  10 (5male,5 female) 
       2 1XTherapeutic dose (9.36mg) 10 (5male,5 female) 
       3 5XTherapeutic dose (46.8mg) 10 (5male,5 female) 
       4 10XTherapeutic dose(93.6mg) 10(5male, 5 female) 
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 Dose selection: 
  The results of acute toxicity studies in Swiss albino mice indicated that 
karpoora silasathu parpam was non toxic and no behavioral changes, mortality was observed. 
On the basis of these results, the doses were selected for the study as per WHO guidelines.  
Preparation and administration of dose:        
  Kariuppu chenduram was suspended in aqueous twin 80 solution (10%). It 
was administered to animals at dose levels of 1X therapeutic dose (9.36mg/animal), 
5XTherapeutic dose (46.8mg/animal) and 10X Therapeutic dose (93.6mg/animal).The 
control animals were administered vehicle only. Administration was by oral (gavage) once a 
day for 30 days. 
METHODOLODY: 
Randomization, numbering and grouping of animal: 
  The animals were randomly divided into three groups for dosing up to 30 
days. Each group consist of 10 animals (5 per sex in each group) were allowed 
acclimatization period of 7 days to laboratory conditions prior to the initiation of treatment. 
Each animal fur was marked with picric acid. The females were nulliparous and non 
pregnant. 
 
OBSERVATION: 
  Experimental animals were kept under observation throughout the course of 
study for the following 
Body weight:  
  Weight of each rat was recorded on day 1 and at weekly intervals throughout 
the course of study and at termination to calculate relative organ weights. From the data mean 
body weights and percent body gain were calculated. 
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Food and water consumption: 
  The quantity of food consumed by groups consisting of an animal for different 
doses was recorded at weekly intervals. Food consumed per animal was calculated for control 
and the treated dose groups 
Clinical sings 
  All animals were observed daily for clinical sings. The time of onset intensity 
and duration of this symptom if any were recorded 
Mortality: 
  All animals were observed twice daily for mortality during entire course of 
study. 
 
TERMINAL STUDIES: 
 LABORATORY INVESTIGATIONS: 
  Following laboratory investigations were carried out. On day 40 animals 
fasted overnight. Blood samples were collected by cardiac puncture using sodium heparin 
(200IU\ml) for blood chemistry and potassium EDTA (1.5 mg/ml) for hematology 
anticoagulant. Blood sample were centrifuged at 3000 r. p .m for 10 minutes. 
 Biochemical investigations: 
          The effect of kariuppu chenduram on certain biochemical parameters were 
examined and compared with those of the control group. The blood samples collected with 
heparinized bottles were centrifuged at 5000 rpm for 10 minutes to obtain clear serum for the 
following investigation. Glucose was estimated using commercial Glucose estimation kit 
(Span Diagnostics) by the method of Barham et al., (1972) and Tenscher. et al., 
(1971),Haemoglobin PCV, RBC, Erythrocyte  count was estimated by Hemocytometer 
method of Ghai (1995). Total Leukocyte Count was estimated by Hemocytometer method of 
John (1972).Total, (Bilirubin test kid-malloy and evelyn 1937) direct and indirect bilirubins 
were determined. Alkaline phosphatase, Alanine amino tranferase (ALT) and Aspartate 
amino transferase (AST) were measured by using ALT and AST test kit (kind & king) .Total 
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protein TP concentration was determined. Albumin was determined based on its reaction with 
bromocresol green (binding method) .Urea was determined according to urease –berthelot 
method and plasma creatinine was estimated using  jaffe reaction. Results of biochemical 
investigations conducted on day 31 revealed significant changes in the values of different 
parameters studied when compared with those of respective controls. 
NECROPSY:  
           All the animals were sacrificed on day 40 under ether anesthesia. Necropsy of 
all animals was carried out and the weights of the organs including liver, kidneys, brain, 
heart, and lungs were recorded. 
HISTOPATHOLOGY: 
  Tissue samples of organs from control and treated animals were preserved in 
10% formalin for preparation of sections using microtome. The organs included liver, 
kidneys, heart, lungs and stomach of the animals were preserved and they were subjected to 
histopathological examination. 
 
  The organ pieces (3-5 micron) were fixed in 10% formalin for 24 hours and 
washed in running water for 24 hours .Samples were dehydrated in tissue processor and then 
cleaned in benzene to remove absolute alcohol. Embedding was done by passing the cleared 
sample through three cups containing molten paraffin at 50 degree c and then a cubical block 
of paraffin made by the L moulds it was followed by microtome and the slides were stained 
with haematoxylin–eosin stain. Stained sections of each organ were examined under light 
microscope at high (40X) power magnification. All the histo pathological slides were 
prepared at Vels university, pallavaram, Chennai. 
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RESULTS:   
                                 CONTROL ANIMALS 
Kidney:  
            Shows normal renal tissue with glomeruli and tubules.  
Spleen:  
            Shows normal spleen with lymphoid aggregation. 
Liver:  
           Shows almost normal hepatocytes and occasional binucleate cells. 
Stomach:  
           Shows normal mucosal glands. 
Ovary: 
           Shows ovarian stroma with follicles and corpus leuteum. 
Lung:  
         Shows normal alveoli. 
Testis:  
           Shows normal tubules with spermatogenesis. 
Heart:  
            Shows normal cardiac muscle bundles. 
Brain:  
             Shows normal brain with nerve fibers and astrocytes. 
Intestine:  
              Shows normal Intestinal mucosal lining with mild exudates. 
Bone:  
              Shows normal osteocytes 
Pancrea:  
               Shows normal acini with islets of β-cells 
IMPRESSION: NORMAL STUDY 
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 2.5MG TREATED (Low dose) 
Kidney: shows normal renal tissue with glomeruli and tubules.  
Spleen: shows normal spleen with lymphoid aggregation. 
Liver: shows almost normal hepatocytes and occasional binucleate cells. 
Stomach: shows normal mucosal glands. 
Ovary: shows ovarian stroma with follicles and corpus leuteum. 
Lung: shows normal alveoli. 
Testis: shows normal tubules with spermatogenesis. 
Heart: shows normal cardiac muscle bundles. 
Brain: shows normal brain with nerve fibers and astrocytes. 
Intestine: Shows normal Intestinal mucosal lining with mild exudates. 
Bone: Shows normal osteocytes 
Pancrea: shows normal acini with islets of β-cells 
5MG TREATED (Mid dose) 
Brain: shows brain with edema, microglial proliferation, shows brain with micro cystic 
change and astrocytic proliferation, shows brain with mononuclear infiltrate around vessel.  
Kidney: shows renal tissue with focal tubular damage, interstitial inflammatory collection. 
Glomeruli shows epithelial proliferation.  
Liver: shows hepatocytes with focal mild fatty change.  
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Spleen: shows congestion with lymphoid hyperplasia.  
Stomach: shows near normal mucosal gland with mild exudates. 
Lung: shows congested alveolar wall with mild thickening and mild emphysematous 
changes.  
Pancreas: shows pancreas with acini and normal islets.  
Testis: shows normal tubules with spermatogenesis. 
Heart: shows congestion and mild inflammatory infiltration in between cardiac muscle 
bundles. 
Ovary: shows ovarian stroma with follicles and corpus leuteum. 
Intestine: Shows normal Intestinal mucosal lining with mild exudates. 
Bone: Shows normal osteocytes 
10MG TREATED (High dose) 
Stomach: shows stomach with superficial erosion and congestion.  
Heart: shows hypertrophic cardiac muscle bundles.  
Spleen: shows lymphoid hyperplasia. 
Brain: shows brain with edema. Astrocytes show degenerative changes.shows brain with 
pyknotic irregular nucleus, shows brain with vesicular nuclei and micro cystic changes.  
Liver: shows marked dilatation of sinusoids, degeneration of hepatocytes, necrosis.   
Kidney: shows renal tissue with tubular epithelial damage.  
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Pancreas: shows atrophic islet cells. 
Testis: Giant cells were formed in the lumen of the seminiferous tubules and the 
spermatogenic cells degenerated. Lung: shows congestion, narrowed alveolar space and 
thickened alveolar     wall. 
Ovary: shows ovarian follicles and corpus leuteum. 
Intestine:Shows normal Intestinal mucosal lining with mild exudates. 
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Preliminary phytochemical screening: 
 Qualitative phytochemical analysis of Acidic/Basic radicals and  constituents in test drug -  Preliminary  
Qualitative analysis of drug –CPM 
 
Procedure Observation Inference 
Test for Calcium : 2 ml of extract 
is taken in a clean test tube. To this 
add 2 ml of  4% ammonium oxide 
solution.   
 white precipitate is formed  
Presence of calcium  
Test for Sulphate : 2 ml of the 
extract is added to 5 % barium 
chloride solution. 
 
Cloudy appearance present 
 
Presence of Sulphate  
Test for Chloride : The extract is 
treated with Silver nitrate solution  
 White precipitate is formed Presence of Chloride 
Test for carbonate : The substance 
is treated with Conc. HCl. 
No effervescence is formed  Absence of carbonate 
Test for Starch : The extract is 
added with weak iodine solution  
No blue colour is formed Absence of starch  
Test for Iron (Ferric) : The extract 
is treated with glacial acetic acid 
and potassium ferrocyanide  
No blue colour is formed Absence of Ferric iron 
Test for Iron (Ferrous) : The 
extract is treated with Conc. HNO3 
and ammonium thiocynate 
Blood red colour is formed Presence of Ferrous iron 
Test for phosphate : The extract is 
treated with ammonium molybdate 
and conc. HNO3 
Yellow precipitate is formed Presence of phosphate 
Test for Tannic acid : The extract 
is treated with Ferric chloride  
No black precipitate is formed Absence of Tannic acid 
Test for Unsaturation : 1 ml of 
Potassium permanganate solution is 
added to the extract.    
Does not get decolourised  Absence of unsaturated compound 
Test for saponins: Dilute extract+ 
1ml of distilled water shake well. 
No Froth formation Absence of saponins 
Test for sugars :  
 Benedict method ; 5ml of  
Benedict solution heated gently then 
add 8 drops of diluted extract then 
heated in a boiling water bath. 
No colour change occured 
 
 
 
    
Indicates the Absence of sugar 
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Molisch test; Dilute extract+2 drops 
of Molisch+3ml conc.H2SO4. 
 
 
 No Reddish violet zones appeared 
 
Absence of carbohydrate 
Test for steroids : Liberman 
Burchard test ; Dilute extract +2 ml 
acetic anhydride+conc.H2SO4 . 
No Formation of red colour  Absence of steroids 
Test for amino acids: Dilute extract 
+2ml of Ninhydrin‟s soln . 
No formation of  violet colour Absence of  amino acids 
Test for proteins: Biuret method ; 
1ml of dilute 
extract+1mlof5%CuSO4+ 
1%NaOH. 
No formation of deep blue  colour Absence of proteins 
Test for Flavanoids : Dilute 
extract+ mg  bits+2drops of 
conc.HCl  and gently heated. 
No formation of pink colour Absence of Flavanoids 
Test for phenol; Dilute 
extract+2drops of FeCl3 soln. 
 No green colour is formed Absence of phenols 
Test for Tannins ; dilute extract 
+2ml of 10%lead acetate add. 
No white precipitate formed Absence of tannins 
Test for alkaloids; 
 Mayer‟s method;1ml of dilute 
extract + 1ml reagent. 
 
Dragendroff‟s method; 1ml of dilute 
extract+ 1ml of reagent. 
 
 
No precipitate 
 
 
 
No orange colour precipitate 
 
Absence of alkaloids 
 
 
 
Absence of alkaloids 
 
 
 
 
 
 
 
 
 
 
144 
 
Table 1 
Preliminary acid, basic radicals and phytochemical screening of CPM 
 
 
 
S.No. Constituents CPM 
1. Calcium present 
2. Iron (Ferric) absent 
3. Iron (Ferrous) present 
4. Sulphate present 
5. Chloride absent 
6. Carbonate  absent 
7. Starch absent 
8. Phosphate present 
9. Tannic acid absent 
10. Unsaturated absent 
11. Sugar absent 
12. Alkaloids absent 
13. Steroids absent 
14. Protein absent 
15. Tannins absent 
16. Phenols absent 
17. Flavanoids absent 
18. Saponins absent 
19. Amino acid absent 
20. Glycosides absent 
21 Sterols absent 
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SOPHISTICATED ANALYTICAL INSTRUMENT FACILITY 
IITM, CHENNAI-36 
 
Table-1. 
Colour  characters of kariuppu Chenduram. 
 
S No 
 
Solvent used 
 
Under ordinary light 
 
Under ultra violet light 
 
1 PM Light Brown Light Brown 
 
PM-Powdered  material 
Table-2. 
Physicochemical properties of kariuppu Chenduram. 
 
S No. 
 
Parameters  
Values 
obtained 
(%w/w) 
Heavy/ toxic metals 
1 Total ash value  10.35 Lead BDL 
2 Acid insoluble ash  0.56 Cadmium BDL 
3 Water soluble ash  7.16 Mercury BDL 
4 Moisture content  10.74 Arsenic BDL 
 
Table-3. 
Colour, nature and percent yields of extracts of  kariuppu Chenduram. 
 
S.no. 
 
Extract 
Solvents 
 
Colour 
 
Nature 
 
 
% Yield(w/w) 
 
SEM-Micro 
graph partical 
size range in 
micron 
 
pH 
1 Water Light 
Brown 
Solid      50 0.5 -1.5     micron 8.7 – 8.9 
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The following medicine was used in the study was processed by the methods prescribed in 
standard text books of siddha medicines. 
                Kariuppu chenduram) was prepared by the method prescribed in the text book of  
anuboga vaithiya navaneetham. 
HR SEM-METHODOLOGY: 
An SEM is essentially a high magnification microscope, which uses a focussed scanned 
electron beam to produce images of the sample, both top-down and, with the necessary sample 
preparation, cross-sections. The primary electron beam interacts with the sample in a number of key 
ways:- 
 Primary electrons generate low energy secondary electrons, which tend to 
emphasize the topographic nature of the specimen.  
 Primary electrons can be backscattered which produces images with a high degree 
of atomic number (Z) contrast.  
 Ionized atoms can relax by electron shell-to-shell transitions, which lead to either 
X-ray emission or Auger electron ejection. The X-rays emitted are characteristic 
of the elements in the top few μm of the sample.  
SAMPLE PREPARATION: 
Sample preparation can be minimal or elaborate for SEM analysis, depending on the 
nature of the samples and the data required. Minimal preparation includes acquisition of a 
sample that will fit into the SEM chamber and some accommodation to prevent charge build-
up on electrically insulating samples. Most electrically insulating samples are coated with a 
thin layer of conducting material, commonly carbon, gold, or some other metal or alloy. The 
choice of material for conductive coatings depends on the data to be acquired: carbon is most 
desirable if elemental analysis is a priority, while metal coatings are most effective for high 
resolution electron imaging applications. Alternatively, an electrically insulating sample can 
be examined without a conductive coating in an instrument capable of "low vacuum" 
operation.  
 The SEM is carried out by using FEI-Quanta FEG 200-High Resolution Instrument. 
Resolution : 1.2 nm gold particle separation on a carbon substrate 
Magnification: From a min of 12x to greater than 1, 00,000 X 
Application : To evaluate grain size, particle size distributions, material homogeneity  and  
inter metallic distributions 
   . 
Experimental Procedure: Done at SAIF, IIT Madras, Chennai-36 
148 
 
SEM – Micro graph partical size 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS  PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT)&KUNTHIRIKA THAILAM(EXT) 
FORM l -SCREENING & SELECTION PROFORMA 
1 OP/IP NO   -------------   2 BED NO ----------------    3 SI NO---------- 
4 NAME --------------         5 AGE ---------                   6 GENDER -------- 
7 OCCUPATION ------------------  8 INCOME   ----------- 
9 ADDRESS  ----------------------                         10 CONTACT NO ------------------- 
                      ---------------------- 
                      ----------------------- 
 INCLUSION CRITERIA: 
 Age :25-50Yrs                                                                                                  Yes / No 
 Sex : Both male and female                                                                             Yes / No 
 Patients with pain in nape,radiating to upper limbs with or without                        Yes / No                                                         
       numbness,giddiness and neck stiffness. 
 Patients willing to take x-ray before and after treatment.                                         Yes / No 
 Patients willing   to give blood sample for laboratory investigations                       Yes / No 
before and after  treatment.   
 
 Patient willing to sign the informed consent stating that he/she will 
        conscientiously stick to the treatment during 48days.                                              Yes / No 
  
EXCLUSION CRITERIA: 
 
ADMITTED TO TRAIL:     YES                 NO                    If Yes Serial No: 
Date:                               Station: 
Signature of the Investigator:  
 
Signature of the Lecturer:                                                  
                                                                                                                  Signature of the HOD 
 
 
Rheumatoid arthritis Y/N Pregnancy &lactation Y/N Use of narcotic drugs Y/N 
Renal diseases Y/N Diabetes mellitus Y/N       Any other illness Y/N 
Hypertension Y/N Cardiac diseases Y/N   
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS  PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT)&KUNTHIRIKA THAILAM(EXT) 
FORM I-AHISTORY PROFORMA ON ENROLLMENT 
1. Serial No :   _______________                                             2. OP/IP No:---------- 
 
3. Name: ________________                                                    4. Gender:   Female/male 
 
5. Age (years): _________   DOB    
      Date       Month            Year 
6.Address:     -------------------------------------- 
                     ------------------------------------- 
                     -------------------------------------- 
 
7.A.Occupation:    -----------------------------                         B. Nature of work  ----------------- 
 
8. Educational  Status:   A) Illiterate                  B)Literate  
 
9.Height:           cms                10.Weight:           kg 
 
 
11. Complaints and Duration:   
________________________________________________________________________ 
 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
 
12. Habit of 
 
A) Smoking                   1. Yes; duration ________ years;    Number-                  2.No 
B) Alcoholism               1. Yes; duration ________ years;    Quantity-      ml       2.No 
C) Tobacco chewing     1. Yes; duration ________ years                                      2.No 
D) Betel chewing          1. Yes; duration ________ years                                      2.No 
 
 
13.Dietry style: A.Pure vegetarian           B.Non-vegetarian             
 
 
14. Drug History: Had the patient been treated before with allopathy drug? A) Yes            B)No 
 
If Yes Name of the drugs ______________, duration of treatment ______________                               
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15. MARITAL STATUS    1.Married       2.Unmarried      
                                               No of children:             male:          female: 
16. FAMILY HISTORY 
Whether this problem runs in family?                         1. Yes                               2.No   
 If yes, mention the relationship of affected person(s)        ------------------------- 
17. MENSTURAL HISTORY:------------------------- 
18. BOWEL HABITS & MICTURITION: 
 Historyof habitual constipation              Yes / No 
 History of frequent diarrhoea                  Yes / No 
 History of frequent dysuria                      Yes / No 
   
19. PSYCHOLOGICAL STATE: 
 
Normal                                        Anxiety                                       Depression 
 
 
  Date:         
  Station: 
 
  Signature of the Investigator: 
 
 
  Signature of the Lecturer:                                                         
 
                                                                                         Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS  PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT)&KUNTHIRIKA THAILAM(EXT) 
 FORM II AND II-A CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS   
1. S NO -----------                            2. OP/IP NO ------------------   REG NO:32101205/2012-13 
3.  NAME --------------- -------------                           4.GENDER M/F                         
 5. DATE OF  ASSESSMENT   :    ---------------------- 
 
          Initial (0
th
 day)                12
th 
day               24
th  
day               36
th
 day            48
th
 day 
 
SIDDHA SYSTEM OF EXAMINATION 
6. ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
I. NAADI: [PULSE PERCEPTION] 
 
 
II. NAA:[TONGUE] 
 0th Day 12th Day 24th Day 36th Day 48th Day 
Colour Dark / Yellow/Red 
/ Pale/Normal 
Dark/Yellow/ 
Red/Pale/Normal 
Dark/Yellow/ 
Red/Pale/Normal 
Dark/Yellow/ 
Red/Pale/Normal 
Dark/Yellow 
Red/Pale/normal 
Taste Sweet/Bitter/Sour 
Pungent/None 
Sweet/Bitter/Sour 
Pungent/None 
Sweet/Bitter/Sour 
Pungent/None 
Sweet/Bitter/Sour 
Pungent/None 
Sweet/Bitter/Sour 
Pungent/None 
Coating Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
Fissure Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
Saliva Normal/Increased/ 
Decreased 
Normal/Increased 
Decreased 
Normal/Increased/ 
Decreased 
Normal/Increased/ 
Decreased 
Normal/Increased/ 
Decreased 
Dryness Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
Glossitis Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
Baldness Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
 
III.NIRAM: [COMPLEXION]    
0
th
 Day  12th day 24
th
 Day 36
th 
Day 48
th
 Day 
Dark/Yellow 
tinted/Wheatish 
brown / Pale 
Dark/Yellow tinted  / 
Wheatish brown/ 
Pale 
Dark/Yellow tinted/       
Wheatish brown / 
Pale 
Dark/ Yellow tinted / 
Wheatish brown /Pale                                                      
Dark/ Yellow tinted/ 
Wheatish brown/ Pale
 
 
IV.MOZHI: [VOICE] 
0
th
 Day  12th day 24
th
 Day 36
th 
Day 48
th
 Day 
Medium/High 
Low pitched 
Medium/High/ 
Low pitched 
Medium/High/ 
Low pitched 
Medium/High/ 
Low pitched 
Medium/High/ 
Low pitched 
 
V.VIZHI: [EYES] (Lower palpabrel conjunctiva) 
0
th
 Day  12th day 24
th
 Day 36
th 
Day 48
th
 Day 
Yellow 
Red/ Pale/Normal 
Dark/Yellow 
Red/ Pale/Normal 
Dark/Yellow 
Red/ Pale/Normal 
Dark/Yellow 
Red/ Pale/Normal 
Dark/Yellow 
Red/ Pale/Normal 
 0
th
 
day 
12
th 
day
 
24
th 
day
 
36
th 
 Day 
48
th
 
day 
 0
th
 
day 
12
th 
Day 
24
th
 
day 
36
th
 
Day 
48
th
 
day 
Vali      Iyyavali      
Azhal      ValiIyyam      
Iyyam      AzhalIyyam      
ValiAzhal      IyyaAzhal      
Azhalvali            
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VI. MALAM; [BOWEL HABITS / STOOLS] 
 0
th
 Day 12
th
 Day 24 
th
 Day 36
th
 Day 48
th
 day 
Colour Dark/ Yellow/ 
Pale/Others 
Dark/ Yellow/ 
Pale 
Dark/ Yellow 
Pale 
Dark/ Yellow/ 
Pale 
Dark/ Yellow/ 
Pale 
Consistency Solid/Semisolid 
Watery 
Solid/Semisolid 
Watery 
Solid/Semisolid 
Watery 
Solid/Semisolid 
Watery 
Solid/Semisolid 
Watery 
Stool  bulk                          Normal/Reduced 
 
Normal/Reduced Normal/Reduced Normal/Reduced Normal/Reduced 
Constipation   Present/Absent 
 
Present/Absent 
 
Present/Absent 
 
Present/Absent 
 
Present/Absent 
 
Diarrhoea Present/Absent Present/Absent Present/Absent Present/Absent Present/Absent 
 
VII. URINE EXAMINATION:    
 
Neikkuri      
Serpentine 
fashion 
     
Annular/Ringed 
fashion 
     
Pearl beaded 
fashion    
     
Mixed fashion      
Other fashion      
 
 
VIII. SPARISAM: [PALPATORY  PERCEPTION] 
0
th
 Day 12
th
 Day 24
th
 Day 36
th
 Day 48
th
 Day 
Warmth/Cold/Normal 
 Sweat 
Warmth/ 
Cold/Normal 
Sweat 
Warmth/ 
Cold/Normal 
Sweat 
Warmth/ 
Cold/Normal 
Sweat 
Warmth/ 
Cold/Normal 
Sweat 
 
7. THEGI: [ TYPE OF BODY CONSTITUTION]   
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha udal  
 
NEERKUR
I 
 
0
th
 Day 12
th
 Day 24 
th
 Day 36
th
 Day 48
th
 day 
Niram 
[Colour]   
White/Yellowish/ 
Strawcoloured/ 
Crystal clear 
White/Yellowish/ 
Strawcoloured 
Crystal clear 
White/Yellowish/ 
Straw  coloured/ 
Crystal clear 
White/Yellowish/ 
Straw coloured/ 
Crystal clear 
White/Yellowish/ 
Straw  coloured/ 
Crystal clear 
Manam 
[Odour] 
Present  
Absent 
 Present  
Absent 
Present  
Absent 
Present  
Absent 
Present  
Absent 
Nurai 
[Froth] 
Nil 
Reduced/Increased 
Nil 
Reduced/Increase
d 
Nil 
Reduced/Increase
d 
Nil 
Reduced/Increase
d 
Nil 
Reduced/Increase
d 
Edai 
[Sp.gra]                                
Normal 
Increased/Reduced  
Normal 
Increased/Reduce
d 
Normal 
Increased/Reduce
d 
Normal 
Increased/Reduce
d 
Normal 
Increased/Reduce
d 
Enjal 
[Deposits] 
Present/ Absent Present/ Absent Present/ Absent Present/ Absent Present/ Absent 
Volume   Normal 
Increased/Reduced 
Normal 
Increased/Reduce
d 
Normal 
Increased/Reduce
d 
Normal 
Increased/Reduce
d 
Normal 
Increased/Reduce
d 
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8.NILAM: [ LAND WHERE PATIENT LIVED MOST] 
 
Kurinji                          Mullai                   Marutham                    Neithal                    Palai 
 
(Hilly terrain)              (Forest range)          (Plains)                  (Coastal belt)        (Arid regions)  
 
 9. KAALAM 
Kaarkalam-                                 Pinpanikalam 
 
Koothirkalam-                            Ilavenil 
 
Munpanikalam -                         Muthuvenil 
 
10. GUNAM 
Sathuvam                        Rasatham                       Thamasam 
 
 
11. IMPORIGAL (SENSORY ORGANS) 
 
 
12. KANMENDRIYAM ( MOTOR ORGANS) 
 
 
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Mei  
(Skin) 
     
Vai 
(BuccalCavity) 
     
Kann 
 (Eye) 
     
Sevi 
 (Ear) 
     
Mooku 
(Nose) 
     
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Kai (upper limb)      
Kaal (lower limbs )      
Vai   (buccal 
cavity) 
     
Eruvai (excretory 
organs) 
     
Karuvai  
(reproductive 
organs) 
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13. KOSANGAL(Sheath)   
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
AnnamayaKosam      
Pranamayakosam      
Manomayakosam      
Vignanamayakosam      
Ananthamayakosam      
 
 
14. MUKKUTRAM:[AFFECTION OF THREE HUMORS] 
A)VATHAM: 
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Praanan      
Abaanan
  
     
Samaanan      
Udhaanan      
Viyaanan      
Naagan      
Koorman      
Kirukaran      
Devathathan      
Dhananjeyan      
 
 
B) PITHAM: 
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Analapitham 
  
     
Ranjakam      
Saathakam      
Prasakam       
Alosakam       
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C) KABAM: 
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Avalambagam      
Kilethagam      
Pothagam      
Tharpagam
  
     
Santhigam
  
     
 
15. SEVEN DHATHUS: (7 SOMATIC COMPONENTS) 
 
16. SYSTEMIC EXAMINATION: 
 
 
 
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Saaram[Chyme]      
Senneer[Blood]       
Oon[Muscle]      
Kozhuppu[Fat]      
Enbu[Bones]      
Moolai[Bone 
marrow] 
     
Sukkilam/Suronitham
[Genital discharges] 
     
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Locomotor system      
Cardio 
vascular  
system 
 
 
    
Respiratory system       
 
    
Gastro 
intestinal 
 system    
 
 
    
Central  
nervous  
system        
 
 
    
Urogenital system      
endocrine  
system 
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17. GENERAL EXAMINATION: 
 
CLINICAL ASSESSMENTS:  
 
 
   COMPLAINTS 
   0
th
 day    12
th
 day   24
th
day    36
th
 day 48
th
 day 
Pain in neck      
Pain in shoulder      
Nature of pain      
Onset of pain      
Radiating pain in right upper 
limb 
     
Radiating pain in left upper limb      
Numbness      
Tenderness       
Restriction of  neck movements      
Burning sensation      
Giddiness      
 0
th
 day 12
th
 day 24
th
 day 36
th 
day 48
th
 day 
 
Height (cms) 
 
     
Weight (kg) 
 
     
Temperature(°F)  
 
     
Pulse rate (per min) 
 
     
Heart rate (per min) 
 
     
Respiratory rate(per min) 
 
     
Blood pressure(mm/Hg) 
 
     
Pallor 
 
     
Jaundice 
 
     
Cyanosis 
 
     
Lymphadenopathy 
 
     
Pedal edema 
 
     
Clubbing 
 
     
Jugular vein pulsation 
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CLINICAL EXAMINATION 
 
I. INSPECTION 
 
 0
th
  day 12
th
 day 24
th
 day 36
t
  day 48
th
  day 
 
Attitude 
 
     
Muscle wasting 
 
     
Swelling 
 
     
 
 
II PALPATION: 
 
 0
th
  day 12
th
 day 24
th
 day 36
th
 day 48
th
  day 
Tenderness 
 
     
Muscle spasm 
 
     
Local heat 
 
     
Local lymph 
Adenopathy 
 
     
Joint stiffness 
 
     
 
II. NECK MOVEMENTS: 
 
 0
th
  day 12
th
 day 24
th
 day 36
th
  day 48
th
  day 
 
Neck Stiffness 
 
     
Rotation 
 
     
Flexion 
 
     
Extension 
 
     
Lateral bending 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
159 
 
III. MOVEMENTS 
 
A. HEALTH ASSESSMENT QUESTIONNAIRE: 
 
 
Date :      
 
Station: 
 
Signature of the Investigator: 
      
 
 
Signature of the Lecturer:                                                  
 
 
                                                                                                                    Signature of the HOD 
 
 
 
 
 
 
  
 
 
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
PAIN 
A. Onset: 
Sudden/Gradual    
     
B. Early morning  
Stiffness (Present/absent) 
     
C. Nature of pain                                             
(Mild/ Moderate/ Severe)                                                                                                                           
   
D. Aggravating   factor-     
     Movement  (Yes/No) 
    
E. Relieving factor –
Rest 
    (Yes/No) 
     
G. Tenderness 
     (Present/absent) 
     
 Restriction of neck 
movements(Fully/Partial/ Nil) 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS  PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT) & KUNTHIRIKA THAILAM (EXT) 
FORM III   LABORATORY PARAMETERS-CHART 
1. OP/IP No: ________                          2.S. No:                                  3.Reg no: 32101205/2012-13 
4. Name: ________________                   5. Age:   _______ years      6. Gender: M/F 
 
BLOOD INVESTIGATION 
0th DAY 
Date: 
48thDay 
Date: 
 
NORMAL VALUES 
HB ( gms%)   M:14-18 ;W:11-15 
T.RBC(milli/cu.mm)   M:4.5-6.5 ;W:3.5-5.5 
 
ESR (mm) 
½ hr.    
1 hr.   M:0-10 ;W:0-20 
T.WBC (cu.mm) 
 
DIFFERENTIAL COUNT (%) 
   4000-11,000 
Polymorphs   40-75 
Lymphocytes   20-35 
Monocytes   2-10 
Eosinophils   1-6 
 Basophils   0-1 
Blood glucose (mg/dl) 
Fasting   80-120 
PP   <130 
Random   <140 
Lipid profile (mg/dl) 
Serum cholesterol   150-250 
HDL   30-60 
LDL   Upto 130 
VLDL   40 
TGL   Upto 160 
RFT (mg/dl) 
Blood urea   16-50 
Serum creatinine   0.6-1.2 
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Serum Uric acid    M:3-9 ;W: 2.5-7.5 
LFT (mg/dl) 
Total bilirubin   0.3-1 
Direct bilirubin   0.1-0.3 
Indirect bilirubin   0.2-0.8 
Serum total 
protein 
  6-8 
Serum Albumin   3.5-5.5 
Serum globulin   2-3.5 
Fibrinogen(g/dl)   0.2-0.4 
Serum calcium   9-11 
Serum 
phosphorous 
  2-5 
SGOT (IU/L)   6-18 
SGPT (IU/L)   3-26 
Alkaline 
phosphatase 
(kingÅ units) 
  3-12 
 
URINE INVESTIGATION 
0
th
 DAY 
Date: 
 
48
th
 DAY 
Date: 
neikkuri   
neerkkuri   
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
Urobilinogen   
MALAM   
Ova   
Cyst   
Occult blood   
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X RAY CHANGES 
X-Ray cervical spine- AP view, Lateral view 
X RAY CHANGES 
 
Before treatment   (0th day) After treatment (48th day) 
 
   
Date: 
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                                      Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS  PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT) & KUNTHIRIKA THAILAM (EXT) 
FORM IV-C CONSENT FORM 
CERTIFICATE OF CONSENT 
“I have read the foregoing information, or it has been read to me. I have had the opportunity to ask 
questions about it and any questions I have asked have been answered to my satisfaction.  
            I   consent voluntarily to participate as a participant in this study and understand that I have 
the   right to withdraw from the study at any time without in any way it affecting my further 
medical care”. 
 
"I have received a copy of the information sheet/consent form". 
In case of illiterate participant 
 
“I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given consent 
freely.”                                                   
 
 
Date: 
 Signature of a witness  
         Left thumb Impression of the   
                     Participant    
 
           (Selected by the participant bearing no connection with the survey team) 
 
Date:    
Station:                                                                                  
Signature of participant:                                            Signature of the Investigator 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É, ¦ºý¨É - 47. 
Àð¼ §ÁüÀÊôÒ ÁÕòÐÅòÐ¨È 
 
º¸ÉÅ¡¾õ §¿¡öì¸¡É º¢ò¾  ÁÕóÐ¸Ç¢ý (¸È¢ÔôÒ ¦ºóàÃõ Ìó¾¢Ã¢ì¸ ¨¾Äõ)  ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É  ´ôÒ¾ø  ÀÊÅõ 
 
FORM  IV- C ´ôÒ¾ø ÀÊÅõ 
 
¿¡ý §ÁüÜÈ¢Â  ¾¸Åø  ÀÊÅò¨¾ ÀÊòÐ «øÄÐ ÀÊì¸ §¸ðÎ ¦¸¡ñ§¼ý. -Ð ¦¾¡¼÷À¡É 
Å¢Çì¸í¸¨ÇÔõ §¸ðÎ ¦¾Ã¢óÐ ¦¸¡ñ§¼ý.±ó¾ Å¢¾ ÅüÒÚò¾Ä¢ýÈ¢, ±ý ¦º¡ó¾ 
Å¢ÕôÀò¾¢ý §ÀÃ¢ø ±ý¨É -ó¾ ¬Ã¡öîº¢ìÌ ¯ðÀÎò¾ ±ý ÓØÁÉ§¾¡Îõ ÍÂ¿¢¨É§Å¡Îõ 
ºõÁ¾õ ¦¾Ã¢Å¢ì¸¢§Èý.±ÉìÌ Å¢ÕôÀÁ¢øÄ¡¾ Àðºò¾¢ø ó¾ ¬Ã¡öîº¢Â¢ø ÕóÐ ±ý¨É 
±ô§À¡Ð§ÅñÎÁ¡É¡Öõ Å¢ÎÅ¢òÐ ¦¸¡ûÙõ ¯Ã¢¨Á¨Â ¦ÀüÚû§Çý ±ýÀ¨¾Ôõ «È¢§Åý. 
 
 
  §¾¾¢:                                                       ¨¸¦Â¡ôÀõ: 
 
¼õ:                                                      ¦ÀÂ÷     : 
 
 
  §¾¾¢:                                                        º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
¼õ:                                                        ¦ÀÂ÷                : 
                                                                  ¯È×Ó¨È         :      
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS  PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT)&KUNTHIRIKA THAILAM(EXT) 
 
FORM IV -E (WITHDRAWAL FORM) 
 
 
S. NO: --------------------                         OPD/ IPD NO: --------          REG  NO: 32101205/2012-13 
NAME:  ------------------                          AGE: --------                           GENDER: M/F 
DATE OF TRIAL COMMENCEMENT: ----------------------- 
DATE OF WITHDRAWAL FROM TRIAL: ------------------- 
 
REASONS FOR WITHDRAWAL: 
 Long absence at reporting :                                        Yes/ No 
 Irregular treatment:                                                     Yes/ No 
 Shift of locality :                                                         Yes/No 
 Increase in severity of symptoms:                              Yes/No 
 Development of severe adverse drug reactions:         Yes/No 
 
 
 
Date :      
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                       
                                                                                                              Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS  PANDITHARHOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT)&KUNTHIRIKA THAILAM(EXT) 
FORM IV A (DRUG COMPLIANCE FORM) 
 
S. NO:            OPD/IPD NO  :       NAME :                                        REG NO: 32101205/2012-13 
Name Of The Drug :KARIUPPU  CHENDURAM (Internal)KUNTHIRIKA THYLUM(External) 
Dose:260 mg with honey[int} 
Drugs issued:   Drugs issued:       
Drugs returned:                               Drugs returned:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date :                  
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                       
                                                                                                              Signature of the HOD 
 
 
 
 
S.NO DATE 
DRUG TAKEN TIME  
MORNING 
After food 
EVENING After food 
Day 1    
Day 2    
Day 3    
Day 4    
Day 5    
Day 6    
Day 7    
Day 8    
Day 9    
Day 10    
Day 11    
Day 12    
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS  PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT)&KUNTHIRIKA THAILAM(EXT) 
FORM IV A (DRUG COMPLIANCE FORM) 
 
 
S. NO:                OPD/IPD NO  :                     NAME :                                        REG NO: 
32101205/2012-13 
Name Of The Drug :KARIUPPU  CHENDURAM  (Internal)KUNTHIRIKA THYLUM(External) 
Dose:260 mg with honey[int} 
Drugs issued:                                                                         Drugs issued:                  
Drugs returned:                                                                                    Drugs returned:  
 
 
 
Date :                
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                        Signature of the HOD 
 
 
 
 
 
DAYS 
                 DATE 
 
DRUG TAKEN TIME  
MORNING 
After food 
EVENING 
After food 
Day 13    
Day 14    
Day 15    
Day 16    
Day 17    
Day 18    
Day 19    
Day 20    
Day 21    
Day 22    
Day 23    
Day 24    
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT)&KUNTHIRIKA THAILAM(EXT) 
FORM IV A (DRUG COMPLIANCE FORM) 
 
S. NO:              OPD/IPD NO  :              NAME :                                        REG NO: 32101205/2012-13 
Name Of The Drug : 
Dose:260 mg with honey[int} 
Drugs issued:                                                                        Drugs issued:                   
Drugs returned:                                                                                     Drugs returned:  
 
 
Date :                
Station:                                                                 
Signature of the Investigato 
Signature of the Lecturer:                                                        
 
                                                                                      Signature of the HOD 
 
 
 
 
S.NO DATE 
DRUG TAKEN TIME  
MORNING EVENING 
Day 25    
Day 26    
Day 27    
Day 28    
Day 29    
Day 30    
Day 31    
Day 32    
Day 33    
Day 34    
Day 35    
Day 36    
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDo PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT)&KUNTHIRIKA THAILAM(EXT) 
FORM IV A (DRUG COMPLIANCE FORM) 
 
S. NO:             OPD/IPD NO  :                     NAME :                                 REG NO: 32101205/2012-13 
Name Of The Drug :KARIUPPU CHENDURAM  (Internal)KUNTHIRIKA THYLUM(External) 
Dose:260 mg with honey[int} 
Drugs issued:                                                                        Drugs issued:                   
Drugs returned:                                                                                   Drugs returned:  
 
 
Date :                
Station:                                                                 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                      
                                                                                                                              Signature of the HOD 
 
 
 
 
 
DAYS DATE 
DRUG TAKEN TIME  
MORNING EVENING 
Day 37    
Day 38    
Day 39    
Day 40    
Day 41    
Day 42    
Day 43    
Day 44    
Day 45    
Day 46    
Day 47    
Day 48    
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS  PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “CEGANAVATHAM” (CERVICAL SPONDYLOSIS) AND THE 
DRUG OF CHOICE IS KARIUPPU CHENDURAM (INT)&KUNTHIRIKA THAILAM(EXT) 
 
FORM IV F 
ADVERSE REACTION FORM 
 
Reg No:32101205/2012-13 
Serial No:                                                                                                          OP/IP No: 
Name:                                                             Age:                                          Gender:  M/F    
Date of trial commencement: 
Date of the adverse reaction occur; 
Time: Description of Adverse reaction: 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
 
Signature of the Lecturer:                                                       
 
                                                                                                                    Signature of the HOD  
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É, ¦ºý¨É - 47. 
Àð¼ §ÁüÀÊôÒ ÁÕòÐÅòÐ¨È 
 
º¸ÉÅ¡¾õ §¿¡öì¸¡É º¢ò¾  ÁÕóÐ¸Ç¢ý (¸È¢ÔôÒ ¦ºóàÃõ Ìó¾¢Ã¢ì¸ ¨¾Äõ)  ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É  ´ôÒ¾ø  ÀÊÅõ 
 
FORM IV- D ¯½× «È¢×¨Ã ÀÊÅõ 
 ¸¡ö¸û 
      ¸ò¾Ã¢À¢ïÍ,ÓÕí¨¸À¢ïÍ,,«Å¨ÃÀ¢ïÍ, 
         ¬¸¢Â¨Å §º÷ì¸ §ÅñÎõ. 
 ¸£¨Ã¸û: 
               ¦À¡ýÉ¡í¸ñ½¢,ãì¸¢Ãð¨¼,àÐ§Å¨Ç, 
               ÓÕí¨¸¸£¨ Ã,¸È¢§ÅôÀ¢¨Ä, Ó¼ì¸Úò¾¡ý «Ú¸£¨ Ã  ¸Ã¢º¡¨Ä             
¬¸¢Â¨Å §º÷ì¸ §ÅñÎõ. 
ÀÆí¸û:  
                    Á¡Ð¨Ç,¬ôÀ¢û, ÀôÀ¡Ç¢, ¬ÃïÍ, §ÀÃ£î¨º, «ò¾¢, 
                             ¿¡Åø ,¬¸¢Â¨Å §º÷ì¸ §ÅñÎõ. 
«¨ºÅõ: 
                    ¦ÅûÇ¡ðÎ¸È¢, ¸¡¨¼, º¢Ú þÈ¡ø Á£¨É ¸ò¾¢Ã¢ì¸¡ö,  
       «Å¨Ãì¸¡ö,Ó¾Ä¢Â¦À¡Ã¢Âø¸§Ç¡Î ÜðÊî   
¦ºöÐ¾ÃÄ¡õ. 
                   ÐÅÃõÀÕôÒÃºõ, §º÷ì¸ §ÅñÎõ. 
 
  ®ÃÁ¢øÄ¡ ¾¨ÃÂ¢Öõ, ÀÎì¨¸Â¢Öõ ÀÎò¾ø §ÅñÎõ                                      
 ÌÇ¢÷¸¡üÚ ÀÎõÀÊÂ¡É¼ò¾¢ø¢ÕôÀ¨¾ ¾Å¢÷ì¸×õ 
 ¾¨Ä ÁüÚõ ¨¸Â¢ø ¸ÉÁ¡É ¦À¡Õû¸û àì¸ Ü¼¡Ð 
 ¾¨ÄìÌ ¾¨ÄÂ¨½ ¨ÅòÐ àí¸ Ü¼¡Ð                                      
§º÷ì¸ Ü¼¡¾¨Å¸û: 
 
 Í¨Ã                              ¯ôÒ 
âº½¢                            ÒÇ¢ôÒ 
¦ÅûÇÃ¢ì¸¡ö                «¾¢¸ ¨¸ôÒ 
Ò¼¨Ä                           «¾¢¸ ¸¡÷ôÒ 
À£÷ìÌ                            Áó¾ô ¦À¡Õû 
¦Á¡î¨º                       ¦ÅüÈ¢¨Ä,À¡ìÌ 
¸¡Ã¡Á½¢                       Ò¨¸Â¢¨Ä          
¯ÙóÐ                          ÁÐ «ÕóÐ¾ø 
¦¸¡ûÙ 
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                                        AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON CEGANAVATHAM  (cervical spondylosis) 
KARIUPPU CHENDURAM (Internal),               
KUNTHIRIKA THYLAM(External) 
                   FORM IV –B (INFORMATION SHEET)  
Name of Principal Investigator:…………………………………..…………………….. 
Part – A Information Sheet 
 
I,  Dr.M.S.SARANYA DEVI studying M.D(S) in National Institute of Siddha, Chennai. 
CEGANAVATHAM is a disease affecting the morbidity and causing discomfort to the 
person. This condition is being treated in NIS with many Siddha formulations. As a part of 
M.D(S) research programme and developing new efficacious medicine, we propose to study 
the KARIUPPU CHENDURAM (Internal), KUNTHIRIKA THYAM(External) 
formulations for treating the condition. This formulation has been mentioned in Siddha 
literature and empirical evidence with contemporary tools is required for documentation. You 
can receive medicines free of cost. The duration of treatment period is 48 days. You have to 
visit NIS once in every 12 days and collect the drugs for 12 days. The diagnosis tests will be 
carried out at free of cost. We will assess the effect of treatment after completions of  days of 
treatment using clinical and laboratory parameters. 
 
In this regard, we need to ask few questions. We will maintain confidentiality of your 
comments and data obtained from you. There will be no risk of disclosing your identity and 
no physical, psychological or professional risk is involved by taking part in this study.  
 
Taking part in this study is voluntary. No compensation will be paid to you for taking part in 
this study. You can choose not to answer any specific question. There is no specific benefit 
for you if you take part of in this study, but you will be under our clinical monitoring and 
specific attention will be given for your help. Taking part in this study may be of benefit to 
the community, as it may help us to develop medicine for Cegana Vaatham. In case of any 
adverse symptoms during the treatment passing loosey stools,irritation in the stomach , 
indigestion  which is expected for few patients during the treatment, shall be reported to PIs 
and care will be taken in NIS for relief. You can withdraw from the study at the midst of 
treatment period, if you are not interested to continue and you will receive our usual 
treatment without condition. 
 
The information we will be collected in the study, will remain between you and the principal 
investigator. We will ask you a few questions through a questionnaire. We will not write your 
name on different forms which send to different investigating / analysis sections and we will 
use a code instead given by principal investigator. Only the principal investigator will know 
the key to this code which will be kept in safe custody. If you agree to be the participant in 
this study, you will be screened as per the study protocol. 
 
If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact, Dr.M.S.SARANYA DEVI P.G  scholar cum principal 
investigator of this study, attached to the National Institute of Siddha, Chennai(Mobile No. 
9698041421). You can also contact the chairman / Member Secretary of ethics committee, 
National Institute of Siddha, Chennai-600047, Tel No.: 914422411611, for rights and 
participation in the study.  
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
 º¸ÉÅ¡¾õ §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý ¸È¢ÔôÒ ¦ºóàÃõ,Ìó¾¢Ã¢ì¸ ¨¾Äõ ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì 
¸ñ¼È¢Ôõ ÁÕòÐÅ  ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
FORM IV ¾¸Åø ÀÊÅõ 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ : Dr.Á.º.ºÃñÂ¡ §¾Å¢  
 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷  : §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
      ¾¡õÀÃõ º¡É§¼¡Ã¢Âõ 
  ¦ºý¨É- 47 
           Dr. Á.º.ºÃñÂ¡ §¾Å¢ ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕ¸¢§Èý. 
º¸ÉÅ¡¾õ ±ýÛõ §¿¡Â¡ÉÐ ¸ØòÐ ±Öõ¨À À¡¾¢ìÌõ §¿¡Â¡Ìõ. þó§¿¡Â¡ÉÐ ¸ØòÐ, §¾¡ûÀð¨¼, ¨¸ Ó¾Ä¢Â 
þ¼í¸Ç¢ø ÅÄ¢, ¿£ðÊ Á¼ì¸ ÓÊÂ¡¨Á, ¬¸¢Â ÌÈ¢Ì½í¸û ¸¡Ïõ. þó§¿¡öìÌ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ÀÄ º¢ò¾ 
ÁÕóÐ¸û ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÐ. º¢ò¾ ÁÕòÐÅ Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ ÀÌ¾¢Â¡¸ Ò¾¢Â ÁÕóÐ¸¨Ç 
ÀÂýÀÎòÐõ §¿¡ì¸¢ø þó§¿¡öìÌ ¸È¢ÔôÒ ¦ºóàÃõ, ,Ìó¾¢Ã¢ì¸ ¨¾Äõ ÅÆí¸ ÀÃ¢óÐ¨Ã ¦ºö¸¢§È¡õ. þó¾ ÁÕó¾¢ý 
¦ºöÓ¨È, «Ç×, «ÛÀ¡Éõ ÁüÚõ ÁÕòÐÅ ÀÂý¸û «¨ÉòÐõ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûÇÐ. 
±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û þó¾ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ ¬öÅ¢ø ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 48 ¿¡ð¸û 
¬Ìõ. ¦ÅÇ¢ ÁÕó¾¡¸ 50 Á¢Ä¢ 48 ¿¡ð¸ÙìÌ §¿¡ÔûÇ þ¼í¸Ç¢ø ¦ÅÇ¢§Â ¾¼Å §ÅñÎõ. ¦ÅÇ¢ §¿¡Â¡Ç÷¸û 12 
¿¡ð¸ÙìÌ ´Õ Ó¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. 48 ¿¡ð¸û ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É 
ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý ÓÊ×¸Ç¢ý «ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý ¸ñ¼È¢ÂôÀÎõ. 
þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì¸¢§Èý. ¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ ¸ÕòÐì¸û ÁüÚõ 
ÌÈ¢ôÒ¸û «¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ À¾¢× ¦ºöÂôÀÎõ.þó¾ ¬öÅ¢ø ¾í¸¨Ç ¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ Å¨¸Â¢Öõ 
À¡¾¢ôÒìÌûÇ¡¸Á¡ðË÷¸û ±É ¯Ú¾¢ «Ç¢ì¸¢§Èý.      
±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ ¬ö× ºõÀó¾Á¡¸ §¸ð¸ôÀÎõ §¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ 
¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ ±ó¾ ºýÁ¡ÉÓõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× 
ÓØÅÐõ ±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û ¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ ¬ö× §Áü¦¸¡ûÇôÀÎõ. ÌõÀÅ¡¾ §¿¡öì¸¡É 
Ò¾¢Â ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢È¨É ºã¸ò¾¢üÌ ¯½÷òÐõ Å¨¸Â¢ø þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ, þó¾ ¬öÅ¢ø, ÁÕóÐ 
¯ð¦¸¡ûÙõ ¸¡Äò¾¢ø ÅÂ¢üÚÅÄ¢, «Êì¸Ê ÁÄõ ¸Æ¢¾ø, ¯ñ¼ ¯½× ¦ºÃ¢Â¡¨Á,§À¡ýÈ Á¡ÚÀð¼ ÌÈ¢Ì½í¸û 
¦¾¡¼÷óÐ þÕìÌõ Àðºò¾¢ø, Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ýÉ¢¼õ ¦¾Ã¢Å¢ì¸ôÀðÎ, §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø 
«¾üì¸¡É ¾£÷× ÅÆí¸ôÀÎõ. þó¾ ¬öÅ¢¨Éò ¦¾¡¼Ã ¾í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ 
¬öÅ¢ý þ¨¼Â¢ø Å¢Ä¸¢ì¦¸¡ûÇ×õ, ÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ þó§¿¡öì¸¡É ÅÆì¸Á¡É ÁÕóÐ¸¨Ç 
¦ÀüÚì¦¸¡ûÇ×õ «È¢×Úò¾ôÀÎ¸¢È£÷¸û. 
þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ 
¨Åì¸ôÀÎõ. §¸ûÅ¢ À¾¢ø ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. «¨ÉòÐô ÀÊÅí¸Ç¢Öõ ¾í¸Ç¢ý ¦ÀÂ÷ 
¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ÇÃ¡ø ¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î ÅÆí¸ôÀÎõ. «ó¾ì ÌÈ¢Â£Î ¬öÅ¡ÇÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ 
þÕìÌõ. ¿£í¸û þó¾ ¬öÅ¢ø Àí§¸ü¸ Å¢ÕôÀôÀð¼¡ø, Óý§É¡ð¼ ¬ö× ¾¸Åø ÀÊ §¾÷× ¦ºöÂôÀÎÅ£÷¸û.  
¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û ¦ÀÈ §ÅñÎ¦ÁÉ Å¢ÕôÀôÀð¼¡ø, þó¾ 
¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ÁüÚõ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ §ÁüÀÊôÒòÐ¨È Á¡½Å÷ Dr Á.º.ºÃñÂ¡ 
§¾Å¢.¬¸¢Â ±ý¨É 9698041421 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ. §ÁÖõ, ¿£í¸û þó¾ ¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ 
ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ ¦¾Ã¢óÐ ¦¸¡ûÇ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüìÌØ ¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ    
91-44-22411611 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ.   
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SL.
NO Before After Before After
treatment treatment treatment treatment
1 C95550 31/F 15.2 14 4.4 4.9
2 D00464 40/F 18.1 18 5 5
3 C95513 40/F 16.5 16 5.5 5.3
4 C94392 31/F 14.8 15 5.5 5.5
5 D004308 45/F 14 14.5 4.4 4.5
6 C098191 40/F 13 13 4 4.1
7 C098214 40/F 14.5 14.6 5.2 5.3
8 C96651 50/F 17.4 17 4.8 5.2
9 C97647 30/F 11 12 4.5 4.3
10 D000836 25/F 13 13.5 4.9 4.9
11 C099666 37/F 14.1 14.5 6 6.2
12 C97598 48/F 10 10.5 5 5.1
13 C098014 32/F 12.9 12.5 3.9 4.9
14 C099250 47/F 9.7 10 4.8 4.4
15 C95436 44/F 8 9 4.5 4.5
16 D000496 38/F 11.5 12.1 5.5 5.2
17 C098239 38/F 12.4 12 5.5 5.5
18 C97940 48/F 14.4 14.2 4.1 4.2
19 C94733 32/F 12.6 12.4 5.1 5.1
20 D000006 32/F 12.6 12.6 5.5 5.7
21 D000425 37/M 11 11.5 5.5 5.6
22 D000205 48/M 12.5 12 4.5 4.7
23 B55586 26/M 11.5 12 4.9 5.2
24 C96984 50/M 11 11 5.5 5.2
25 D004970 47/M 14 14 4.9 4.7
26 C94873 29/M 11.8 12 4.8 5
27 C93620 38/M 13.2 13 5.8 5.4
28 C94833 26/F 12 11.8 5.4 4.9
29 C96489 31/F 13.9 14 4.7 4.5
30 C96802 25/F 11 11 5.6 5.7
31 4185 48/F 10 10.5 4.8 4.9
32 4228 32/F 10.5 10.5 5.4 5.6
33 4258 37/F 11 11 4 4
34 4267 42/F 11.5 11.5 5.8 5.9
35 4251 48/F 12 12 4.9 4.6
36 4255 40/F 12.1 11 4.3 4.1
37 4175 42/F 12.8 13 4.1 4
38 4226 34/F 11.1 11.2 4.3 4.4
39 4209 42/F 10 11 3.6 3.9
40 5217 26/M 13.5 13 4.4 4.9
LAB INVESTIGATION BEFORE AND AFTER TREATMENT
OP/IP NO AGE/SEX
Hbgm%
TRBC
Million cells /cumm
OP/IP   T.Billirubin D.Billirubin ID.billirubin SGOT SGPT SAP T.Protein Albumin Globulin Calcium Phosphorous
    No mg/dl mg/dl mg/dl U/l U/l U/l Gm/dl gm/dl gm/dl mg/dl mg/dl
1 C95550 31/F 0.5 0.3 0.2 20 22 131 6.8 5.4 1.4 11.8 3.3
2 D00464 40/F 0.9 0.5 0.4 24 25 115 7.2 5.3 1.9 13.3 2.9
3 C95513 40/F 0.5 0.3 0.2 18 26 127 7.9 5.8 2.1 12.4 5.1
4 C94392 31/F 0.5 0.3 0.2 22 21 230 7.4 5.4 2 10.6 5.9
5 D004308 45/F 0.4 0.2 0.2 19 21 121 7.6 5.5 2.1 11.6 4.2
6 C098191 40/F 0.7 0.4 0.3 17 16 185 6.9 5.4 1.5 11.5 3.6
7 C098214 40/F 0.5 0.3 0.2 25 27 170 6.9 5.4 1.5 11.9 2.6
8 C96651 50/F 0.5 0.3 0.2 21 28 200 6.7 4.8 1.9 11.7 2.8
9 C97647 30/F 0.7 0.4 0.3 20 22 240 7.7 5.1 2.6 12 3
10 D000836 25/F 0.6 0.2 0.4 17 19 202 7.5 4.4 3.1 13.4 3
11 C099666 37/F 0.6 0.3 0.3 22 25 146 7.9 5 2.9 11 3.9
12 C97598 48/F 0.6 0.3 0.3 20 22 128 7 5.1 1.9 12.1 2.3
13 C098014 32/F 0.7 0.3 0.4 23 25 218 7 4.9 2.1 9.6 2.5
14 C099250 47/F 0.6 0.2 0.4 20 21 129 7.6 4.1 3.5 9.1 3.2
15 C95436 44/F 0.6 0.4 0.2 13 15 138 6.5 4.3 2.2 10 2.3
16 D000496 38/F 0.6 0.2 0.4 18 20 269 6.9 4.3 2.6 11 3.7
17 C098239 38/F 0.6 0.2 0.4 20 24 221 7.5 5.1 2.4 11.2 3.3
18 C97940 48/F 0.6 0.2 0.4 24 26 185 6.2 4 2.2 10.2 3.9
19 C94733 32/F 0.8 0.3 0.5 23 28 166 7.1 4.5 2.6 11.2 4.4
20 D000006 32/F 1.2 0.6 0.6 22 21 129 6.8 4.5 2.3 10.8 4
21 D000425 37/M 0.6 0.2 0.4 27 23 157 6.9 4.6 2.2 10.9 3.1
22 D000205 48/M 0.5 0.2 0.3 16 18 184 7.1 5 2.1 10.3 2.8
23 B55586 26/M 0.5 0.2 0.3 24 22 260 7 4 3 9.8 3.1
24 C96984 50/M 0.9 0.4 0.5 15 16 186 7.1 4.5 2.6 10.1 3
25 D004970 47/M 0.6 0.2 0.4 21 22 238 7.7 4.8 2.9 10.6 3.1
26 C94873 29/M 0.5 0.2 0.3 16 18 170 7.6 5.6 2 9 3.8
27 C93620 38/M 1 0.6 0.4 25 24 165 7.9 4.7 3.2 11.3 3.6
28 C94833 26/F 0.4 0.2 0.2 24 25 200 7 5 2 10.4 3.6
29 C96489 31/F 0.4 0.2 0.2 24 26 180 7 4 3 10 2.9
30 C96802 25/F 0.5 0.2 0.3 25 23 220 7.1 3 4.1 10.7 2.8
31 4185 48/F 0.6 0.2 0.4 17 19 149 6.2 4 2.2 10.4 3
32 4228 32/F 0.5 0.2 0.3 14 15 187 6.9 3.4 3.5 11.4 2.8
33 4258 37/F 0.6 0.2 0.4 15 17 220 5 3 2 10.8 3
34 4267 42/F 0.4 0.2 0.2 24 21 256 7 4.3 2.7 12.8 2.8
35 4251 48/F 0.8 0.3 0.5 18 20 145 7.8 4.6 3.2 10.4 3
36 4255 40/F 0.4 0.2 0.2 21 22 170 6.6 4.5 2.1 10.6 3.1
37 4175 42/F 1 0.6 0.4 12 10 136 6.6 4.5 2.1 10 3
38 4226 34/F 0.5 0.2 0.3 20 22 159 6.4 4.2 2.2 10.5 3
39 4209 42/F 0.6 0.2 0.4 21 23 168 6.8 4.8 2 12.4 2.8
40 5217 26/M 1 0.5 0.5 20 21 166 6.5 4 2.5 10.9 2.9
LAB INVESTIGATION BEFORE TREATMENT
Sno Age/Sex
OP/IP T.Billirubin D.Billirubin ID.billirubin SGOT SGPT SAP T.Protein Albumin Globulin Calcium Phosphorous
No mg/dl mg/dl mg/dl U/l U/l U/l gm/dl gm/dl gm/dl mg/dl mg/dl
1 C95550 31/F 0.6 0.2 0.4 18 19 190 7 5.2 1.8 11 3
2 D00464 40/F 0.7 0.2 0.5 21 26 216 6 4 2 11.3 2.7
3 C95513 40/F 1.1 0.5 0.6 19 28 119 6.1 3.2 2.9 11 3
4 C94392 31/F 0.4 0.2 0.2 24 24 262 6.8 4 2.8 10.1 4.6
5 D004308 45/F 0.5 0.2 0.3 15 16 121 7 5 2 11 3
6 C098191 40/F 0.4 0.2 0.2 21 28 190 6.9 3.9 3 10 3
7 C098214 40/F 0.3 0.2 0.1 16 17 195 7.4 4.4 3 10.6 2.8
8 C96651 50/F 0.6 0.2 0.4 21 24 211 6.5 4.5 2 11 3.6
9 C97647 30/F 0.5 0.2 0.3 19 20 152 7.7 5.7 2 12.2 3.6
10 D000836 25/F 0.5 0.2 0.3 23 26 236 6.4 3.4 3 12.2 2.8
11 C099666 37/F 0.7 0.3 0.4 16 20 186 7.5 5.5 2 10.5 3
12 C97598 48/F 0.5 0.2 0.3 22 27 196 7.5 5.5 2 9.3 2
13 C098014 32/F 0.6 0.2 0.4 24 23 213 6.7 4.2 2.5 11 3.2
14 C099250 47/F 0.5 0.2 0.3 12 14 147 6.6 4.1 2.5 10.1 3
15 C95436 44/F 0.4 0.2 0.2 11 12 145 6 3.6 2.4 9.8 2
16 D000496 38/F 1.1 0.5 0.6 19 25 176 6.6 3.7 2.9 10.8 3.1
17 C098239 38/F 0.4 0.2 0.2 11 23 177 6 3.6 2.4 9.9 2.7
18 C97940 48/F 0.5 0.2 0.3 16 26 186 6.6 4.1 2.4 10.1 3.5
19 C94733 32/F 0.5 0.2 0.3 16 17 183 5.6 3.1 2.5 10.8 3.5
20 D000006 32/F 1 0.5 0.5 18 22 220 6.2 4.2 2 9.2 3.8
21 D000425 37/M 0.7 0.3 0.4 23 26 176 6 4 2 9.8 2.8
22 D000205 48/M 0.7 0.3 0.4 19 20 156 6.4 4.4 2 9.6 2.6
23 B55586 26/M 0.6 0.2 0.4 23 25 170 6.9 4.3 2.6 10.1 3
24 C96984 50/M 1 0.7 0.3 22 27 166 6.5 4.4 2.1 10.8 3
25 D004970 47/M 0.5 0.2 0.3 22 24 198 6.2 4 2.2 10.8 2.9
26 C94873 29/M 0.5 0.2 0.3 24 26 179 6.5 4.5 2 11 3.2
27 C93620 38/M 1 0.5 0.5 23 26 168 5.9 2.6 3.3 10.2 2.9
28 C94833 26/F 0.9 0.3 0.6 16 18 144 5 3 2 10 2.9
29 C96489 31/F 0.5 0.2 0.3 19 21 149 6.6 3.6 3 10.4 2.9
30 C96802 25/F 0.8 0.3 0.5 24 26 242 6.6 4.4 2.2 11.1 3.3
31 4185 48/F 0.6 0.2 0.4 16 14 135 6 4 2 9.6 2.3
32 4228 32/F 0.4 0.2 0.2 13 15 164 6.2 4.2 2 10.2 2.5
33 4258 37/F 0.6 0.2 0.4 13 14 135 5.9 4.5 1.4 9.7 2.9
34 4267 42/F 0.4 0.2 0.2 23 21 220 6.4 4.4 4 10.2 2.4
35 4251 48/F 0.8 0.3 0.5 18 20 145 7.8 4.6 3.2 10 3
36 4255 40/F 1.2 0.6 0.6 16 17 161 7 5 2 10.4 2.9
37 4175 42/F 3.6 1.2 2.4 12 14 150 6.5 4.1 2.4 10.2 2.9
38 4226 34/F 0.5 0.2 0.3 18 16 154 6.2 4.2 2 9.6 2.8
39 4209 42/F 0.5 0.2 0.3 11 12 140 6 3 2 10.8 3.3
40 5217 26/M 0.8 0.4 0.4 18 17 160 6.4 4 2.4 9.8 2.5
Sno Age/Sex
LAB INVESTIGATION AFTER TREATMENT
OP/IP
NO BT AT BT AT BT AT BT AT BT AT
1 C95550 31/F 151 151 37 30 93 102 21 25 103 126
2 D00464 40/F 168 112 38 29 109 61 21 31 104 156
3 C95513 40/F 286 227 59 38 181 108 46 80 229 400
4 C94392 31/F 232 202 60 35 156 160 16 23 78 115
5 D004308 45/F 178 111 35 22 105 62 38 30 189 151
6 C098191 40/F 169 117 36 26 93 44 40 25 200 126
7 C098214 40/F 180 132 35 29 120 50 25 21 124 106
8 C96651 50/F 182 156 37 32 118 90 27 19 136 98
9 C97647 30/F 168 140 43 29 79 82 46 40 234 200
10 D000836 25/F 191 135 35 30 144 90 12 11 62 57
11 C099666 37/F 210 186 38 35 145 120 27 33 139 165
12 C97598 48/F 185 169 32 32 134 106 19 34 98 172
13 C098014 32/F 186 137 38 30 101 92 47 25 239 127
14 C099250 47/F 253 219 42 40 182 175 29 33 149 166
15 C95436 44/F 160 106 35 30 113 63 12 11 61 57
16 D000496 38/F 180 178 30 36 120 112 30 68 154 343
17 C098239 38/F 243 238 47 42 112 172 50 28 250 142
18 C97940 48/F 190 147 36 30 117 108 41 27 206 138
19 C94733 32/F 269 218 40 42 185 126 44 34 218 172
20 D000006 32/F 195 190 38 35 109 102 44 40 223 209
21 D000425 37/M 186 149 36 34 130 119 24 25 123 127
22 D000205 48/M 150 138 30 30 102 99 24 39 123 197
23 B55586 26/M 143 136 26 35 94 86 26 45 132 227
24 C96984 50/M 195 178 38 38 116 1256 54 49 274 245
25 D004970 47/M 95 92 19 30 146 40 16 20 83 101
26 C94873 29/M 176 168 30 40 100 79 41 32 206 163
27 C93620 38/M 225 192 45 45 121 119 51 22 258 112
28 C94833 26/F 176 143 29 31 100 86 42 35 212 178
29 C96489 31/F 180 154 54 35 110 80 30 28 122 140
30 C96802 25/F 194 189 29 36 104 86 49 15 249 79
31 4185 48/F 144 140 30 28 101 98 34 31 170 165
32 4228 32/F 150 148 32 28 90 87 24 23 122 120
33 4258 37/F 176 198 35 36 116 96 36 31 184 156
34 4267 42/F 145 140 36 32 77 75 32 30 161 158
35 4251 48/F 134 158 21 30 45 90 27 46 137 232
36 4255 40/F 140 157 24 34 60 75 13 12 67 61
37 4175 42/F 159 200 32 39 117 98 12 35 62 179
38 4226 34/F 211 200 40 38 146 140 21 20 107 102
39 4209 42/F 153 205 32 35 100 96 13 18 66 94
40 5217 26/M 131 128 30 25 70 64 27 24 139 130
BT-BEFORE TREATMENT            AT-AFTER TREATMENT
ALL THE 40 PATIENTS ARE NEGATIVE IN CRP AND RA FACTOR
TGL mg/dl
LAB INVESTIGATION BEFORE AND AFTER TREATMENT
S.NO
Age/sex T.CHOLESTEROL mg/dl HDL mg/dl LDL mg/dl VLDL mg/dl
OP/IP    TC S.Creatinine S.Uric 
    No Cells/     Mg/dl acid
cumm     P     L    E 1/2 hr 1 hr F PP  mg/dl
1 C95550 31/F 6,900 64 27 2 2 4 102 116 15 0.5 4.3
2 D00464 40/F 6600 45 23 4 5 5 83 1 13 1 3.0
3 C95513 40/F 7700 55 30 5 6 14 103 109 27 0.7 5.9
4 C94392 31/F 6800 48 22 1 4 8 71 98 12 0.4 4.7
5 D004308 45/F 5300 65 26 8 6 12 102 108 15 0.5 4.5
6 C098191 40/F 7400 69 25 6 12 24 104 111 41 1.1 3
7 C098214 40/F 3700 46 27 7 2 6 84 93 22 0.7 4.7
8 C96651 50/F 9000 55 39 6 2 4 83 103 15 0.5 6
9 C97647 30/F 8900 60 35 5 2 4 115 121 15 0.4 5.3
10 D000836 25/F 6700 63 35 2 2 4 88 92 15 0.4 5.4
11 C099666 37/F 8200 66 31 3 2 4 82 104 14 0.4 6.8
12 C97598 48/F 4800 56 30 4 2 4 104 118 33 0.8 4
13 C098014 32/F 5000 61 34 5 2 4 103 120 14 0.4 7.9
14 C099250 47/F 8000 50 34 6 2 4 70 88 19 0.5 4
15 C95436 44/F 6600 38 33 4 2 4 99 111 15 0.4 3.7
16 D000496 38/F 10000 42 28 6 2 4 95 107 17 0.5 6.6
17 C098239 38/F 7800 41 35 24 4 8 99 106 17 0.5 6.2
18 C97940 48/F 7000 72 23 5 2 6 83 106 14 0.4 2.9
19 C94733 32/F 6200 60 34 6 2 8 102 123 18 0.5 6.5
20 D000006 32/F 7200 50 44 6 2 6 96 109 26 0.6 3.1
21 D000425 37/M 5000 34 56 3 4 8 76 102 14 0.4 4.3
22 D000205 48/M 5600 65 30 5 8 18 87 100 14 0.4 4.7
23 B55586 26/M 8200 54 42 4 2 10 86 98 16 0,5 5.3
24 C96984 50/M 7300 64 31 5 2 4 98 109 24 0.7 5.5
25 D004970 47/M 7700 52 26 2 2 4 91 102 22 0.6 5
26 C94873 29/M 7100 56 39 5 2 10 94 106 20 0.6 3.8
27 C93620 38/M 7800 55 40 5 2 4 94 108 17 0.5 4.8
28 C94833 26/F 7000 55 40 5 6 12 82 101 15 0.4 5
29 C96489 31/F 7700 60 35 5 8 16 96 103 16 0.5 3.5
30 C96802 25/F 8600 38 45 7 2 4 99 108 21 0.7 5
31 4185 48/F 5600 48 32 4 2 4 109 112 15 0.5 5.2
32 4228 32/F 7600 58 32 3 2 4 82 103 19 0.5 3.8
33 4258 37/F 8600 74 23 3 4 8 87 98 14 0.4 3.8
34 4267 42/F 8700 53 32 3 5 10 74 90 21 0.8 5.2
35 4251 48/F 7300 66 30 4 12 24 82 102 15 0.6 3.4
36 4255 40/F 6800 66 30 4 10 20 116 123 15 0.5 4.5
37 4175 42/F 10800 76 20 4 8 16 103 124 25 0.5 6.9
38 4226 34/F 10900 52 28 2 6 12 92 109 15 0.3 3
39 4209 42/F 8800 67 30 3 8 18 96 102 18 0.6 3
40 5217 26/M 6400 44 23 4 4 12 80 93 16 0.4 4
OP/IP    TC S.Creatinine S.Uric 
    No Cells/     Mg/dl acid
cumm     P     L    E 1/2 hr 1 hr F PP  mg/dl
1 C95550 31/F 9900 67 30 3 2 6 92 113 30 0.9 6
2 D00464 40/F 9300 66 27 5 2 4 98 109 19 0.6 5
3 C95513 40/F 7700 55 30 5 6 14 103 109 27 0.7 5.9
4 C94392 31/F 6800 48 22 1 4 8 71 98 12 0.4 4.7
5 D004308 45/F 5300 65 26 8 6 12 102 108 15 0.5 4.5
6 C098191 40/F 7400 69 25 6 12 24 104 111 41 1.1 3
7 C098214 40/F 3700 46 27 7 2 6 84 93 22 0.7 4.7
8 C96651 50/F 9000 55 39 6 2 4 83 103 15 0.5 6
9 C97647 30/F 8900 60 35 5 2 4 115 121 15 0.4 5.3
10 D000836 25/F 6700 63 35 2 2 4 88 92 15 0.4 5.4
11 C099666 37/F 8200 66 31 3 2 4 82 104 14 0.4 6.8
12 C97598 48/F 4800 56 30 4 2 4 104 118 33 0.8 4
13 C098014 32/F 5000 61 34 5 2 4 103 120 14 0.4 7.9
14 C099250 47/F 8000 50 34 6 2 4 70 88 19 0.5 4
15 C95436 44/F 6600 38 33 4 2 4 99 111 15 0.4 3.7
16 D000496 38/F 10000 42 28 6 2 4 95 107 17 0.5 6.6
17 C098239 38/F 7800 41 35 24 4 8 99 106 17 0.5 6.2
18 C97940 48/F 7000 72 23 5 2 6 83 106 14 0.4 2.9
19 C94733 32/F 6200 60 34 6 2 8 102 123 18 0.5 6.5
20 D000006 32/F 7200 50 44 6 2 6 96 109 26 0.6 3.1
21 D000425 37/M 5000 34 56 3 4 8 76 102 14 0.4 4.3
22 D000205 48/M 5600 65 30 5 8 18 87 100 14 0.4 4.7
23 B55586 26/M 8200 54 42 4 2 10 86 98 16 0,5 5.3
24 C96984 50/M 7300 64 31 5 2 4 98 109 24 0.7 5.5
25 D004970 47/M 7700 52 26 2 2 4 91 102 22 0.6 5
26 C94873 29/M 7100 56 39 5 2 10 94 106 20 0.6 3.8
27 C93620 38/M 7800 55 40 5 2 4 94 108 17 0.5 4.8
28 C94833 26/F 7000 55 40 5 6 12 82 101 15 0.4 5
29 C96489 31/F 7700 60 35 5 8 16 96 103 16 0.5 3.5
30 C96802 25/F 8600 38 45 7 2 4 99 108 21 0.7 5
31 4185 48/F 5600 48 32 4 2 4 109 112 15 0.5 5.2
32 4228 32/F 7600 58 32 3 2 4 82 103 19 0.5 3.8
33 4258 37/F 8600 74 23 3 4 8 87 98 14 0.4 3.8
34 4267 42/F 8700 53 32 3 5 10 74 90 21 0.8 5.2
35 4251 48/F 7300 66 30 4 12 24 82 102 15 0.6 3.4
36 4255 40/F 6800 66 30 4 10 20 116 123 15 0.5 4.5
37 4175 42/F 10800 76 20 4 8 16 103 124 25 0.5 6.9
38 4226 34/F 10900 52 28 2 6 12 92 109 15 0.3 3
39 4209 42/F 8800 67 30 3 8 18 96 102 18 0.6 3
40 5217 26/M 6400 44 23 4 4 12 80 93 16 0.4 4
SL.
NO Before After Before After
1 C95550 31/F 15.2 14 4.4 4.9
2 D00464 40/F 18.1 18 5 5
3 C95513 40/F 16.5 16 5.5 5.3
4 C94392 31/F 14.8 15 5.5 5.5
5 D004308 45/F 14 14.5 4.4 4.5
6 C098191 40/F 13 13 4 4.1
7 C098214 40/F 14.5 14.6 5.2 5.3
8 C96651 50/F 17.4 17 4.8 5.2
9 C97647 30/F 11 12 4.5 4.3
10 D000836 25/F 13 13.5 4.9 4.9
11 C099666 37/F 14.1 14.5 6 6.2
12 C97598 48/F 10 10.5 5 5.1
13 C098014 32/F 12.9 12.5 3.9 4.9
14 C099250 47/F 9.7 10 4.8 4.4
15 C95436 44/F 8 9 4.5 4.5
16 D000496 38/F 11.5 12.1 5.5 5.2
17 C098239 38/F 12.4 12 5.5 5.5
18 C97940 48/F 14.4 14.2 4.1 4.2
19 C94733 32/F 12.6 12.4 5.1 5.1
20 D000006 32/F 12.6 12.6 5.5 5.7
21 D000425 37/M 11 11.5 5.5 5.6
22 D000205 48/M 12.5 12 4.5 4.7
23 B55586 26/M 11.5 12 4.9 5.2
24 C96984 50/M 11 11 5.5 5.2
25 D004970 47/M 14 14 4.9 4.7
26 C94873 29/M 11.8 12 4.8 5
27 C93620 38/M 13.2 13 5.8 5.4
28 C94833 26/F 12 11.8 5.4 4.9
29 C96489 31/F 13.9 14 4.7 4.5
30 C96802 25/F 11 11 5.6 5.7
31 4185 48/F 10 10.5 4.8 4.9
32 4228 32/F 10.5 10.5 5.4 5.6
33 4258 37/F 11 11 4 4
34 4267 42/F 11.5 11.5 5.8 5.9
35 4251 48/F 12 12 4.9 4.6
36 4255 40/F 12.1 11 4.3 4.1
37 4175 42/F 12.8 13 4.1 4
38 4226 34/F 11.1 11.2 4.3 4.4
39 4209 42/F 10 11 3.6 3.9
40 5217 26/M 13.5 13 4.4 4.9
OP/IP   T.Billirubin D.Billirubin ID.billirubin SGOT SGPT SAP T.Protein Albumin Globulin Calcium Phosphorous
    No mg/dl mg/dl mg/dl U/l U/l U/l Gm/dl gm/dl gm/dl mg/dl mg/dl
1 C95550 31/F 0.5 0.3 0.2 20 22 131 6.8 5.4 1.4 11.8 3.3
2 D00464 40/F 0.9 0.5 0.4 24 25 115 7.2 5.3 1.9 13.3 2.9
3 C95513 40/F 0.5 0.3 0.2 18 26 127 7.9 5.8 2.1 12.4 5.1
4 C94392 31/F 0.5 0.3 0.2 22 21 230 7.4 5.4 2 10.6 5.9
5 D004308 45/F 0.4 0.2 0.2 19 21 121 7.6 5.5 2.1 11.6 4.2
6 C098191 40/F 0.7 0.4 0.3 17 16 185 6.9 5.4 1.5 11.5 3.6
7 C098214 40/F 0.5 0.3 0.2 25 27 170 6.9 5.4 1.5 11.9 2.6
8 C96651 50/F 0.5 0.3 0.2 21 28 200 6.7 4.8 1.9 11.7 2.8
9 C97647 30/F 0.7 0.4 0.3 20 22 240 7.7 5.1 2.6 12 3
10 D000836 25/F 0.6 0.2 0.4 17 19 202 7.5 4.4 3.1 13.4 3
11 C099666 37/F 0.6 0.3 0.3 22 25 146 7.9 5 2.9 11 3.9
12 C97598 48/F 0.6 0.3 0.3 20 22 128 7 5.1 1.9 12.1 2.3
13 C098014 32/F 0.7 0.3 0.4 23 25 218 7 4.9 2.1 9.6 2.5
14 C099250 47/F 0.6 0.2 0.4 20 21 129 7.6 4.1 3.5 9.1 3.2
15 C95436 44/F 0.6 0.4 0.2 13 15 138 6.5 4.3 2.2 10 2.3
16 D000496 38/F 0.6 0.2 0.4 18 20 269 6.9 4.3 2.6 11 3.7
17 C098239 38/F 0.6 0.2 0.4 20 24 221 7.5 5.1 2.4 11.2 3.3
18 C97940 48/F 0.6 0.2 0.4 24 26 185 6.2 4 2.2 10.2 3.9
19 C94733 32/F 0.8 0.3 0.5 23 28 166 7.1 4.5 2.6 11.2 4.4
20 D000006 32/F 1.2 0.6 0.6 22 21 129 6.8 4.5 2.3 10.8 4
21 D000425 37/M 0.6 0.2 0.4 27 23 157 6.9 4.6 2.2 10.9 3.1
22 D000205 48/M 0.5 0.2 0.3 16 18 184 7.1 5 2.1 10.3 2.8
23 B55586 26/M 0.5 0.2 0.3 24 22 260 7 4 3 9.8 3.1
24 C96984 50/M 0.9 0.4 0.5 15 16 186 7.1 4.5 2.6 10.1 3
25 D004970 47/M 0.6 0.2 0.4 21 22 238 7.7 4.8 2.9 10.6 3.1
26 C94873 29/M 0.5 0.2 0.3 16 18 170 7.6 5.6 2 9 3.8
27 C93620 38/M 1 0.6 0.4 25 24 165 7.9 4.7 3.2 11.3 3.6
28 C94833 26/F 0.4 0.2 0.2 24 25 200 7 5 2 10.4 3.6
29 C96489 31/F 0.4 0.2 0.2 24 26 180 7 4 3 10 2.9
30 C96802 25/F 0.5 0.2 0.3 25 23 220 7.1 3 4.1 10.7 2.8
31 4185 48/F 0.6 0.2 0.4 17 19 149 6.2 4 2.2 10.4 3
32 4228 32/F 0.5 0.2 0.3 14 15 187 6.9 3.4 3.5 11.4 2.8
33 4258 37/F 0.6 0.2 0.4 15 17 220 5 3 2 10.8 3
34 4267 42/F 0.4 0.2 0.2 24 21 256 7 4.3 2.7 12.8 2.8
35 4251 48/F 0.8 0.3 0.5 18 20 145 7.8 4.6 3.2 10.4 3
36 4255 40/F 0.4 0.2 0.2 21 22 170 6.6 4.5 2.1 10.6 3.1
37 4175 42/F 1 0.6 0.4 12 10 136 6.6 4.5 2.1 10 3
38 4226 34/F 0.5 0.2 0.3 20 22 159 6.4 4.2 2.2 10.5 3
39 4209 42/F 0.6 0.2 0.4 21 23 168 6.8 4.8 2 12.4 2.8
40 5217 26/M 1 0.5 0.5 20 21 166 6.5 4 2.5 10.9 2.9
AFTER TREATMENT
OP/IP T.Billirubin D.Billirubin ID.billirubin SGOT SGPT SAP T.Protein Albumin Globulin Calcium Phosphorous
No mg/dl mg/dl mg/dl U/l U/l U/l gm/dl gm/dl gm/dl mg/dl mg/dl
1 C95550 31/F 0.6 0.2 0.4 18 19 190 7 5.2 1.8 11 3
2 D00464 40/F 0.7 0.2 0.5 21 26 216 6 4 2 11.3 2.7
3 C95513 40/F 1.1 0.5 0.6 19 28 119 6.1 3.2 2.9 11 3
4 C94392 31/F 0.4 0.2 0.2 24 24 262 6.8 4 2.8 10.1 4.6
5 D004308 45/F 0.5 0.2 0.3 15 16 121 7 5 2 11 3
6 C098191 40/F 0.4 0.2 0.2 21 28 190 6.9 3.9 3 10 3
7 C098214 40/F 0.3 0.2 0.1 16 17 195 7.4 4.4 3 10.6 2.8
8 C96651 50/F 0.6 0.2 0.4 21 24 211 6.5 4.5 2 11 3.6
9 C97647 30/F 0.5 0.2 0.3 19 20 152 7.7 5.7 2 12.2 3.6
10 D000836 25/F 0.5 0.2 0.3 23 26 236 6.4 3.4 3 12.2 2.8
11 C099666 37/F 0.7 0.3 0.4 16 20 186 7.5 5.5 2 10.5 3
12 C97598 48/F 0.5 0.2 0.3 22 27 196 7.5 5.5 2 9.3 2
13 C098014 32/F 0.6 0.2 0.4 24 23 213 6.7 4.2 2.5 11 3.2
14 C099250 47/F 0.5 0.2 0.3 12 14 147 6.6 4.1 2.5 10.1 3
15 C95436 44/F 0.4 0.2 0.2 11 12 145 6 3.6 2.4 9.8 2
16 D000496 38/F 1.1 0.5 0.6 19 25 176 6.6 3.7 2.9 10.8 3.1
17 C098239 38/F 0.4 0.2 0.2 11 23 177 6 3.6 2.4 9.9 2.7
18 C97940 48/F 0.5 0.2 0.3 16 26 186 6.6 4.1 2.4 10.1 3.5
19 C94733 32/F 0.5 0.2 0.3 16 17 183 5.6 3.1 2.5 10.8 3.5
20 D000006 32/F 1 0.5 0.5 18 22 220 6.2 4.2 2 9.2 3.8
21 D000425 37/M 0.7 0.3 0.4 23 26 176 6 4 2 9.8 2.8
22 D000205 48/M 0.7 0.3 0.4 19 20 156 6.4 4.4 2 9.6 2.6
23 B55586 26/M 0.6 0.2 0.4 23 25 170 6.9 4.3 2.6 10.1 3
24 C96984 50/M 1 0.7 0.3 22 27 166 6.5 4.4 2.1 10.8 3
25 D004970 47/M 0.5 0.2 0.3 22 24 198 6.2 4 2.2 10.8 2.9
26 C94873 29/M 0.5 0.2 0.3 24 26 179 6.5 4.5 2 11 3.2
27 C93620 38/M 1 0.5 0.5 23 26 168 5.9 2.6 3.3 10.2 2.9
28 C94833 26/F 0.9 0.3 0.6 16 18 144 5 3 2 10 2.9
29 C96489 31/F 0.5 0.2 0.3 19 21 149 6.6 3.6 3 10.4 2.9
30 C96802 25/F 0.8 0.3 0.5 24 26 242 6.6 4.4 2.2 11.1 3.3
31 4185 48/F 0.6 0.2 0.4 16 14 135 6 4 2 9.6 2.3
32 4228 32/F 0.4 0.2 0.2 13 15 164 6.2 4.2 2 10.2 2.5
33 4258 37/F 0.6 0.2 0.4 13 14 135 5.9 4.5 1.4 9.7 2.9
34 4267 42/F 0.4 0.2 0.2 23 21 220 6.4 4.4 4 10.2 2.4
35 4251 48/F 0.8 0.3 0.5 18 20 145 7.8 4.6 3.2 10 3
36 4255 40/F 1.2 0.6 0.6 16 17 161 7 5 2 10.4 2.9
37 4175 42/F 3.6 1.2 2.4 12 14 150 6.5 4.1 2.4 10.2 2.9
38 4226 34/F 0.5 0.2 0.3 18 16 154 6.2 4.2 2 9.6 2.8
39 4209 42/F 0.5 0.2 0.3 11 12 140 6 3 2 10.8 3.3
40 5217 26/M 0.8 0.4 0.4 18 17 160 6.4 4 2.4 9.8 2.5
LAB INVESTIGATION BEFORE TREATMENT AND AFTER TREATMENTAFTER TREATMENT
OP/IP
NO BT AT BT AT BT AT BT AT BT AT
1 C95550 31/F 151 151 37 30 93 102 21 25 103 126
2 D00464 40/F 168 112 38 29 109 61 21 31 104 156
3 C95513 40/F 286 227 59 38 181 108 46 80 229 400
4 C94392 31/F 232 202 60 35 156 160 16 23 78 115
5 D004308 45/F 178 111 35 22 105 62 38 30 189 151
6 C098191 40/F 169 117 36 26 93 44 40 25 200 126
7 C098214 40/F 180 132 35 29 120 50 25 21 124 106
8 C96651 50/F 182 156 37 32 118 90 27 19 136 98
9 C97647 30/F 168 140 43 29 79 82 46 40 234 200
10 D000836 25/F 191 135 35 30 144 90 12 11 62 57
11 C099666 37/F 210 186 38 35 145 120 27 33 139 165
12 C97598 48/F 185 169 32 32 134 106 19 34 98 172
13 C098014 32/F 186 137 38 30 101 92 47 25 239 127
14 C099250 47/F 253 219 42 40 182 175 29 33 149 166
15 C95436 44/F 160 106 35 30 113 63 12 11 61 57
16 D000496 38/F 180 178 30 36 120 112 30 68 154 343
17 C098239 38/F 243 238 47 42 112 172 50 28 250 142
18 C97940 48/F 190 147 36 30 117 108 41 27 206 138
19 C94733 32/F 269 218 40 42 185 126 44 34 218 172
20 D000006 32/F 195 190 38 35 109 102 44 40 223 209
21 D000425 37/M 186 149 36 34 130 119 24 25 123 127
22 D000205 48/M 150 138 30 30 102 99 24 39 123 197
23 B55586 26/M 143 136 26 35 94 86 26 45 132 227
24 C96984 50/M 195 178 38 38 116 1256 54 49 274 245
25 D004970 47/M 95 92 19 30 146 40 16 20 83 101
26 C94873 29/M 176 168 30 40 100 79 41 32 206 163
27 C93620 38/M 225 192 45 45 121 119 51 22 258 112
28 C94833 26/F 176 143 29 31 100 86 42 35 212 178
29 C96489 31/F 180 154 54 35 110 80 30 28 122 140
30 C96802 25/F 194 189 29 36 104 86 49 15 249 79
31 4185 48/F 144 140 30 28 101 98 34 31 170 165
32 4228 32/F 150 148 32 28 90 87 24 23 122 120
33 4258 37/F 176 198 35 36 116 96 36 31 184 156
34 4267 42/F 145 140 36 32 77 75 32 30 161 158
35 4251 48/F 134 158 21 30 45 90 27 46 137 232
36 4255 40/F 140 157 24 34 60 75 13 12 67 61
37 4175 42/F 159 200 32 39 117 98 12 35 62 179
38 4226 34/F 211 200 40 38 146 140 21 20 107 102
39 4209 42/F 153 205 32 35 100 96 13 18 66 94
40 5217 26/M 131 128 30 25 70 64 27 24 139 130
BT-BEFORE TREATMENT AT-AFTER TREATMENTAT – FTER T EATMENT
ALL THE 40 PATIENTS ARE NEGATIVE IN CRP AND RA FACTO R
Blood sugar 
mg/dl
Blood urea 
mg/dl
Sno
Age/Sex                    DC      ESR   
    mm/hr
mg/dl
Sno Age/Sex                    DC      ESR   Blood sugar 
    mm/hr
OP/IP NO AGE/SEX
Hbgm%
TRBC
Million cells /cumm
BLO O D INVESTIGATIO N BEFO RE TREATEMENT
BLO O D INVESTIGATIO N AFTER TREATEMENT
LAB INVESTIGATION BEFORE AND AFTER TREATMENT
LAB INVESTIGATION BEFORE TREATMENT
T.CHOLESTEROL mg/dl HDL mg/dl LDL mg/dl VLDL mg/dl TGL mg/dl
Sno Age/Sex
Sno Age/Sex
S.NO
Age/sex
Blood urea mg/dl
BT AT BT AT        BT        AT
C94833 26 F Nil Nil Nil Nil 2 epi.cells 3 epi.cells
C098191 40 F Nil Nil Nil Nil 3  epi.cells 2  epi.cells
D004664 42 F Nil Nil Nil Nil 1-2 epi.cells        -
C95550 36 F Nil Nil Nil Nil 2-6 epi.cells 2 epi.cells
C94392 31 F Nil Nil Nil Nil 3-6 epi.cells 4 epi.cells
1-2 epi.cells
2-4 pus cells
C098239 38 F Nil Nil Nil Nil 2-4 epi.cells         -
D000836 25 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells
C96489 31 F Nil Nil Nil Nil 2-5 epi.cells 2 epi.cells
C09925 47 F Nil Nil Nil Nil           -         -
4185 48 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells
4228 32 F Nil Nil Nil Nil         -        -
4258 37 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells
3-5 epi.cells
4-6 pus cells
4255 48 F Nil Nil Nil Nil 1-2 epi.cells         -
4226 40 F Nil Nil Nil Nil          -          -
4208 42 F Nil Nil Nil Nil          -          -
4251 34 F Nil Nil Nil Nil          -          -
4175 42 F Nil Nil Nil Nil 4-6 pus cells -
5217 26 M Nil Nil Nil Nil 2 epi.cells 2 epi.cells
5
Sl.no op .no age SEX
               Deposits
1
2
3
4
   Albumin      Sugar 
9
6 C098014 32 F Nil Nil 1-2 epi.cells
7
8
Nil Nil 
10
11
12
13
14
20
2-4 epi.cells
15
16
17
18
19
42 F Nil Nil Nil Nil 4267
1 Nil 1-2 epi.cells
2 Nil 2-3epi.cells
3 Nil 1-2 epi.cells
4 Nil -
6 Nil 1-2 epi.cells
7 Nil -
8 Nil 1-2 epi.cells
9 Nil 2 epi.cells
10 Nil 
12 Nil  2-4 epi.cells
13 Nil -
14 Nil 2-4epi.cells
15 Nil 1-2 epi.cells
17 Nil 1-2 epi.cells
1-2 epi.cells,
2 pus cells
19 2-4 epi.cells
20 Nil 2-4  epi.cells
D000496 36 F Nil Nil 
URINE INVESTIGATION 
1-2 epi.cells
Nil 2 epi.cells
D000006 32 F Nil Nil Nil 
1-2 epi.cells,
2-4 epi.cells
C96802 24 F Nil Nil Nil 1-2 epi.cells
18 C95436 38 F Nil Nil Nil 
2-4 pus cells
16 C94733 32 F Nil Nil Nil Nil 
3-4 epi.cells,
4-6pus cells.
C95513 40 F Nil Nil Nil 3-6 epi.cells
C97598 48 F Nil Nil Nil 1-2 epi.cells
1-2 epi.cells
C97940 48 F Nil Nil Nil  2 epi.cells
C97647 33    F Nil Nil Nil -
1-2 epi.cells
11 C098214 40 F Nil Nil Nil 
D004308 45 F Nil Nil Nil 
Nil 
1-2 epi.cells
1-2 pus cells
C099666 37                Nil Nil Nil 1-2 epi.cells
C96651 50 F Nil Nil Nil 2-3 epi.cells
1-2 epi.cells
D000425 37 M Nil Nil Nil 2-3 epi.cells
D000205 48 M Nil Nil Nil 
Nil Nil 
1-2 epi.cells,
3 pus cells
1-2 epi.cells,5 B55586 26 M Nil Nil 
C93620 38 M Nil Nil Nil 1-2 epi.cells
D004970 47 M Nil Nil Nil -
1-2 epi.cells
C96984 50 M Nil Nil Nil 2-5 epi.cells
C94873 29 M Nil Nil Nil 
Sl.no   Op/ip .no AGE
           
SEX
   Albumin      Sugar                Deposits
ATBT AT BT AT        BT
BT AT BT AT        BT        AT
C94833 26 F Nil Nil Nil Nil 2 epi.cells 3 epi.cells
C098191 40 F Nil Nil Nil Nil 3  epi.cells 2  epi.cells
D004664 42 F Nil Nil Nil Nil 1-2 epi.cells        -
C95550 36 F Nil Nil Nil Nil 2-6 epi.cells 2 epi.cells
C94392 31 F Nil Nil Nil Nil 3-6 epi.cells 4 epi.cells
1-2 epi.cells
2-4 pus cells
C098239 38 F Nil Nil Nil Nil 2-4 epi.cells         -
D000836 25 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells
C96489 31 F Nil Nil Nil Nil 2-5 epi.cells 2 epi.cells
C09925 47 F Nil Nil Nil Nil           -         -
4185 48 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells
4228 32 F Nil Nil Nil Nil         -        -
4258 37 F Nil Nil Nil Nil 1-2 epi.cells 1-2 epi.cells
3-5 epi.cells
4-6 pus cells
4255 48 F Nil Nil Nil Nil 1-2 epi.cells         -
4226 40 F Nil Nil Nil Nil          -          -
4208 42 F Nil Nil Nil Nil          -          -
4251 34 F Nil Nil Nil Nil          -          -
4175 42 F Nil Nil Nil Nil 4-6 pus cells -
5217 26 M Nil Nil Nil Nil 2 epi.cells 2 epi.cells
5
Sl.no op .no age SEX
               Deposits
1
2
3
4
   Albumin      Sugar 
9
6 C098014 32 F Nil Nil 1-2 epi.cells
7
8
Nil Nil 
10
11
12
13
14
20
2-4 epi.cells
15
16
17
18
19
42 F Nil Nil Nil Nil 4267
